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1 General introduction
Part of this data has been published in:
-  Preti M, van Seters M, Sideri M, van Beurden M. Squamous vulvar 
intraepithelial neoplasia. Clin Obstet Gynecol 2005; 48: 845-61.
-  van Beurden M, van Seters M, Helmerhorst ThJM. Vulvaire intra-
epitheliale neoplasie. In: van der Meijden WI, ter Harmsel WA, 
eds. Vulvapathologie. 1st ed. Assen: Koninklijke Van Gorcum 2007; 
117-29.
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1. Vulvar intraepithelial neoplasia
Vulvar intraepithelial neoplasia (VIN) is a rare condition which can develop into an invasive 
carcinoma.1 This skin-disease affects mainly young women, and causes many severe and 
long-lasting symptoms such as pruritus, vulvodynia and psychosexual dysfunction. Over 
80% of VIN-affected women present with multifocal vulvar disease, and often neoplastic 
changes can be found in the entire lower genital tract.2 Clinically, it is important to dis-
tinguish unifocal from multifocal lesions, since unifocal VIN tends to progress to invasive 
carcinoma ten times more often than multifocal VIN does.3
1.1 Epidemiology
Since the early seventies, the incidence of VIN has increased.4 This trend continued dur-
ing the following two decades. Nevertheless, the incidence of vulvar cancer remained 
unchanged.5 Recently, however, first case reports and then cohort studies documented 
an increasing incidence of VIN-associated carcinoma in younger women.6-8 Spontaneous 
regression of VIN has been reported in only a few cases. Forty-one patients (13 studies), all 
younger than 35 years, showed spontaneous complete regression of their VIN-lesions.1,9-20 
This was related to pregnancy in 41%.
1.2 Nomenclature
Historically, various terms have been used to define VIN: morbus Bowen, Queyrat’s 
erythroplasia, carcinoma simplex, bowenoid papulosis, early vulvar cancer, vulvar atypia, 
hyperplastic dystrophy, carcinoma in situ, dysplasia. In 1976, the International Society for 
the Study of Vulvovaginal Diseases (ISSVD) simplified terminology into carcinoma in situ 
and vulvar atypia.21 Ten years later, in 1986, the ISSVD adopted a single term, VIN, dis-
couraging any other terminology including carcinoma in situ and vulvar atypia.22 In that 
ISSVD report the term VIN, as a general category, included three subdivisions: VIN 1 (mild 
dysplasia), VIN 2 (moderate dysplasia) and VIN 3 (severe dysplasia) (Table 1). In addition, 
the report described a separate lesion - differentiated VIN - and recommended this lesion 
to be also classified as VIN 3. The three-grade system of VIN was set up equivalent to the 
classification of cervical intraepithelial neoplasia (CIN), although there is no evidence that 
the morphologic spectrum of VIN 1 to 3 reflects a biologic continuum or that VIN behaves 
similarly to CIN. In 2004, this was reason for the ISSVD to modify VIN terminology again, 
this time into a two-tier classification: VIN, usual type (warty, basaloid and mixed) and VIN, 
differentiated type. The two types differ in morphology, biology and clinical features.23 
VIN, usual type, is human papillomavirus (HPV)-associated, occurs predominantly in 
younger patients and tends to be a multifocal and multicentric disease. It is seen adjacent 
to approximately 30% of squamous cell carcinomas (SCC) of the vulva (basaloid and 
warty type). VIN, differentiated type, on the other hand, is less common, not related to 
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HPV, usually found in older women and often observed in association with keratinizing 
SCC. It is commonly thought that differentiated VIN is associated with lichen sclerosus 
(LS),24,25 although argumentation for this is limited to a small number of studies describing 
epithelial alterations adjacent to vulvar SCC.26-29 In this currently used classification, the 
term VIN 1 no longer exists. VIN should apply only to histologically ‘high grade’ squamous 
lesions. Therefore, it is recommended that the former terms VIN 2 and 3 are combined as a 
single diagnostic category, and referred to as high grade VIN, usual or differentiated type 
(Table 1).
1.3 Etiology
In 1982 it became apparent that HPV might be involved in the etiology of VIN.30 Since then, 
several studies demonstrated a high prevalence of HPV DNA in high grade VIN lesions, 
usual type (between 78-92%).2,31-34 In most cases HPV-16 DNA was detected. It is shown 
that HPV DNA is significantly more present in multifocal VIN than in unifocal VIN and more 
often in VIN coexisting with other multicentric intraepithelial lesions in the lower genital 
tract.2
HPV is a sexually transmitted virus. The estimated life-time risk of infection with HPV is 
80%.35 Most infections proceed asymptomatically, and cure spontaneously as the immune 
system is capable of eliminating the virus.36 Persistence, on the other hand, can result in 
neoplastic changes of the anogenital tract.37,38 So far, more than 100 types of HPV have 
been identified that can be grouped into high-risk (oncogenic) types and low-risk (non-
oncogenic) types. High-risk HPV, of which HPV-16 is the most prevalent type, is associated 
with cervical carcinoma and high grade CIN or VIN, whereas low-risk HPV is mainly seen 
in genital warts or low grade cervical or vulvar lesions. HPV encodes for several viral pro-
teins, of which ‘early’ oncoproteins E6 and E7 are the most important. E6 and E7 bind and 
inactivate gene products of tumor suppressor genes p53 and Rb, respectively.39,40 These 
complexes cause disruption of cell cycle control in the proliferative cell and disable the cell 
to repair DNA damage. This can result in genetic instability, leading to mutations that are 
involved in (pre-) malignancy.41
Table 1. Squamous Vulvar Intraepithelial Neoplasia (VIN) terminology
ISSVD, 1986 ISSVD, 2005
- VIN 1, mild atypia - VIN, usual type
- VIN 2, moderate dysplasia (warty, basaloid, mixed)
- VIN 3, severe dysplasia, CIS
- VIN 3, differentiated type - VIN, differentiated type
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2. Histology
VIN is characterized by loss of epithelial cell maturation with associated nuclear hyper-
chromasia, pleomorphism, cellular crowding and abnormal mitotic figures. VIN can be 
subclassified into different histologic subtypes – warty, basaloid and differentiated VIN.24
Warty VIN (Figure 1) is characterized by a condylomatous appearance, parakeratosis, 
hyperkeratosis and striking cellular pleomorphism. There is evidence of abnormal cell 
maturation. Multinucleation, corps rounds, acanthosis and koilocytosis are common, as 
are (abnormal) mitotic figures. The rete ridges are typically wide and deep, often reaching 
close to the surface.
Basaloid VIN (Figure 2) is characterized by thickened epithelium, with a relatively flat 
and non-papillomatous surface. The epidermis consists of a monotonous proliferation 
of relatively uniform undifferentiated cells with a basaloid appearance. Koilocytotic cells 
and corps ronds may be present, but less frequently than in warty VIN. Mitotic figures are 
numerous. As with warty VIN, the intraepithelial process may involve the underlying skin 
appendages.42-45 Warty and basaloid VIN often coexist in one lesion, which is referred to as 
mixed VIN. Both types are related to the presence of HPV.2,46
Differentiated VIN (Figure 3) is characterized by prominent eosinophilic cells in the 
basal and parabasal area, often with keratin formation or ‘pearl-like’ changes within the 
rete ridges. These prematurely differentiated keratinocytes usually have large vesicular 
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Figure 1. VIN usual type, warty. H&E staining x100. Figure 2. VIN usual type, basaloid. H&E staining x100
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nuclei and prominent nucleoli. A high degree of cellular differentiation and an absence 
of widespread architectural disarray make it difficult to recognize this type of VIN. Since 
histopathological changes are subtle, differentiated VIN is easily mistaken for benign 
lesions.47,48 Immunostaining for p53 protein might be helpful in this situation. In 10 of 12 
patients with differentiated VIN, overexpression of the p53 tumor suppressor gene has 
been demonstrated.48
3. Therapy
Until now, the choice of therapy for high grade VIN has been dominated by the pre-
malignant nature of the disease. Although extensive surgery, such as vulvectomy, is not 
the advised treatment anymore, standard therapy for patients with VIN still comprises 
surgical removal of all visible lesions to relieve symptoms and to prevent the development 
of invasive disease. In 1995, Kaufman underlined the importance of individualization of 
treatment. Treatment should be directed towards preservation of the normal anatomy 
and function of the vulva.49 Shortly after, van Beurden et al demonstrated vulvoscopically 
directed biopsies to be a safe method to exclude invasive disease, and restricted surgery to 
be effective in relieving symptoms in multifocal VIN 3.50 In the Dutch consensus guidelines 
(1999), it is advised to radically excise unifocal VIN with a margin of 5mm, and to treat 
multifocal VIN as conservative as possible.51
Figure 3. 
 
 
 
 
 
 
 
Figure 3. VIN differentiated type, H&E staining x100
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3.1 Surgical treatment
Surgical treatment can be performed with different techniques. Cold knife surgery or CO2-
laser vaporization are used as a single technique or in combination. When representative 
biopsies have been taken beforehand, vaporization can be an effective treatment especially 
in non-hair bearing areas. Unfortunately, irrespective of the type and extent of operation 
performed, surgical margins are often positive and high recurrence rates are common.52-54 
Besides, one has to be aware of the correlation between (the extent of ) surgical treatment 
and mutilation of the vulva, possibly resulting in psychosexual distress.55-58
3.2 Medical treatment
Because VIN is being diagnosed more often in younger patients, effective treatment is 
needed that does not mutilate or functionally incapacitate the patient. Therefore several 
medical treatment options in the management of VIN have been investigated in the 
past, varying from local chemotherapy to immunotherapy. Topical treatment is attrac-
tive because it can be applied directly by the patient and is easily monitored for efficacy. 
Unfortunately, study results have been disappointing thus far, with only a few responses 
and high complication and recurrence rates. For medical therapy, diagnosis has to rely on 
the biopsy only, with the risk that an early invasive lesion is overlooked.
3.2.1 Chemotherapy
The use of topical 5-fluorouracil (5-FU) in VIN 3 was first described in 1967.59 5-FU is a 
chemotherapeutic agent inhibiting DNA synthesis in the “S” phase of cell division. In addi-
tion, it works as a cell marker being incorporated into the neoplastic cell, where it can be 
recognized and destroyed by the patients’ immune system.60 A review summarized the 
results obtained by treatment with topical 5-FU in 68 patients with VIN 3 (15 studies).61 
Overall, remission was seen in 34%, improvement in 7%, while 59% failed therapy. As a 
result of severe side-effects, including painful ulcerations, duration of treatment with 5-FU 
was frequently limited by the patient.
The use of topical and intradermal bleomycin in the treatment of VIN resulted in poor 
response rates. Additionally, in five out of 12 patients, progression to an invasive lesion 
was seen.62
3.2.2 Immunotherapy
In studies with dinitrochlorobenzene (DNCB), inducing a type of delayed hypersensitivity 
reaction on topical application, generally a successful treatment of recurrent VIN 3 has 
been shown. However, recurrences still developed after treatment with DNCB, and side-
effects were extensive, if not intolerable.63
Better results have been accomplished with interferon-α (IFN-α), an attractive therapeu-
tic agent in HPV-related diseases, because of its inhibitory effect on viral replication and 
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cell growth. IFN-α can be administered systemically, intralesionally or topically, resulting 
in high response rates (biopsy-proven) with low morbidity.64-66 In 1998, a high failure rate 
of interferon in combination with isotretinoin in HPV-related VIN 3 was reported. Despite 
clinical regression, histologic features of VIN 3 were still present.67
3.3 New treatment modalities
As no curative treatment of VIN has yet been identified, continuous efforts are being made 
to investigate new treatment strategies.
3.3.1 Photodynamic therapy
Photodynamic therapy (PDT) is a relatively new technique that uses a tumor-localizing 
photosensitizer, 5-aminolevulinic acid (ALA), in combination with non-thermal light of an 
appropriate wavelength to generate oxygen-induced cell death. Because PDT has been 
shown to be very effective in the treatment of nonmelanoma skin carcinomas, it was 
expected to be useful in the management of VIN. A clearance rate of 37% in 8 patients 
with high-grade VIN was found.68 Similar results (31-46%) were reported in two other stud-
ies.69,70 Both studies showed that unifocal lesions are more responsive to ALA-PDT than 
multifocal high-grade VIN, and that increased pigmentation and hyperkeratosis of the 
lesions are associated with low response rates. Fehr et al reported promising results in 11 
of 15 patients (73%) being free of VIN 3 after treatment with ALA-PDT.71 During follow-up, 
recurrence rate was not significantly different from patients treated with laser evaporation 
or local excision. PDT has the advantage of minimal tissue destruction with a short healing 
time and only few side-effects.68-71
3.3.2 Imiquimod
The first promising results on treatment of VIN with imiquimod were reported in 2000 in 
four patients.72 Imiquimod is an immune response modifier with antiviral and antitumor 
properties, that has been shown safe and efficacious in the treatment of external genital 
warts caused by HPV.73 Imiquimod binds to Toll-like receptor 7, a cell surface receptor on 
the immature plasmacytoid dendritic cell (DC). Binding initiates an intracellular signaling 
cascade that finally results in induction of an innate and cell-mediated immune response. 
It is hypothesized that topical treatment with imiquimod may be effective in stimulating 
cell-mediated immunity against different types of HPV and thus encourage regression of 
HPV-related preneoplastic vulvar lesions. Small observational, non-controlled series of 
patients with high response rates to imiquimod have been described since then.74-76 A 
potential effect of treatment with imiquimod in the entire lower genital tract was also 
demonstrated.74 One study reported clinical improvement in only 27% (n=15). Local side-
effects limited the frequency of application, which might be an explanation for this low 
response rate.77
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4. Immunology
The immune response to invading HPV is regulated by cells of both the innate and adaptive 
immune system. Innate immune cells, including monocytes, granulocytes, macrophages, 
mast cells, natural killer (NK) cells and DCs, recognize, internalize and/or phagocytose the 
invading virus or viral antigens. They release soluble effector molecules, e.g. complement 
components and cytokines, which regulate and coordinate many of their activities. DCs, 
important antigen-presenting cells (APCs), bind viral antigens by a set of specific receptors 
(Toll-like receptors), internalize and process bound antigens and transport them, under 
the influence of immune mediators such as chemokines, to secondary lymphoid organs. 
There, naïve T-cells are primed to mature into antigen-specific CD4+ T-helper cells, (Th-
cells), CD8+ cytotoxic T-cells (CTLs), or regulatory T-cells (Treg cells), which are effector cells 
of the adaptive immune system.78,79
The adaptive immune system consists of cell-mediated and humoral immune responses. 
The cellular immune response targets the intracellular virus or viral antigens presented 
by APCs as described above. CD4+ T-helper cells play a central role in regulating immune 
responses and are essential in antitumor immunity.80,81 They activate and stimulate 
innate effector cells and CD8+ cytotoxic cells through the release of immuno-stimulating 
Th1-type cytokines, such as IFN-γ, TNF-β and IL-2. They also produce immuno-inhibitory 
Th2-type cytokines, such as IL-4, IL-5, IL-10 and TGF-β. Th2-type cytokines predominantly 
induce humoral immune responses.
The effector cells for humoral immune responses, B-lymfocytes, produce antibodies 
that specifically recognize and bind to the extracellular virus that now can be eliminated 
by various mechanisms.
4.1 Local immune response
HPV-infection begins with binding of virions to the basal cells of the epithelium. In the 
upper layers where viral replication takes place, HPV DNA is encapsidated, and virions 
are released at the epithelial surface.82 Since persistence of HPV-infection is necessary to 
cause anogenital disease, it is of interest to see how HPV effects the distribution of immu-
nocompetent (effector) cells in the skin of patients with VIN. Only a few studies reported 
on the number of immunocompetent cells in VIN-affected skin, mostly dealing with CD4+ 
and CD8+ T-cells, and/or CD1a+ DCs.69,83,84 Overall, these studies demonstrated ambigu-
ous results on the distribution of CD1a+ DCs, and an increasing number of CD4+ and CD8+ 
T-cells in dermis or upper dermis of VIN patients. The distribution of a broader range of 
immunocompetent cells in both VIN-affected skin and normal vulvar skin is not yet fully 
investigated. More information is needed in order to understand the possible effect of the 
immune modifier imiquimod on immmunocompetent cells in vulvar dysplasia.
Ch
ap
te
r 1
18
4.2 Systemic immune response
Little is known about the effect of HPV-infection on the systemic immune response. The 
importance of cell-mediated immune responses of the host in the course of infection is 
illustrated by an increased incidence of HPV-induced diseases in T-cell immuno-deficient 
individuals (Petry, 1996).85 It was also demonstrated that type 1 (IFNγ) T-cell immunity 
against HPV 16 early antigens E2, E6 and E7 can be detected in the circulation of the 
majority of healthy sexually active individuals, but is weak or absent in patients with HPV 
16-induced cervical neoplasia.86-88 These data argue that the CD4+ type 1 T-cell response 
against the early antigens of HPV 16 may play an important role in the protection against 
progressive HPV-16 induced disease.
5. Outline of this thesis
In Chapter 2 ninety-seven studies, published between 1943 and 2003, are systematically 
reviewed to establish the true natural history of high grade VIN from literature data. The 
aim was to assess both the risk of progres si on of VIN in untreated pa tients, and the effect 
of surgi cal treat ment in relation to recur rences and progression of VIN.
In Chapter 3 the coexistence between VIN and LS is further analyzed, since the pre-
sumption that differentiated VIN is related to LS is not based on much evidence.
Chapter 4 describes the results of a pilot study investigating imiquimod 5% cream in 
the treatment of high grade VIN.
Chapter 5 describes the results of a randomized controlled trial (RCT) investigating the 
effectiveness of imiquimod 5% cream in patients with multifocal high grade VIN. Outcome 
measures are reduction in lesion size, histological regression, clearance of HPV, changes in 
immunocompetent cells in (epi-)dermis, relief of symptoms, improvement of quality of life 
and durability of clinical response.
In Chapter 6 the distribution of immunocompetent cells in the epidermis and dermis 
of HPV-related VIN-affected skin is characterized, and compared with HPV-negative vulvar 
skin from healthy controls.
Chapter 7 describes the role of HPV-16 specific CD4+ T-cell immunity in the success or 
failure of treatment with imiquimod in 29 patients with high grade VIN.
The results presented in the previous chapters are discussed in chapter 8.
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Abstract
Objective To establish the true natural history of VIN 3 from litera tu re data.
Methods In a systematic review, data of women with VIN 3 in dexed in several compu ter 
databases were pool ed. The effect of treat ment was correlated with recurrences and pro-
gres sion of VIN 3.
Results Ninety-seven articles met the inclusion criteria. Data of 3322 patients were avail-
able. The mean age at diagnosis of VIN 3 was 46. This decreased over time, although not 
signifi cantly (P=0.08). Recurren ces were seen as often after local excision as after vulvec-
tomy. The percentage of recurren ces was lower, but not absent, after free surgical margins 
than after involved surgical margins (P<0.001). 6.5% of the 3322 patients progressed to 
an inva si ve vulvar  carcino ma. Occult  carci nomas were diagnosed in 3.2% of patients and 
3.3% carcino mas were diagnosed during follow-up. The mean age at diagno sis of invasive 
vulvar carci noma was 52 years. Nine percent of 88 untreated patients progres sed in 12 to 
96 months to invasive vulvar carcinoma. Only 1.2% of the 3322 pa tients showed complete 
regressi on, mostly during the first 10 months after dia gnosis, 41% of which was related to 
preg nancy.
Conclusion Evidence exists that VIN 3 may progress to invasive vulvar carcinoma. However, 
the available literature suggests that the progression rate to invasive vulvar carcinoma is 
low. The incidence of invasion as found in this systematic review is probably even too high, 
because overreporting of (micro)invasive cases cannot be excluded. Only a prospective 
registration using a standardized pathology examination will provide information about 
the real natural history of VIN 3.
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Introduction
The natural history of untreated VIN 3 is unclear. Untreated patients who hardly ever prog-
ress to an invasive vulvar carcinoma have been published.1-3 Others have seen progression 
in nearly all untreated patients.4 Since data on the follow-up of untreated VIN 3 are scarce, 
the natural histo ry of VIN 3 is main ly based on the fol low-up after surgi cal treat ment of 
VIN 3 and is considered low.2 Although extensive sur gery, such as vulvec to my, is not the 
advised standard treatment anymore, removal of all visible lesions to exclude the pre sence 
of an occult invasive squamous cell carcino ma is still recommended.5
The aim of this study was, by means of a systematic review, to assess both the risk of 
progres si on of VIN 3 in untreated pa tients and the effect of surgi cal treat ment in relation 
to recur rences and progression of VIN 3.
Material and Methods
Data Identification and Extraction
Articles were located in November 2004 using various strategies. Firstly, com puter searches 
of MEDLINE (from 1964), CANCERLIT (from 1980), EMBASE (from 1974), BIOSIS PREVIEWS 
AB (from 1970) and SCIENCE CITATION INDEX (from 1970) were perfor med. The follo wing 
key words were used: vulvar neo plasms in combination with intrae pi thelial neoplasi a, 
Bowen, bowenoid, Queyrat, carcino ma simplex, early vulvar can cer, hyper plastic dys trophy, 
condylomatous dys plasia, in trae pithe lial carci noma, carcinoma in situ, vulvar atypia and 
pre cance rous conditions. Secondly, references from chapters on VIN 3 in several hand-
books were checked. The titles and, if available, the abstracts of all citations were checked. 
Any citati on that did not obvi ously fail the inclu sion criteria on the basis of the title or the 
abstract was retrieved and revie wed in grea ter detail. Of the citations that met the inclu-
sion criteria, all referen ces were checked. Crite ria for inclusi on were (1) articles written in 
English, German or Fren ch and (2) data, clearly retrie vable, on the sur gical treat ment and/or 
pro gression and/or regressi on of VIN 3. All relevant data for the evaluation were extracted 
from text, tables and figures. Articles in which data of VIN 3 were not distinguishable from 
data of VIN 1-2, (mi cro)invasi ve vulvar carcinoma or other vulvar disea ses, were excluded. 
Case histories were exclu ded, ex cept those concer ning regres si on or progres si on of VIN 3. 
Surgi cal treat ment was defined as cold knife surge ry, laser excisi on, lase r e va poriza tion, 
LEEP excision or cryo surgery. The following items were recorded, if mentioned: year of 
publi cation, study period, mini mum, maximum and mean age, pre sence of complaints 
(pain, pruritus) and visible lesions, previous radiothera py, immu nosu ppressi on, unifocal or 
multifocal VIN 3, coexis ting genital tract neoplasia (vagina, cervix), type of surgical treat-
ment, free or invol ved surgical margins, occult inva sion (i.e., an invasive vulvar carcinoma 
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in the surgical speci men, while only VIN 3 was assumed preoperatively), duration of 
follow-up, (time to) pro gression to invasi ve vulvar carcino ma, location of invasive vul var 
carcino ma, depth of invasion and (time to) re gres sion of VIN 3.
In the analysis radical vulvectomy, vulvectomy, complete vulvectomy, total vulvectomy, 
simple vulvectomy and skinning vulvectomy are defined as vul vec tomy. Subto tal vul vec-
tomy, hemivulvectomy and partial vul vectomy are defi ned as partial vulvec tomy. Excisi on, 
local excisi on, wide excision, wide local excisi on, laser excision and LEEP are defi ned as 
local excisi on.
Statistical Analysis
Study and patient characteristics are presented as means or as proportions. Each study 
was weighted by the sum of the inverse of the within and between study variance (random 
effect model).6 Random effects models incorporate potential heterogeneity of the mean 
or proportion between different studies by assuming that each study estimates a unique 
mean or proportion. In case of continuous data (e.g. mean age of patients in the study), 
each standard deviation was estimated from the range since this was usually not reported 
in the articles.7 To assess whether mean age of diagnosis dropped over the years, linear 
regression analysis with mean age as dependent variable and the year of publication as 
independent variable was used. Each study was weighted by the inverse of its sam pling 
variance. The year of publication was determined by calculating the average of the years 
the articles originated from. Whenever this was not reported, the year of publication was 
used in the analysis. Statistical analysis was performed with SAS, version 6.12.
Results
A total of 97 articles with data on 3322 patients met the inclusion criteria.1-4,8-100 Seventy-
nine studies dealt with treatment results, progression and regression of VIN 3. Twelve case 
reports only gave data on progression of VIN 3 and 6 case reports only dealt with regres-
sion of VIN 3.
Patients
The mean age was 46 (48 studies, 2152 patients), the mean mini mum age was 21 (59 stud-
ies, 2585 patients) and the mean max im um age was 80 (56 studies, 2467 pa tients). The 
mean age at dia gno sis in the published articles had decreased since the first publis hed 
series in 1943, although not signifi cantly (P=0.08) (Figure 1). The percentage of patients 
with complaints (pain and/or pruritus) was 64 (1777 patients, 43 studies). The percent-
age of patients that sought medical help be cau se of visible lesions was 30 (1116 patients, 
25 studies). The percentage of multifo cal VIN 3 was 49 (1878 patients, 45 stu dies). The 
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percentage of multicentric genital tract neopla sia was 32 (2067 pa tients, 46 studies). 
There was no change in time of complaints, visible lesions, multifocal VIN 3 or multicentric 
VIN 3.
Treatment and recurrences
The effect of 1921 surgically treated pa tients (68 studies) could be evalu a ted. The mean 
duration of follow-up was 39 months, mean range 12-75 months (15 studies, 597 pa tients). 
Recurrences could be found after vulvectomy (n=613) in 19%, after partial vulvectomy 
(n=62) in 18%, after local excision (n=808) in 22%, after laser-evaporization (n=253) in 
23% and after cryocoagulation (n=16) in 56%. There was no statistical significant differ-
ence between recurrences after vulvectomy, partial vulvectomy, local excision and laser-
evaporization. Recurren ces were significantly lower after free surgical margins than after 
involved surgical margins (17% of 291 patients versus 47% of 189 patients, P<0.001).
Progression
A total of 215 invasive vulvar carcinomas (6.5%) were found. Nineteen cases of progres-
si on were repor ted as case histo ries. There were 107 occult carcinomas (3.2%) and 108 
carcinomas (3.3%) were diagnosed during follow-up after treat ment. The mean age at 
diagnosis of the carcinoma was 52, range 21-87 (118 patients). Eight patients were immu-
nosuppressed and nine patients previously received radiothe ra py in the lower genital 
tract. Previous type of surgery was known in 58 patients. Fifty-two percent progressed 
after a vulvec tomy and 48% progres sed after local  excision. We could not find a difference 
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Figure 1. Regression analysis of the mean age of 2152 patients with VIN 3 at diagnosis, reported in 48 articles. 
Two articles gave 2 different study periods. The mean age decreased, although not significantly (P=0.08).
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between progression of unifo cal or multifocal VIN 3. In 11 out of the 31 women in whom 
the place of the carcinoma was known, it was located in the peria nal area; in 15 out of 31 
in the labial area. The mean time to pro gression was 55 months, range 4 to 216 months. 
In only 91 patients, the depth of invasion was mentioned. In 32 patients, invasion was 
described as superficial, early, initial or microinvasion. In 59 patients, invasion was mea-
sured. Of these 59 patients, 33 patients had invasion less than 1 mm and in 26 patients, it 
was more than 1 mm.
Spontaneous regression
Forty-one patients (13 studies) showed complete regression of all lesions. The mean age 
of these patients was 20 years, all were younger than 35 years. In 31 of the 33 patients 
in whom focality was known, multi fo cal VIN 3 regressed. In 17 patients, regression was 
related to preg nancy. In 68% of the patients, regression was found within 10 mont hs.
Untreated patients
Ten studies reported on 88 untreated patients, who either received no treatment at all 
(n=61), or in whom gross macroscopic VIN 3 was left behind (n=27). Eight pa tients (9%) 
progressed in 12 to 96 months, four of whom had been treated previously with radio-
therapy and one of whom was immuno suppressed. The mean follow-up of these 88 
patients was 33 months (four studies, 43 patients, mean range 10-87 months).
Discussion
The dropping age (Figure 1) coincides with the increased incidence of VIN 3 between 1975 
and 1981 [101]. However, one must realize that both these findings could be due to an 
increased awareness of this disease.
In this systematic review, the mean age at diagnosis of the invasive vulvar carcinoma 
was 52 years, while the mean age at diagno sis of VIN 3 was 46 years. The young age of the 
patients with invasive vulvar cancer in this study gives support to the idea that there are 
two different etiologies for vulvar carcino ma. One type is related to HPV and VIN 3 and 
occurs in younger women, such as in our study, and the other is related to the presence of 
lichen sclerosis and appears in older women.102,103 However, one must keep in mind that 
VIN 3 can be seen in the adjacent skin in only 11-32% of all squamous cell carcinomas. 
Lichen sclerosis is seen in 47% of the cases in the adjacent skin.104-109
From our data, there is no indication that recurrences of VIN 3 depend on the type of 
surgery used, except for cryosurgery, which has a high failure rate. However, recurren ces 
do occur significantly more often after involved surgical margins than after free surgical 
margins. The unknown extent of VIN 3 on the vulva in the majority of the articles may have 
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biased these results. This potential bias and the mean duration of follow-up of only 39 
months should be taken into consideration while interpreting the value of these data.
If treatment of VIN 3 is aimed at avoiding an invasive vulvar carcinoma in the future 
several points should be remembered. Firstly, from our data, there is no diffe rence in 
progressi on after diffe rent surgical procedu res. Secondly, it could not be esta blished 
whether free surgical margins diminish the change to progres sion in comparison to 
involved surgical margins. This me ans in our opinion that one should not enlarge the 
extent of excisi on hoping to obtain free surgical margins and thus dimi nishing the change 
of progression to invasive vulvar carci noma. Thirdly, in 71% of the patients in whom depth 
of invasion is known, it is superficial. Besides this high percentage of superficially invasive 
carcinomas, one must be aware of the problems related to overdiagnosing early invasion. 
The finding of involved pilosebaceous units completely separated from the epidermis and 
tangential cuts may give an erroneous interpretation of invasive carcino ma.110 Even when 
the depth of invasion was measured, it was not described in the articles revie wed herein 
how this was done exactly, that is, from the deepest rete pegs, from the most superficial 
dermal papillae or from the base of the epithelium. Since depth of infiltration was not 
mentioned in the majority of the articles, one can have doubts whether infiltration was 
not overdiagnosed in at least some of the reported cases of (micro)invasion. Finally, the 
mean time to pro gression was 55 months, range from 4 to 216 months. This means that 
patients with VIN 3 should be followed carefully for a very long period of time.
We could not find a difference between progression from unifocal or multifocal VIN 3, 
thus we could not support the suggestion that unifocal lesions are more likely to progress 
than multifocal lesions.79 In one study the aspect of the lesion in relati on to progression 
was examined. Lesions with a raised irregu lar surface more often contained an occult 
invasive vulvar carcinoma than flat, ulcera tive and papular lesions.64
In this systematic review, untreated patients do have a 9% risk of progression to invasive 
vulvar carci no ma. Previous radiotherapy and immunosuppression may have play ed a role 
in the progression of those untreated patients.
Regression may be anticipated during several months in young women under 35 
years of age with multifocal disease and without immunosuppression. Pregnancy was a 
substantial factor that may contribute to spontaneous regression.
It is found that more than 50% of women with VIN 3 have complaints (pain and/ or pruri-
tus). Up until now, mana gement of com plaints is still a matter of se condary con cern, since 
treatment of VIN 3 is aimed at removal of all visible lesions to exclude the presence of an 
occult carcinoma.5 The negati ve effect of vulvar surgery for the patient is great and irrever-
sible. It has been shown that half of the women suffer from both a sexual dysfunction 
and psycho logical problems following radical or simple vulvectomy.111 It has also been 
suggested that sexual functi o ning and somatopsychic reactions after treatment for VIN 
3 correlate with the magnitude of the excision.112 On the other hand, repeat local resec-
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tions preser ve the anatomy and functi oning of the vulva better than primary extensi ve 
surgery50 and sympto matic relief is best achi eved by local excisi on in stead of a (skinning) 
vulvecto my.71 Finally, it has been shown that after the presence of an invasi ve vulvar carci-
noma has been excluded by way of mul tiple colpo scopic-directed biopsies, long-term 
con trol of this disease in terms of com plaints as well as progres si on is feasible by only 
removing the affected vulvar skin which is giving com plaints.3
In conclusion, we underline that VIN 3 has a certain invasive potential both in untreated 
patients (9%) and in patients after treatment (3.3%). Invasion may occur many years after 
VIN 3 was dia gnosed. Most of these invasive carcinomas are superficial and overdiag-
nosing early invasi on is well known. Spontaneous regression may occur (1.2%). At this 
moment, there is not enough evidence from the available data to support the removal of 
all involved vulvar skin which would give many psycho sexual seque lae. Only a prospective 
registration with standardized pathology exami nation will give information about the real 
natural history of VIN 3.
The natural history of VIN 31
References
 1. Buscema J, Woodruff JD, Parmley TH, Genadry R. Carcinoma in situ of the vulva. Obstet Gynecol 1980; 
55: 225-30.
 2. Friedrich EG Jr, Wilkinson EJ, Fu YS. Carcinoma in situ of the vulva: a continuing challenge. Am J Obstet 
Gynecol 1980; 136: 830-43.
 3. van Beurden M, van der Vange N, ten Kate FJ, de Craen AJ, Schilthuis MS, Lammes FB. Restricted 
surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on 
relief of symptoms. Int J Gynecol Cancer 1998; 8: 73-7.
 4. Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases 
with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 1994; 84: 741-5.
 5. Kaufman RH. Intraepithelial neoplasia of the vulva. Gynecol Oncol 1995; 56: 8-21.
 6. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol 
Assess Health Care 1990; 6: 5-30.
 7. Diem K, Lentner C. Wissentschaftliche Tabellen: Documenta Geigy. 7th ed. Basel, Switserland: Geigy 
JR; 1968.
 8. van Dyck Knight R . Bowen’s disease of the vulva. Am J Obstet Gynecol 1943; 46: 514-24.
 9. Gardiner SH, Stout FE, Arbogast JL, Huber CP. Intraepithelial carcinoma of the vulva. Am J Obstet 
Gynecol 1953; 65: 539-49.
 10. McAdams AJ Jr, Kistner RW. The relationship of chronic vulvar disease, leukoplakia, and carcinoma in 
situ to carcinoma of the vulva. Cancer 1958; 11: 740-57.
 11. Woodruff JD, Hildebrandt EE. Carcinoma in situ of the vulva. Obstet Gynecol 1958; 12: 414-24.
 12. Limburg H. Über den morbus Bowen der vulva und das beginnende vulvacarcinom. (Histologische, 
klinische und therapeutische ergebnisse). Arch Gynakol 1961; 196: 207-37.
 13. Barclay DL, Collins CG. Intraepithelial cancer of the vulva. Am J Obstet Gynecol 1963; 86: 95-106.
 14. Abell MR. Intraepithelial carcinomas of epidermis and squamous mucosa of vulva and perineum. 
Surg Clin North Am 1965; 45: 1179-98.
 15. Rutledge F, Sinclair M. Treatment of intraepithelial carcinoma of the vulva by skin excision and graft. 
Am J Obstet Gynecol 1968; 102: 807-18.
 16. Collins CG, Roman-Lopez JJ, Lee FY. Intraepithelial carcinoma of the vulva. Am J Obstet Gynecol 1970; 
108: 1187-91.
 17. Basset A, Maleville J, Grosshans E, Heid E, Pradinaud R, Khochnevis A. La forme condylomateuse de la 
maladie de Bowen vulvaire. Sem Hop 1972; 48: 1343-9.
 18. Boutselis JG. Intraepithelial carcinoma of the vulva. Am J Obstet Gynecol 1972; 113: 733-8.
 19. Friedrich EG Jr. Reversible vulvar atypia. A case report. Obstet Gynecol 1972; 39: 173-81.
 20. Skinner MS, Sternberg WH, Ichinose H, Collins J. Spontaneous regression of Bowenoid atypia of the 
vulva. Obstet Gynecol 1973; 42: 40-6.
 21. Woodruff JD, Julian C, Puray T, Mermut S, Katayama P. The contemporary challenge of carcinoma in 
situ of the vulva. Am J Obstet Gynecol 1973; 115: 677-86.
 22. Burket JM. Dark plaques in nether regions. A sign of carcinoma in situ. JAMA 1974; 230: 439-40.
 23. Dean RE, Taylor ES, Weisbrod DM, Martin JW. The treatment of premalignant and malignant lesions of 
the vulva. Am J Obstet Gynecol 1974; 119: 59-68.
 24. Forney JP, Morrow CP, Townsend DE, DiSaia PJ. Management of carcinoma in situ of the vulva. Am J 
Obstet Gynecol 1977; 127: 801-6.
 25. Japaze H, Garcia-Bunuel R, Woodruff JD. Primary vulvar neoplasia: a review of in situ and invasive 
carcinoma, 1935-1972. Obstet Gynecol 1977; 49: 404-11.
 26. Berger BW, Hori Y. Multicentric Bowen’s disease of the genitalia: spontaneous regression of lesions. 
Arch Dermatol 1978; 114: 1698-9.
 27. Jones I, Buntine D. Progression of vulval carcinoma-in-situ. Aust N Z J Obstet Gynaecol 1978; 18: 
274-6.
Ch
ap
te
r 2
32
 28. Hilliard GD, Massey FM, O’Toole RV Jr. Vulvar neoplasia in the young. Am J Obstet Gynecol 1979; 135: 
185-8.
 29. Bender ME, Katz HI, Posalaky Z. Carcinoma in situ of the genitalia. JAMA 1980; 243: 145-6.
 30. Buscema J, Woodruff JD. Progressive histobiologic alterations in the development of vulvar cancer. 
Am J Obstet Gynecol 1980; 138: 146-50.
 31. Fleury FJ. Bowenoid papulosis of the genitalia. Arch Dermatol 1980; 116: 274.
 32. Baggish MS, Dorsey JH. CO2 laser for the treatment of vulvar carcinoma in situ. Obstet Gynecol 1981; 
57: 371-5.
 33. Di Saia PJ, Rich WM. Surgical approach to multifocal carcinoma in situ of the vulva. Am J Obstet 
Gynecol 1981; 140: 136-45.
 34. Iversen T, Abeler V, Kolstad P. Squamous cell carcinoma in situ of the vulva. A clinical and histopatho-
logical study. Gynecol Oncol 1981; 11: 224-9.
 35. Kaplan AL, Kaufman RH, Birken RA, Simkin S. Intraepithelial carcinoma of the vulva with extension to 
the anal canal. Obstet Gynecol 1981; 58: 368-71.
 36. Benedet JL, Murphy KJ. Squamous carcinoma in situ of the vulva. Gynecol Oncol 1982; 14: 213-9.
 37. Caglar H, Tamer S, Hreshchyshyn MM. Vulvar intraepithelial neoplasia. Obstet Gynecol 1982; 60: 
346-9.
 38. di Paola GR, Rueda-Leverone NG, Belardi MG, Vighi S. Vulvar carcinoma in situ: a report of 28 cases. 
Gynecol Oncol 1982; 14: 236-42.
 39. Genton CY, Engeler V, Schreiner WE. Bowenoide papulose und morbus Bowen der vulva. Schweiz 
Med Wochenschr 1982; 112: 1664-9.
 40. Ulbright TM, Stehman FB, Roth LM, Ehrlich CE, Ransburg RC. Bowenoid dysplasia of the vulva. Cancer 
1982; 50: 2910-9.
 41. Bernstein SG, Kovacs BR, Townsend DE, Morrow CP. Vulvar carcinoma in situ. Obstet Gynecol 1983; 61: 
304-7.
 42. Ferenczy A. Using the laser to treat vulvar condylomata acuminata and intraepidermal neoplasia. Can 
Med Assoc J 1983; 128: 135-7.
 43. Friedman M, White RG, Moar JJ, Browde S. Progression of vulval carcinoma in situ. A case report. S Afr 
Med J 1983; 64: 748-9.
 44. Crum CP, Liskow A, Petras P, Keng WC, Frick HC. Vulvar intraepithelial neoplasia (severe atypia and 
carcinoma in situ). A clinicopathologic analysis of 41 cases. Cancer 1984; 54: 1429-34.
 45. Leuchter RS, Townsend DE, Hacker NF, Pretorius RG, Lagasse LD, Wade ME. Treatment of vulvar carci-
noma in situ with the CO2 laser. Gynecol Oncol 1984; 19: 314-22.
 46. Ostor AG, Sfameni SF, Kneale BL, Fortune DW. Progression of squamous carcinoma in situ of the vulva 
to invasive carcinoma after systemic bleomycin therapy. Aust N Z J Obstet Gynaecol 1984; 24: 55-8.
 47. Reynolds VH, Madden JJ, Franklin JD, Burnett LS, Jones HW III, Lynch JB. Preservation of anal function 
after total excision of the anal mucosa for Bowen’s disease. Ann Surg 1984; 199: 563-8.
 48. Schlaerth JB, Morrow CP, Nalick RH, Gaddis O Jr. Anal involvement by carcinoma in situ of the perineum 
in women. Obstet Gynecol 1984; 64: 406-11.
 49. Wolcott HD, Gallup DG. Wide local excision in the treatment of vulvar carcinoma in situ: a reappraisal. 
Am J Obstet Gynecol 1984; 150: 695-8.
 50. Andreasson B, Bock JE. Intraepithelial neoplasia in the vulvar region. Gynecol Oncol 1985; 21: 300-5.
 51. George M, Avril MF, Duvillard P, Michel G, Wolff JP. Epithélioma intraépithélial de la vulve. Etude de 19 
cas traités à l’institut Gustave-Roussy de 1970 à 1984. Gynecologie 1985; 36: 243-5.
 52. Roy M, Bellemare G, Ouellet S. Les lésions pré-cancéreuses de la vulve. Union Med Can 1985; 114: 
748-50.
 53. Caglar H, Delgado G, Hreshchyshyn MM. Partial and total skinning vulvectomy in treatment of carci-
noma in situ of the vulva. Obstet Gynecol 1986; 68: 504-7.
The natural history of VIN 33
 54. Eibach HW, Zippel HH. Klinische und pathomorphologische untersuchungen zur präkanzerösen 
bedeutung und prognostischen wertung epithelialer vulvaveränderungen. Geburtshilfe Frauen-
heilkd 1986; 46: 495-500.
 55. Halasz C, Silvers D, Crum CP. Bowenoid papulosis in three-year-old girl. J Am Acad Dermatol 1986; 14: 
326-30.
 56. Landthaler M, Haina D, Brunner R, Waidelich W, Braun-Falco O. Laser therapy of bowenoid papulosis 
and Bowen‘s disease. J Dermatol Surg Oncol 1986; 12: 1253-7.
 57. Powell LC Jr, Dinh TV, Rajaraman S, Hannigan EV, Dillard EA Jr, Yandell RB, et al. Carcinoma in situ of the 
vulva. A clinicopathologic study of 50 cases. J Reprod Med 1986; 31: 808-14.
 58. Bonnekoh B, Mahrle G, Steigleder GK. Ubergang in kutanes plattenepithelkarzinom bei zwei patienten 
mit bowenoider papulose (HPV-16). Z Hautkr 1987; 62: 773-4.
 59. Planner RS, Andersen HE, Hobbs JB, Williams RA, Fogarty LF, Hudson PJ. Multifocal invasive carcinoma 
of the vulva in a 25-year-old woman with bowenoid papulosis. Aust N Z J Obstet Gynaecol 1987; 27: 
291-5.
 60. Ragnarsson B, Raabe N, Willems J, Pettersson F. Carcinoma in situ of the vulva. Long term prognosis. 
Acta Oncol 1987; 26: 277-80.
 61. Rettenmaier MA, Berman ML, DiSaia PJ. Skinning vulvectomy for the treatment of multifocal vulvar 
intraepithelial neoplasia. Obstet Gynecol 1987; 69: 247-50.
 62. Wright VC, Davies E. Laser surgery for vulvar intraepithelial neoplasia: principles and results. Am J 
Obstet Gynecol 1987; 156: 374-8.
 63. Bornstein J, Kaufman RH. Combination of surgical excision and carbon dioxide laser vaporization for 
multifocal vulvar intraepithelial neoplasia. Am J Obstet Gynecol 1988; 158: 459-64.
 64. Chafe W, Richards A, Morgan L, Wilkinson E. Unrecognized invasive carcinoma in vulvar intraepithelial 
neoplasia (VIN). Gynecol Oncol 1988; 31: 154-65.
 65. Fiorica JV, Cavanagh D, Marsden DE, Shepherd JH, Ruffolo EH, Songster CL. Carcinoma in situ of the 
vulva: 24 years’ experience in southwest Florida. South Med J 1988; 81: 589-93.
 66. Fung-Kee-Funk M, Beresford JM, McLean D. Vulvar intraepithelial neoplasia: treatment and follow-up. 
Colposc Gynecol Surg 1988; 4: 223-8.
 67. Garsia S, Origoni M, Sideri M, Arnoletti E, Maggi R. Preneoplastic lesions of the vulva. Eur J Gynaecol 
Oncol 1988; 9: 342-5.
 68. Levavi H, Ziv E, Segal J, Tadir Y, Ovadia J. Carbon dioxide laser therapy for vulvar intraepithelial neopla-
sia. Colposc Gynecol Surg 1988; 4: 95-9.
 69. Basta A. Diagnostic and therapeutic procedures in the vulvar intraepithelial neoplasia (VIN) and early 
invasive cancer of the vulva. Eur J Gynaecol Oncol 1989; 10: 55-9.
 70. Husseinzadeh N, Newman NJ, Wesseler TA. Vulvar intraepithelial neoplasia: a clinicopathological 
study of carcinoma in situ of the vulva. Gynecol Oncol 1989; 33: 157-63.
 71. Shafi MI, Luesley DM, Byrne P, Samra JS, Redman CW, Jordan JA, et al. Vulval intraepithelial neoplasia-
-management and outcome. Br J Obstet Gynaecol 1989; 96: 1339-44.
 72. Simonsen EF. CO2 laser used for cancer in situ/Bowen’s disease (VIN) and lichen sclerosus in the vulvar 
region. Acta Obstet Gynecol Scand 1989; 68: 551-3.
 73. Barbero M, Micheletti L, Preti M, Cavanna L, Boselli F, Garuti G, et al. Vulvar intraepithelial neoplasia. A 
clinicopathologic study of 60 cases. J Reprod Med 1990; 35: 1023-8.
 74. Colov NP, Thranov I, Berget A. Treatment of vulvar intraepithelial neoplasia with the CO2 laser. Laser 
Med Sci 1990; 5: 61-4.
 75. Helmerhorst TJ, van der Vaart CH, Dijkhuizen GH, Calame JJ, Kenemans P, Stolk JG. CO2-laser therapy 
in patients with vulvar intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol 1990; 34: 149-55.
 76. Hoffman MS, Pinelli DM, Finan M, Roberts WS, Fiorica JV, Cavanagh D. Laser vaporization for vulvar 
intraepithelial neoplasia III. J Reprod Med 1992; 37: 135-7.
Ch
ap
te
r 2
34
 77. De Palo G, Stefanon B, Pilotti S, Zurrida S, Della Torre G, et al. High grade vulvar intraepithelial neo-
plasia. A clinical, pathological and molecular virologic study. The cervix and the lower female genital 
tract 1992; 10: 23-31.
 78. Barbero M, Micheletti L, Preti M, Valentino MC, Nicolaci P, Canni M, et al. Biologic behavior of vulvar 
intraepithelial neoplasia. Histologic and clinical parameters. J Reprod Med 1993; 38: 108-12.
 79. de Belilovsky C, Lessana-Leibowitch M. Maladie de Bowen et papulose bowénoïde: données cliniques 
virologiques et évolutives comparatives. Contracept Fertil Sex 1993; 21: 231-6.
 80. Genolet PM, Gyr Th, Bratschi HU, Gorgievski M, Altmann HJ, Dreher E. Vulväre intraepitheliale neo-
plasie grad III - therapie und verlauf. Arch Gynecol Obstet 1993; 254: 1022-4.
 81. Marren P, Dawber R, Wojnarowska F, Millard P, Charnock M. Failure of cryosurgery to eradicate vulval 
intraepithelial neoplasia: a pilot study. J Eur Acad Dermatol Venereol 1993; 2: 247-52.
 82. Ferenczy A, Wright TC, Richart RM. Comparison of CO2 laser surgery and loop electrosurgical excision/
fulguration procedure (LEEP) for the treatment of vulvar intraepithelial neoplasia (VIN). Int J Gynecol 
Cancer 1994; 4: 22-8.
 83. Chang DY, Wu MY, Huang SC. Bowen’s disease and Bowenoid papulosis of the vulva. Int J Gynaecol 
Obstet 1995; 48: 227-9.
 84. Doberauer C, Voigtmann R. Bowenoide papulose, morbus Bowen und plattenepithelkarzinom von 
anus und vulva bei kongenitaler intestinaler lymphangiektasie. Dtsch Med Wochenschr 1995; 120: 
130-3.
 85. Hording U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of unde-
termined progressive potential. Gynecol Oncol 1995; 56: 276-9.
 86. Sadler LC, Jones RW. The progression of noncontiguous intra-epithelial neoplasia in the lower urinary 
and genital tracts to invasive carcinoma. Br J Obstet Gynaecol 1995; 102: 162.
 87. Tan AL, Jones RW, White JE. Progression of vulvar intraepithelial neoplasia III to invasive carcinoma in 
a young woman. J Obstet Gynaecol 1995; 21: 467-9.
 88. Herod JJ, Shafi MI, Rollason TP, Jordan JA, Luesley DM. Vulvar intraepithelial neoplasia: long term 
follow up of treated and untreated women. Br J Obstet Gynaecol 1996; 103: 446-52.
 89. Thomas SS, Chenoy R, Fielding JW, Rollason TP, Jordan JA, Bracka A. Vulvoperineal reconstruction after 
excision of anogenital multifocal intraepithelial neoplasia (“MIN”). Br J Plast Surg 1996; 49: 539-46.
 90. Wright TC, Koulos JP, Liu P, Sun XW. Invasive vulvar carcinoma in two women infected with human 
immunodeficiency virus. Gynecol Oncol 1996; 60: 500-3.
 91. Kuppers V, Stiller M, Somville T, Bender HG. Risk factors for recurrent VIN. Role of multifocality and 
grade of disease. J Reprod Med 1997; 42: 140-4.
 92. Junge J, Poulsen H, Horn T, Hording U, Lundvall F. Prognosis of vulvar dysplasia and carcinoma in 
situ with special reference to histology and types of human papillomavirus (HPV). APMIS 1997; 105: 
963-71.
 93. Ayhan A, Tuncer ZS, Dogan L, Yuce K, Kucukali T. Skinning vulvectomy for the treatment of vulvar 
intraepithelial neoplasia 2-3: a study of 21 cases. Eur J Gynaecol Oncol 1998; 19: 508-10.
 94. Modesitt SC, Waters AB, Walton L, Fowler WC Jr, van Le L. Vulvar intraepithelial neoplasia III: occult 
cancer and the impact of margin status on recurrence. Obstet Gynecol 1998; 92: 962-6.
 95. Husseinzadeh N, Recinto C. Frequency of invasive cancer in surgically excised vulvar lesions with 
intraepithelial neoplasia (VIN 3). Gynecol Oncol 1999; 73: 119-20.
 96. Jones RW, Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2-3. Obstet Gynecol 
2000; 96: 470-2.
 97. McNally OM, Mulvany NJ, Pagano R, Quinn MA, Rome RM. VIN 3: a clinicopathologic review. Int J 
Gynecol Cancer 2002; 12: 490-5.
 98. Penna C, Fallani MG, Fambrini M, Zipoli E, Marchionni M. CO2 laser surgery for vulvar intraepithelial 
neoplasia. Excisional, destructive and combined techniques. J Reprod Med 2002; 47: 913-8.
The natural history of VIN 35
 99. Sykes P, Smith N, McCormick P, Frizelle FA. High-grade vulval intraepithelial neoplasia (VIN 3): a retro-
spective analysis of patient characteristics, management, outcome and relationship to squamous cell 
carcinoma of the vulva 1989-1999. Aust N Z J Obstet Gynaecol 2002; 42: 69-74.
 100. Rodolakis A, Diakomanolis E, Vlachos G, Iconomou T, Protopappas A, Stefanidis C, et al. Vulvar 
intraepithelial neoplasia (VIN)--diagnostic and therapeutic challenges. Eur J Gynaecol Oncol 2003; 24: 
317-22.
 101. Sturgeon SR, Brinton LA, Devesa SS, Kurman RJ. In situ and invasive vulvar cancer incidence trends 
(1973 to 1987). Am J Obstet Gynecol 1992; 166: 1482-5.
 102. Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinomas of the vulva. Distinctive types of 
squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol 
1993; 17: 133-45.
 103. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of 
vulvar intraepithelial neoplasia. Obstet Gynecol 1997; 90: 448-52.
 104. Buscema J, Stern J, Woodruff JD. The significance of the histologic alterations adjacent to invasive 
vulvar carcinoma. Am J Obstet Gynecol 1980; 137: 902-9.
 105. Zaino RJ, Husseinzadeh N, Nahhas W, Mortel R. Epithelial alterations in proximity to invasive squamous 
carcinoma of the vulva. Int J Gynecol Pathol 1982; 1: 173-84.
 106. Borgno G, Micheletti L, Barbero M, Preti M, Cavanna L, Ghiringhello B. Epithelial alterations adjacent 
to 111 vulvar carcinomas. J Reprod Med 1988; 33: 500-2.
 107. Leibowitch M, Neill S, Pelisse M, Moyal-Baracco M. The epithelial changes associated with squamous 
cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women. Br J 
Obstet Gynaecol 1990; 97: 1135-9.
 108. Gomez Rueda N, Garcia A, Vighi S, Belardi MG, Cardinal L, di Paola G. Epithelial alterations adjacent to 
invasive squamous carcinoma of the vulva. J Reprod Med 1994; 39: 526-30.
 109. Kagie MJ, Kenter GG, Hermans J, Trimbos JB, Fleuren GJ. The relevance of various vulvar epithelial 
changes in the early detection of squamous cell carcinoma of the vulva. Int J Gynecol Cancer 1997; 7: 
50-7.
 110. Fu YS, Reagan JW. Benign and malignant epithelial tumors of the vulva. In: Pathology of the uterine 
cervix, vagina and vulva. Philadelphia, PA: Saunders; 1989. p. 138-92.
 111. Andreasson B, Moth I, Jensen SB, Bock JE. Sexual function and somatopsychic reactions in vulvectomy-
operated women and their partners. Acta Obstet Gynecol Scand 1986; 65: 7-10.
 112. Thuesen B, Andreasson B, Bock JE. Sexual function and somatopsychic reactions after local excision 
of vulvar intra-epithelial neoplasia. Acta Obstet Gynecol Scand 1992; 71: 126-8.

3 In the absence of (early) invasive 
carcinoma, vulvar intraepithelial 
neoplasia associated with 
lichen sclerosus is mainly of 
undifferentiated type: new 
insights in histology and aetiology
Manon van Seters
Fiebo JW ten Kate
Marc van Beurden
René HM Verheijen
Chris JLM Meijer
Matthé PM Burger
Theo JM Helmerhorst
J Clin Pathol 2007; 60: 504-9
Ch
ap
te
r 3
38
Abstract
Background Differentiated vulvar intraepithelial neoplasia (VIN) is presumed to be the 
precursor of invasive squamous cell carcinoma (SCC) of the vulva. It is commonly assumed 
that differentiated VIN is related to lichen sclerosus (LS). However, evidence for this is lim-
ited to a small number of studies describing epithelial alterations adjacent to vulvar SCC.
Aim To study the histology and human papillomavirus (HPV) status in patients with a his-
tory of both LS and VIN without coexistent SCC.
Methods Original biopsy specimens and surgical specimens of patients retrieved from the 
pathology files were revised for the presence of LS, VIN and (early) invasive SCC, specifically 
focused on the two different types of VIN: differentiated and undifferentiated. Thereafter, 
VIN lesions were tested for the presence of HPV DNA.
Results Twenty-seven patients fulfilled the criteria for LS and VIN without SCC. In all 27 
patients, LS was found to be related to undifferentiated VIN. Grading yielded the follow-
ing results: VIN 1 (n=10), VIN 2 (n=11) and VIN 3 (n=6). Additionally, VIN lesions from 26 
patients could be tested for the presence of HPV DNA. HPV DNA, predominantly type 16, 
was present in eight (31%) of them. Seven of these eight patients had VIN 2 or 3. During 
follow-up, three patients progressed to (early) invasive carcinoma. In two of these patients, 
differentiated VIN was observed overlying early invasive SCC.
Conclusions VIN related to LS without coexisting SCC is likely to be undifferentiated, 
in contrast to what was previously thought. HPV DNA was demonstrated in 31% of the 
lesions, and was strongly related to high grade VIN.
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Introduction
Invasive squamous cell carcinoma (SCC) of the vulva often arises in association with other 
vulvar abnormalities.1-9 These abnormalities usually fall into two main categories, which 
can be considered as the main precursor states for invasive carcinoma of the vulva: vulvar 
intraepithelial neoplasia (VIN) and lichen sclerosus (LS).
According to the International Society for the Study of Vulvovaginal Diseases (ISSVD) 
and the International Society for Gynecological Pathologists (ISGYP), LS is a non-neoplastic 
disorder of the vulvar skin and mucosa.10 Although the presence of LS in the adjacent skin 
of vulvar SCC is suggestive of a premalignant disease, longitudinal studies report only a 
slight tendency for LS to evolve into SCC (1-5%).11-14
VIN, on the other hand, is considered a pre-neoplastic disorder of the vulvar skin,15 
although progression to invasive carcinoma remains uncertain. Data on the follow-up 
of untreated VIN 3 are scarce, and the natural history is mainly based on follow-up after 
surgery. In the only systematic review on treatment of VIN, with data on 3322 patients, 
progression to invasive carcinoma was seen in 9% of the untreated patients and in 3% of 
patients after treatment.16 VIN can be classified into undifferentiated (classic or bowenoid) 
and differentiated (simplex) VIN.17 Undifferentiated VIN is associated with human papil-
lomavirus (HPV), occurs predominantly in younger patients, and tends to be a multifocal 
and multicentric disease, whereas differentiated VIN is not related to HPV, is usually found 
in older women, and is commonly unifocal and unicentric. Differentiated VIN is rather 
uncommon. It is supposed to be associated with LS,17,18 although evidence for this is 
limited to a small number of studies describing epithelial alterations adjacent to vulvar 
SCC.4,7,19,20 Since differentiated VIN is often observed adjacent to or overlying superficially 
invasive SCC, it is presumed to be the precursor of most invasive SCCs of the vulva.18
Only four studies reported on the coexistence of LS and VIN, either differentiated or 
undifferentiated, without SCC.19-22 A major disadvantage of all the four studies is that 
the coexistence of LS and VIN was not the main research question, but was a coincident 
finding. In a series of 86 patients with LS, differentiated VIN was observed twice, as was 
undifferentiated VIN.20 Three other studies describing the histological features of VIN men-
tioned the presence of LS in 41 of 437 (9%) cases.19,21,22 HPV DNA testing was performed 
in only one of them.19 Since these three studies involved hardly any differentiated VIN, no 
conclusions can be drawn regarding the type of VIN and its relationship to LS.
As the relationship between differentiated or undifferentiated VIN and LS was never 
deliberately investigated, and since the role of HPV is not yet clarified, we studied the 
histology and HPV status in a large group of patients with a history of both LS and VIN 
without SCC.
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Material and Methods
Patients
All cases with both histologically diagnosed LS and VIN were retrieved from the pathol-
ogy files (1984–2004) of the Academic Medical Centre, the VU University Medical Centre 
and the Netherlands Cancer Institute in Amsterdam, and the Erasmus University Medical 
Centre in Rotterdam, The Netherlands. Firstly, a computer search for lichen sclerosus or 
sclerosis (et atrophicus) was performed (1807 specimens). Secondly, cases of women with 
anogenital LS were extracted from the list (1207 vulvar specimens). Thirdly, the pathology 
files of these patients with anogenital LS were searched for VIN without the initial presence 
of coexistent SCC (46 patients, 137 specimens).
Histology
Slides from the original biopsies as well as those from all subsequent surgical specimens 
of these 46 patients were collected and revised by an experienced pathologist (FJWtK) for 
the presence of LS, VIN and (early) invasive SCC.
The diagnosis of LS was based on the presence of dermal hyalinisation, vacuolar 
alterations of the dermal-epidermal junction and a variable dense lymphocyte infiltrate, 
whether or not accompanied by epidermal atrophy, progressive loss of rete ridges, hyper-
plasia and/or acanthosis.23 VIN terminology was used according to the classification of 
the ISSVD.15 We specifically looked for the two different types of VIN: undifferentiated and 
differentiated. Undifferentiated VIN is characterized by disorientation and loss of squamous 
epithelial architecture and maturation, together with a variable degree of cellular atypia. 
Depending on the level of cellular disarray, undifferentiated VIN was graded into VIN 1, 
2 or 3. Subsequently, all revised VIN 1 cases were stained with MIB 1, a cell proliferation 
marker. Differentiated VIN, on the other hand, shows little or no atypia above the basal 
or parabasal layers, and is therefore a far more subtle lesion than undifferentiated VIN. 
Enlarged pre mature ly differentiated keratinocytes with prominent eosinophilic cytoplasm 
and abnormal nuclei are found deep within the epidermis, frequently near the tips of 
elongated and branching rete ridges. Deeply located squamous whorls with or without 
keratin pearls are sometimes seen.15,17,24,25 Differentiated VIN should be regarded as VIN 3, 
owing to its supposed invasive potential.15,24
Depth of invasion, if present during follow-up, is described as early invasive or invasive 
carcinoma.
Human papillomavirus testing
All confirmed dysplastic lesions were tested for the presence of HPV. To this end, we 
extracted cellular DNA from corresponding formalin-fixed, paraffin-wax-embedded tissue. 
Testing for HPV was conducted by using a standard GP5+/6+ PCR enzyme immunoassay, 
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followed by reverse line blot analysis.26 This test is clinically validated.27 We used one assay 
for the 14 most prevalent high-risk types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66 and 68), and another for 22 low-risk HPVs (6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 
61, 70, 71, 72, 73, 81, 82 [both subtypes MM4 and IS39], 83, 84, and CP6108). In addition, 
PCR amplification products were analysed for individual types of HPV (reverse line blot). 
A β-globin test was performed as a control for the presence and quality of DNA in the 
paraffin-wax-embedded tissue.
Results
Patients
In 31 of the 46 patients who met our computer search criteria, the diagnosis of both LS and 
VIN could be confirmed after histological revision. Fifteen patients did not fulfil the criteria 
for VIN (n=11), LS (n=2), or both VIN and LS (n=2). Four more patients presented with lesions 
suspected to be malignant at first onset of either LS or VIN, and were therefore excluded. 
Twenty-seven patients (82 vulvar specimens) remained for evaluation of histology and HPV 
status. Their mean (range) age at first histological diagnosis was 64 (38-87) years.
Histology
In these 27 patients with both LS and VIN, VIN lesions were all classified as undifferentiated 
(100%). This was further graded into VIN 1 (n=10), VIN 2 (n=11) and VIN 3 (n=6) (Table 1).
To conform the diagnosis, MIB staining in VIN 1 showed increased mitotic activity in 
all cases. A warty histological pattern was seen in 24 (89%) lesions; basaloid-type VIN was 
Table 1. Human papillomavirus DNA in 27 patients with lichen sclerosus and vulvar intraepithelial neoplasia 
without vulvar squamous cell carcinoma
HPV-DNA
VIN
1 2 3 total
HPV-positive 1* 4† 3‡ 8
HPV-negative 8 7¶ 3∫ 18
unknown 1§ - - 1
HPV, human papillomavirus;
*HPV16;
†HPV16 (n=3) and HPV59 (n=1);
‡HPV16 (n=3), one of these patients developed squamous cell carcinoma (SCC) surrounded by HPV-positive 
undifferentiated vulvar intraepithelial neoplasia (VIN) after 4 years;
¶One of these patients developed early invasive SCC surrounded by differentiated VIN not related to HPV 
after 4 years;
∫One of these patients developed early invasive SCC surrounded by differentiated VIN not related to HPV 
after 1 year;
§No material available.
Ch
ap
te
r 3
42
found in one (4%) lesion, and in two (7%) VIN 1 lesions it was not possible to distinguish 
warty and basaloid VIN. We diagnosed LS and VIN at the same time in the same lesion in 13 
patients (Figure 1, patient 1-3), mostly contiguous, and at the same time but in a different 
lesion in three more patients (Figure 2, patient 4). In the other 11 cases, a period of 1-9 
years was observed between first diagnosis of the two skin disorders (Figure 2, patients 5 
and 6). VIN arose in pre-existent LS in nine of 11 (82%) cases, whereas LS was diagnosed in 
pre-existent VIN twice.
Three patients developed (early) invasive SCC 1-4 years after the initial diagnosis of 
undifferentiated high grade VIN in pre-existing LS. In one case the epithelium adjacent to 
invasive SCC showed undifferentiated VIN 3, whereas in the other two cases differentiated 
VIN was found in the epithelium surrounding early invasive SCC (Figure 3, patient 7).
Chapter 3 
 
Figure 1. 
 
 
 
 
 
 
Figure 1. Patient 1: (A) vulvar biopsy with both condylomatous dysplasia and classic lichen sclerosus (LS; H&E, 
x20); (B) in more detail, verricuform dysplastic changes that tested positive for human papillomavirus (HPV)‑
59 DNA, showing mild‑to‑moderate disturbance of the epithelial architecture with acanthosis and koilocytosis, 
conform vulvar intraepithelial neoplasia (VIN) 2 (H&E, x100); (C) classic LS in more detail, showing oedema and 
hyalinisation of the dermis, vacuolisation of the dermal‑epidermal junction, and hyperkeratosis, with normal 
architecture of the squamous epithelium (H&E, x100). Patient 2: (D) local excision of the vulva in a patient 
with a diagnosis of VIN 3, showing undifferentiated HPV16‑positive VIN in the background of LS (H&E, x80); 
(E) a higher magnification of (D), showing the transition of normal to dysplastic epithelium (H&E, x200); (F) 
histological findings of LS in the same tissue with hyperkeratosis, thinning of the epidermis, and oedema with 
homogenisation of the dermal stroma (H&E, x125). Patient 3: (G) coexistence of LS and undifferentiated VIN 2 in 
the vulva (H&E, x200); (H) a higher magnification of (G), illustrating dysplastic changes that tested negative for 
HPV DNA (H&E, x400). See also Color Figures, page 145.
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Human papillomavirus testing
Paraffin-wax-embedded tissue for HPV testing was available in 26 patients. HPV DNA 
was detected in eight of 26 (31%) tissue samples, whereas 18 lesions were found to be 
negative. Seven lesions contained HPV-16 DNA, and one contained HPV-59. There was a 
strong correlation between HPV-positive lesions and high grade VIN. Whereas almost all 
VIN 1 lesions were HPV negative (89%), a considerable number of VIN 2 and 3 lesions were 
Figure 2. 
 
 
Figure 2. Patient 4: (A) lichen sclerosus (LS) showing a broad band of hyalinisation underlying an atrophic 
epidermis with loss of rete ridges (H&E, x50); (B) undifferentiated human papillomavirus (HPV) 16‑positive vulvar 
intraepithelial neoplasia (VIN) 3 biopsied at the same time in the same patient, but in a different lesion (H&E, 
x100). Patient 5: (C) LS with normal epidermal maturation (H&E, x100); (D) undifferentiated HPV‑negative VIN 
3 in the same patient, which was diagnosed 6 years after the diagnosis of LS (H&E, x64). Patient 6: (E) classic 
LS showing extensive dermal hyalinisation with vacuolisation of the dermal‑epidermal junction (H&E, x64); (F) 
undifferentiated HPV‑negative VIN 1, with focal VIN 2 diagnosed 2 years after the diagnosis of LS (H&E, x160). See 
also Color Figures, page 146.
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positive for HPV (41%). One of these patients with high grade HPV-related VIN developed 
SCC after four years, the epithelium being surrounded by HPV-positive undifferentiated 
VIN. The other two patients with progressive disease developed SCC with differentiated 
VIN not related to HPV in the adjacent skin (Table 1).
Discussion
This is the first study describing the histology and HPV status of a large series of patients 
with both LS and VIN without coexistent SCC. In this study, VIN associated with LS was 
always of undifferentiated type. HPV DNA was detected in eight of 26 (31%) patients, 
seven of whom had high grade VIN.
It is commonly thought that there is a relationship between differentiated VIN and LS.17,18 
There are, however, only few data available on this subject, and almost all these concern 
Figure 3. 
 
Figure 3. Patient 7: (A) lichen sclerosus (LS; H&E, x50); (B) undifferentiated vulvar intraepithelial neoplasia (VIN) 3 
not related to human papillomavirus (HPV), which was diagnosed 9 years after the diagnosis of LS (H&E, x60); (C) 
one year later, this patient developed a lesion suspicious for squamous cell carcinoma, which was surrounded by 
HPV‑negative differentiated VIN (H&E, x50). Little or no atypia is shown above the (para‑) basal layer; (D) pearl‑
like changes can be distinguished (H&E, x250). See also Color Figures, page 147.
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the adjacent skin of vulvar SCC (Table 2).4,5,7,9,19,20,22,28,29 In 153 of 467 (33%) patients whose 
skin lesions in the surrounding tissue of vulvar SCC were analysed, the existence of both 
VIN and LS has been observed (range 5-58%). Predominantly, this VIN was of differentiated 
type (74%). Sporadically, the coexistence of VIN and LS has been described in vulvar skin 
without invasive carcinoma (Table 3).19-22 Since these studies were on either LS or VIN, 
mostly of undifferentiated type, selection bias might have affected the results.
To date, the presence of HPV DNA in VIN related to LS has been described only once.19 
Haefner et al reported on three patients with HPV-negative differentiated VIN, all in the 
adjacent skin of vulvar SCC, and on three patients with HPV-positive undifferentiated VIN 
3, in one of whom VIN was adjacent to SCC and in the other two it was not. The detection 
of HPV DNA in 41% of our high grade VIN lesions supports the diagnosis of undifferenti-
ated VIN, although, compared with the prevalence of HPV DNA in VIN not related to LS 
(78-92%), this percentage is rather low.19,30-32 This lack of similarity between undifferenti-
Table 2. Histological findings of vulvar intraepithelial neoplasia and/or lichen sclerosus in the adjacent skin of 
vulvar squamous cell carcinoma
Study population N
skin adjacent to SCC
uVIN 
only
dVIN 
only
LS only both VIN and LS Other*
uVIN 
(%)
dVIN 
(%)
Leibowitch et al4
BJOG, 1990
SCC 78 24† - 20‡ - 28 (36) 6
Gómez Rueda et al5
J Reprod Med, 1994
SCC 64 5 - 18 11 (17) 3 (5) 27
Haefner et al19
Hum Pathol, 1995
SCC + VIN 15 8 3 - 1§ (7) 3¶ (20) -
Scurry et al20
Int J Gynecol Cancer, 1997
SCC 132 31 18 29 1 (1) 33 (25) 20
Carlson et al28
Hum Pathol, 1998
SCC 60 16 - 14 19 (32) 6 (10) 5
Vilmer et al7
Eur J Gynaecol Oncol, 1998
SCC 67 13 - 12 - 39 (58) 3
Carlson et al22
Am J Pathol, 2000
SCC 16 1 - 13 1 (6) - 1
Derrick et al29
Br J Dermatol, 2000
SCC 21 3 - 13 - 1 (5) 4
Poulsen et al9
APMIS, 2003
SCC 14 7 - - 7 (50) - -
Total 467 40 (9) 113 (24)
dVIN, differentiated VIN; LS, lichen sclerosus; SCC, squamous cell carcinoma; uVIN, undifferentiated VIN; VIN, 
vulvar intraepithelial neoplasia;
*Normal (n=22), squamous cell hyperplasia (n=31), lichen simplex chronicus (n=5), granulomatous vulvitis 
(n=1), lichen planus (n=4), or not associated with LS or VIN (n=3); †7/11 samples tested were HPV-positive by 
in situ hybridisation (ISH): HPV16 (n=6), HPV31 (n=1); ‡No samples tested were HPV-positive (ISH); §HPV16 
DNA positive (PCR and ISH); ¶3 of 3 samples tested were HPV DNA negative (PCR).
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ated VIN with and without associated LS might point to a different pathogenesis, at least 
in half of the cases.
It is known that there are some difficulties in the histological diagnosis of VIN. Firstly, it 
can be very difficult to distinguish VIN 1 from atypical inflammatory reactive changes or 
(damaged) normal skin, resulting in a high inter-observer variability.33-35 In our study, we 
excluded 10 of 46 patients, in whom low grade VIN diagnosed in the original histology 
report was not confirmed at revision following the definition given by the ISSVD.15 The 
high prevalence of VIN 1 lesions that tested negative for HPV after revision (89%) gives 
the impression that we still overdiagnosed VIN. However, MIB 1 staining, which has been 
suggested to be useful in accurate grading of VIN,35 supported the diagnosis of VIN 1 in 
all cases. Today, this VIN 1-3 classification is the subject of discussion, and a new classifica-
tion in which the term VIN 1 will no longer be used has been proposed by the ISSVD. 
Similarly, Medeiros et al recently recommended a distinction between low grade VIN (VIN 
1) and high grade VIN (VIN 2 or 3 and differentiated VIN) to identify those lesions at risk 
for vulvar carcinoma.36 In our study, such a new classification would affect the number of 
patients considerably, causing a significant increase in the number of HPV-related high 
grade VIN associated with LS (43%). Secondly, the presence of differentiated VIN has to 
be considered when there seems to be only a slight degree of squamous atypia or it is 
limited to the lower epidermis. Because of its highly differentiated features and absence 
of widespread architectural disarray, the diagnosis can be easily missed. We specifically 
looked into the subtle but characteristic features of differentiated VIN, as described in 
Material and Methods. However, we did not observe any of these features, except during 
follow-up, surrounding early invasive SCC. Furthermore, it may be difficult to agree upon 
Table 3. Coexistence of both vulvar intraepithelial neoplasia and lichen sclerosus without vulvar squamous cell 
carcinoma
Study population N
both VIN and LS
uVIN dVIN uVIN /dVIN
Haefner et al19
Hum Pathol, 1995
VIN* 50 2† - -
Italian Study Group21
J Reprod Med, 1996
VIN‡ 370 36 - -
Carlson et al22
Am J Pathol, 2000
VIN§ 17
-
2 1
437 38 2 1
Scurry et al20
Int J Gynecol Cancer, 1997
LS 86 2 2 -
dVIN, differentiated VIN; LS, lichen sclerosus; SCC, squamous cell carcinoma; uVIN, undifferentiated VIN; VIN, 
vulvar intraepithelial neoplasia;
*48 uVIN 3, 2 dVIN;
†Both human papillomavirus 16 DNA positive (PCR and in situ hybridization);
‡370 uVIN: VIN 1 (n=148), VIN 2 (n=53), VIN 3 (n=169);
§14 uVIN 3, 3 dVIN.
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whether early invasive growth has already occurred in differentiated VIN.25 Conversely, 
differentiated VIN is easily diagnosed when there is an invasive SCC. The fact that none of 
our revised VIN 1 cases progressed to invasion strengthens our claim of not having missed 
any differentiated VIN.
As we studied only those cases with both LS and VIN from the start, a selection bias 
might have been caused by the design of our study. Revising all LS cases over several years 
could result in a higher prevalence of LS with coexisting VIN, and therefore possibly in a 
higher number of differentiated VIN. Revising all VIN cases, on the other hand, might result 
in a higher number of coexistent diseases as well, with VIN most likely to be of undifferenti-
ated type.
In conclusion, it seems from an overview of the literature that the assumed relation 
between differentiated VIN and LS can be supported in the case of coexistent vulvar 
SCC,4,7,19,20,29 but has been described in only five patients without SCC.20,22 In this study, 
we found that VIN related to LS without SCC was always of the undifferentiated type. These 
data suggest that VIN in the background of LS without SCC is a different type of VIN than 
that was thought previously, with a different aetiology and perhaps a different prognosis. 
In that case, we might question ourselves whether or not we tend to overtreat patients if 
we radically excise VIN in the background of LS. In our opinion, treatment of VIN associated 
with LS should be individualised, based on type and localization of the lesion, in order to 
achieve a better conservation of the anatomy and function of the vulva.
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Abstract
Objective To investigate the efficacy of topical treatment with imiquimod 5% cream, an 
immune response modifier, in patients with vulvar intraepithelial neoplasia (VIN) 2/3.
Study design Fifteen women (aged 35-51) with histologically proven multifocal VIN 2/3 
without invasion, were entered into a prospective, observational, pilot study. Imiquimod 
5% cream was applied by the patient to the vulvar lesions one to three times a week at 
night. Clinical response was analyzed by macroscopic examination and categorized as 
complete (CR) or partial (PR).
Results Four patients achieved CR (27%) and nine patients PR (60%) after 6-34 weeks of 
treatment. Two patients discontinued medication. CR was reached after 6, 7, 11 and 30 
weeks of treatment.
Conclusion This pilot study showed the potential beneficial effect of imiquimod 5% cream 
in multifocal VIN 2/3. In contrast to current surgical treatment, imiquimod focuses on the 
cause of VIN and preserves the anatomy and function of the vulva. Therefore, imiquimod 
may prove to be the treatment of choice in multifocal, high grade VIN.
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Introduction
The incidence of vulvar intraepithelial neoplasia (VIN) 2/3 has increased in recent decades,1,2 
and patients are affected at younger ages than before.3 The disease is often multifocal on 
the vulva,4 and neoplastic changes can be found in a high proportion on the cervix and 
less frequently in the vagina.5 High grade VIN is a skin disease causing many severe and 
long-lasting symptoms, such as pruritus, vulvar pain and sexual dysfunction.6,7
Human papillomavirus (HPV) plays a key role in the etiology of VIN. The prevalence of 
HPV DNA in VIN 3 has been studied by several groups using polymerase chain reaction. 
All of them showed the same high prevalence of HPV-16 DNA (around 90%).8-12 Moreover, 
HPV RNA E6/E7 transcripts could be detected in almost 100% of the HPV-16 DNA-positive 
VIN lesions that were tested.8,13,14 That underlines the oncogenic activity of HPV-16 in 
these lesions.
Management of patients with VIN remains a challenge for the gynecologist. Although 
extensive surgery, such as vulvectomy, has been abandoned, standard therapy still 
comprises radical removal of all visible lesions to prevent invasive disease.15 However, 
surgical margins are often positive, irrespective of the type of operation performed.3,16-19 
This means that recurrences of VIN are still common, even after these extensive surgical 
procedures.3,7,17,20 Moreover, a surgical approach often results in mutilation of the vulva 
and consequently leads to major psychosexual distress.21,22
As imiquimod 5% cream, an immune response modifier with indirect antiviral and 
antitumor properties, has been shown to be effective and safe in the treatment of HPV-
associated external genital warts (EGWs),23,24 it was hypothesized that this topical treat-
ment may also be effective in stimulating cell-mediated immunity against cells infected 
with different HPV types and thus induce regression of dysplastic vulvar lesions.
The objective of this pilot study was to evaluate the effect of imiquimod 5% cream on 
VIN 2/3 lesions and related symptoms.
Material and Methods
Fifteen women with histologically proven multifocal VIN 2/3 without invasion, were 
entered into a prospective, observational, pilot study at the Academic Medical Center 
in Amsterdam, The Netherlands. Unifocal VIN 3 lesions were excluded from the study. 
For each patient the following items were recorded: age; previous surgical treatment; 
presence of symptoms; coexisting genital tract neoplasia (cervix, vagina, perianal region); 
use of immunosuppressives; history of smoking; frequency, length and discontinuation of 
treatment; response of lesions and symptoms to treatment; and side effects.
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Imiquimod 5% cream (3M Medica, Borken, Germany) was applied by the patient to the 
vulvar lesions restricted to one side one to three times a week at night, depending on 
the side effects. Sulfur precipitate was applied the day after application of imiquimod to 
reduce the chance of a secondary bacterial infection. In the event of severe side effects, 
the medication was to be discontinued indefinitely.
At each visit a history was taken to evaluate the effect on the symptoms. Clinical response 
was analyzed by macroscopic examination with photodocumentation and categorized as 
complete response (CR) when all visible lesions had disappeared and partial response (PR) 
when more than 25% regression of the original VIN lesion had been reached.
Results
The mean age of our study population was 42.7 years (range, 35-51). Eleven of the 15 
patients had been treated previously with surgical procedures (local excision, laser 
evaporation, partial vulvectomy), and four had never been treated before. Most of the 
women were experiencing vulvar pain and pruritus at baseline; two were without vulvar 
complaints. Nine women had a prior history of cervical intraepithelial neoplasia. Two of 
them had concomitant anal intraepithelial neoplasia. One patient had a history of previous 
severe immunosuppression: she had achieved complete remission of chronic, recurrent, 
low grade non-Hodgkin’s lymphoma after allogen stem cell transplantation and total body 
irradiation in November 1998. Tobacco was used by 12 women in our study population; 
most (67%) smoked ≥20 cigarettes per day.
The frequency of study drug application varied from one to three times a week, accord-
ing to clinical response and side effects. Most of the patients tolerated treatment well at 
a frequency of two times a week. If treatment produced severe side effects, a drug-free 
period was allowed. Eight patients were able to continue therapy without any rest periods; 
six patients stopped treatment for a variable period (one to eight weeks), after which they 
continued treatment with imiquimod. One patient discontinued treatment after four 
weeks.
After a treatment period ranging from 6 to 34 weeks, CR was achieved in four patients 
(27%) and PR achieved in nine patients (60%). Eleven of these 13 (85%) patients noted 
a significant reduction of symptoms. Two patients discontinued therapy; one was the 
patient with the history of non-Hodgkin’s lymphoma, and she stopped after 11 weeks of 
treatment as she did not respond to the therapy and had severe side effects. The other 
patient stopped after four weeks of treatment because of side effects. CRs were reached 
after 6, 7, 11 and 30 weeks of treatment (Figures 1A-C). Two of the patients (one CR and 
one PR) showed regression of the lesions on the side where no imiquimod was applied. No 
correlation was found between response and smoking behavior.
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Discussion
Until now, the premalignant character of high grade VIN has dominated the choice of 
therapy, leading to extensive surgery.15 Although surgical margins are often positive3,16-19 
and high recurrence rates of VIN 2/3 are common,3,7,17,20 irrespective of the type of opera-
tion performed, local excision, laser vaporization and skinning vulvectomy are still the 
standard treatments used today.15 Therefore, the malignant potential of untreated VIN 3 
has seldom been described and is unclear. In the only available systematic review in the 
literature, with data on 2,864 patients, 8 of the 88 (9%) untreated patients showed progres-
sion to invasive carcinoma. In treated patients this was the case in only 2-3%.25
HPV-16 is the cause of VIN 3.8-14 Therefore, research on the potential benefit of anti-
viral and immune-stimulating medication has emerged. Imiquimod 5% cream is such an 
immune response modifier and has been shown to be safe and efficacious in the treatment 
of EGWs caused by HPV.23,24 The activity of imiquimod is mediated through stimulation 
of cells involved in the innate immune response, such as monocytes, macrophages and 
dendritic cells. These immune cells secrete a number of cytokines (IFN-α, TNF-α, IL-12) and 
chemokines (IL-6, IL-8 and IL-10). Some of the cytokines induced by imiquimod, including 
IFN-α and IL-12, can also enhance acquired immune responses, in particular by stimulat-
ing T-helper cells type 1 and other cell-mediated immune responses that are important 
in the control of viruses, tumors and intracellular pathogens.24 The clinical response is 
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Figure 1.  A, VIN 3 lesion of the clitoris in a 42‑year‑old woman who was diagnosed with VIN in 1996. She had 
been treated previously with local excision with the exception of the clitoral lesion. In January 2000 the patient 
started treatment with imiquimod as the clitoral lesion was still present and pruritus worsened. B, Same patient 
as in Figure 1A. The patient started treatment three times a week. After five weeks of treatment, vulvoscopic 
examination showed a clear response. However, side effects, such as a burning sensation, pruritus and vulvar 
irritation, were noted. Treatment was continued with a frequency of once a week. C, Same patient as in Figures 
1A and B. After 17 weeks of treatment the clitoral lesion has completely disappeared, and the patient did not 
have any more symptoms. One year after she finished treatment, the patient still had a complete response.
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accompanied by a decrease in the amount of HPV DNA and of mRNA for HPV proteins L1 
and E7.26 Therefore, it is hypothesized that this topical treatment may also be effective in 
stimulating cell-mediated immunity against different HPV types and thus inducing regres-
sion of dysplastic vulvar lesions.
Davis et al published the first results of imiquimod treatment in VIN 3.27 In four cases 
imiquimod cream was applied three times a week for a maximum treatment period of 16 
weeks. Treatment resulted in complete clearing of all lesions, and post treatment biopsies 
were negative. One patient developed a recurrence one year after treatment. In our pilot 
study, 15 patients with histologically proven multifocal VIN 2/3 without invasion were 
included. Of these 15 women, 13 (87%) achieved CR or PR (four CR, nine PR) after various 
treatment times (6-34 weeks). Eleven of the 13 (85%) patients with CR or PR noted a reduc-
tion in symptoms. One of the patients who had been severely immunosuppressed failed 
therapy. One stopped treatment because of side effects. Recently, Todd et al published 
results on 15 patients similar to our group. In contrast to the positive results of our pilot 
study, Todd found a response rate in only four of 13 patients treated with imiquimod.28
In conclusion, this pilot study showed the potential beneficial effect of imiquimod 5% 
cream in patients with multifocal VIN 2/3 in whom invasion has been ruled out by map-
ping. In contrast to current surgical treatments, imiquimod permits more specific target-
ing of the cause of VIN. This nonsurgical approach leaves the anatomy of the vulva intact. 
Therefore, imiquimod may prove to be the treatment of choice in patients with multifocal, 
high grade VIN in whom risk factors for micro-invasion, such as unifocal diseases,29 raised 
lesions,6 older age6,30 and previous radiotherapy,30 have been ruled out. To further study 
this potential effect, we have started a prospective, randomized, double-blind, placebo-
controlled clinical trial.
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Abstract
Background Alternatives to surgery are needed for the treatment of vulvar intraepithelial 
neoplasia. We investigated the effectiveness of imiquimod 5% cream, a topical immune-
response modulator, for the treatment of this condition.
Methods Fifty-two patients with grade 2 or 3 vulvar intraepithelial neoplasia were 
randomly assigned to receive either imiquimod or placebo, applied twice weekly for 16 
weeks. The primary outcome was a reduction of more than 25% in lesion size at 20 weeks. 
Secondary outcomes were histologic regression, clearance of human papillomavirus (HPV) 
from the lesion, changes in immune cells in the epidermis and dermis of the vulva, relief of 
symptoms, improvement of quality of life, and durability of response. Reduction in lesion 
size was classified as complete response (elimination), strong partial response (76 to 99% 
reduction), weak partial response (26 to 75% reduction), or no response (≤25% reduction). 
The follow-up period was 12 months.
Results Lesion size was reduced by more than 25% at 20 weeks in 21 of the 26 patients 
(81%) treated with imiquimod and in none of those treated with placebo (P<0.001). His-
tologic regression was significantly greater in the imiquimod group than in the placebo 
group (P<0.001). At baseline, 50 patients (96%) tested positive for HPV DNA. HPV cleared 
from the lesion in 15 patients in the imiquimod group (58%), as compared with two in the 
placebo group (8%) (P<0.001). The number of immune epidermal cells increased signifi-
cantly and the number of immune dermal cells decreased significantly with imiquimod 
as compared with placebo. Imiquimod reduced pruritus and pain at 20 weeks (P=0.008 
and P=0.004, respectively) and at 12 months (P=0.04 and P=0.02, respectively). The lesion 
progressed to invasion (to a depth of <1 mm) in three of 49 patients (6%) followed for 12 
months (two in the placebo group and one in the imiquimod group). Nine patients, all 
treated with imiquimod, had a complete response at 20 weeks and remained free from 
disease at 12 months.
Conclusions Imiquimod is effective in the treatment of vulvar intraepithelial neoplasia.
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Surgery, the treatment of choice for vulvar intraepithelial neoplasia, removes all visible 
lesions, with the aim of relieving symptoms and preventing vulvar cancer.1 However, there 
are limitations to surgery. The percentage of lesions with positive surgical margins ranges 
from 24 to 68%.2,3 Recurrences are common, because surgery does not eliminate human 
papillomavirus (HPV), the cause of most vulvar intraepithelial neoplasia.4,5 Progression is 
not influenced by radical excision,4,6 and surgery can mutilate the vulva, thereby causing 
psychosexual distress.7-10 Thus, alternative treatments are needed.
Vulvar intraepithelial neoplasia is caused by HPV,11 which has prompted the use of imi-
quimod 5% cream (Aldara, 3M Pharmaceuticals), a topical immune-response modifier,12 
for treatment of the disease. Efficacy has been reported, although only in small, uncon-
trolled studies.13-16 The aim of this study was to assess the effectiveness of imiquimod 5% 
cream in patients with multifocal grade 2 or 3 vulvar intraepithelial neoplasia in a placebo-
controlled, double-blind, randomized clinical trial.
Materials and Methods
Patients
All patients 18 years of age or older with grade 2 or 3 vulvar intraepithelial neoplasia who 
were seen at the Academic Medical Center of the University of Amsterdam or the Erasmus 
University Medical Center of Rotterdam between April 2001 and July 2003 were asked 
to participate. The inclusion criteria were histologically proven, multifocal grade 2 or 3 
vulvar intraepithelial neoplasia without microinvasion and contraceptive use for sexually 
active, premenopausal women (to avoid any possible teratogenic effects of imiquimod). 
The exclusion criteria were a history of cancer or inflammatory dermatosis of the vulva, 
pregnancy, immunodeficiency, any treatment for vulvar intraepithelial neoplasia or warts 
within the previous month, hypersensitivity to the cream, or an inability to understand 
Dutch or English. A Consolidated Standards for the Reporting of Trials (CONSORT) diagram 
appears in the Supplementary Appendix.
Study Design
A formalin-fixed biopsy specimen was obtained for histologic analysis within 3 months 
before enrollment. A second specimen from the same lesion was frozen in liquid nitrogen 
and stored at –80°C for HPV DNA testing and immunohistochemical analysis. Patients with 
extensive vulvar intraepithelial neoplasia underwent surgical mapping before enrollment 
to establish the extent and grade of neoplasia and to rule out invasive disease. If a lesion 
was suspicious for invasion (i.e., was raised, erosive, ulcerative, or indurated), a wide local 
excision was performed.
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During the first visit, a medical history was taken and a physical examination was per-
formed. Blood samples were drawn for pregnancy testing and for hematologic and serum 
chemical analysis at the first visit and at 4 weeks after treatment (20 weeks after the first 
visit). A cervical smear was taken at the first and last study visits.
Eligible patients were randomly assigned to receive 250 mg of imiquimod 5% or pla-
cebo cream, a complete vehicle control. Neither the patients nor the examining physicians 
were aware of the treatment assignments. Randomization was carried out by 3M Pharma-
ceuticals in blocks of four (with a two-by-two design) without stratification. The patients 
applied a thin layer of study medication to the lesions and let it remain overnight without 
a cover twice a week for a period of 16 weeks. In case of severe side effects, application 
could be reduced to once a week, or a treatment-free period of 1 week was permitted. The 
patients were advised to use sulfur precipitate 5% in zinc oxide ointment the day after 
application of the cream to avoid superinfection.
The patients used a diary to report concomitant medication and side effects. Every 4 
weeks, the patients were monitored for the efficacy of treatment, symptoms, and side 
effects. At 20 weeks, a post-treatment biopsy specimen was obtained for histologic analy-
sis, and a sample was stored at –80°C for detection of HPV DNA and immunohistochemical 
analysis. Photographs were used to ensure that the post-treatment biopsy specimen was 
taken from the same site.
To investigate long-term effects and to evaluate possible recurrences of vulvar intra-
epithelial neoplasia, we performed post-treatment assessments at 7 months and at 12 
months. If a recurrence was suspected at 12 months, a biopsy specimen was obtained. In 
cases of persistent or residual disease after one year, treatment with imiquimod or surgery 
was recommended. If lesions suspicious for invasion developed during the study, wide 
local excision was performed. Except for cases of serious side effects, the randomization 
code was not broken until all women had been seen at 12 months. The ethics committees 
of the Academic Medical Center of the University of Amsterdam and the Erasmus Uni-
versity Medical Center of Rotterdam approved the study protocol. All women voluntarily 
provided written informed consent; they were informed that surgery was the treatment of 
choice for vulvar intraepithelial neoplasia.
All vulvar intraepithelial neoplasia lesions were measured with calipers and photo-
graphed at baseline, every 4 weeks during treatment, and at follow-up visits. A computer 
program (ImageJ) was used to calculate the total lesion size in square centimeters by 
adding the measurements for each separate lesion together. To avoid bias caused by side 
effects, one of the investigators and an independent gynecologist with expertise in vulvar 
pathology evaluated the clinical response with the use of photographs taken at the first 
study visit and at 20 weeks. Clinical response was defined as a reduction in total lesion size 
and was classified as a complete response, a strong partial response (76 to 99% reduction 
in lesion size), a weak partial response (26 to 75% reduction in lesion size), or no response 
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(reduction in lesion size of 25% or less). Skin reactions during treatment were recorded. To 
evaluate the long-term response, photographs taken at 12 months were compared with 
those taken at baseline.
All biopsy evaluations were reviewed independently by two experienced gynecologic 
pathologists who were unaware of the clinical data. Biopsy specimens were classified as 
grade 1, 2, or 3 vulvar intraepithelial neoplasia.17 A consensus meeting was arranged when 
the pathologists did not agree. Histologic regression was defined as regression from grade 
2 or 3 vulvar intraepithelial neoplasia to a lower grade. If infiltration was present, the depth 
of infiltration was measured by Wilkinson’s method.18
Frozen biopsy specimens were analyzed for the presence of HPV DNA with the use of 
a standard GP5+/6+ polymerase-chain-reaction (PCR) enzyme immunoassay, followed by 
reverse line-blot analysis.19,20 High-risk and low-risk probe cocktails were used to identify 
the 14 most prevalent high-risk and the 22 most prevalent low-risk types of HPV. In addi-
tion, PCR amplification products were analyzed to identify individual HPV types by reverse 
line-blot analysis. A PCR assay for the β-globin gene was performed to ascertain the 
presence and quality of target DNA. The histochemical analysis of immune cells and the 
statistical analysis of immunologic data are described in the Supplementary Appendix.
Pruritus and pain were rated by the patients every 4 weeks during treatment and at 
follow-up visits on a visual analogue scale from 0 (no symptoms) to 10 (severe symptoms). 
The mental health scale of the Medical Outcomes Study 36-Item Short-Form General 
Health Survey (ranging from 0 to 100, with higher numbers indicating a better health-
related quality of life) and the overall quality-of-life scale of the European Organization for 
Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (QLQ-C30) were 
used to assess generic and cancer-specific health-related quality of life, respectively.21-23 
Body image and sexuality were assessed with the EORTC QLQ-BR23.24 These question-
naires were administered at baseline, at 20 weeks, and at 12 months.
Primary and Secondary End Points
The primary outcome was a reduction in lesion size of more than 25% 4 weeks after the 
end of treatment (20 weeks after the beginning of treatment). The secondary outcomes 
were histologic regression from grade 2 or 3 vulvar intraepithelial neoplasia to a lower 
grade, clearance of HPV, and changes in immune cells in the epidermis and dermis at 20 
weeks; relief of clinical symptoms and improvement of quality of life at 20 weeks and at 12 
months; and durability of the clinical response at 12 months.
Statistical Analysis
In the placebo group, we expected no reduction in lesion size in 95% of the patients. 
For the purpose of calculating sample size, we considered treatment with imiquimod 
adequate if 50% of the patients showed at least a weak partial response. To detect such a 
Ch
ap
te
r 5
64
difference with a power of 80% (α=0.05 and β=0.20), a sample size of 36 patients would 
be needed. Taking into account the possibility of withdrawal by some patients, we chose 
to include 52 patients.
Analyses were performed according to the intention-to-treat principle. For a comparison 
of responses between the two groups, Fisher’s exact test was used. The Pearson chi-square 
test was used to compare clinical, histologic, and viral outcomes between the groups. To 
assess the correlation between post-treatment histologic findings and viral clearance, a 
test for trend was performed. Repeated-measures analysis of variance was used to test for 
between-group differences over time in self-reported symptoms, health-related quality of 
life, body image, and sexuality. Analysis of covariance was used to compare group scores 
on these outcomes at 20 weeks and at 12 months, with adjustment for baseline scores. 
All reported P values are two-sided and are not adjusted for multiple testing. No interim 
analyses of efficacy were performed. 3M Pharmaceuticals was not involved in the study 
except to provide study medication and to perform randomization.
Results
Study population
Table 1 shows the baseline characteristics of the 52 patients assigned to study groups. The 
two groups were well balanced. The patients had received a diagnosis of vulvar intraepi-
thelial neoplasia at a mean of 5.4 years before enrollment (range, one month to 20 years). 
The most recent surgery was performed more than three months before enrollment in 
all patients. Mapping (which involved more than three biopsies) was performed in 12 
patients (six in the imiquimod group and six in the placebo group). To rule out invasion, 
wide local excision was performed in three patients (all in the placebo group). One patient 
in the imiquimod group with a positive test result for HPV DNA had coexisting lichen 
sclerosus. Two patients were using local corticosteroids at enrollment and discontinued 
corticosteroid use before starting the study.
One patient in the imiquimod group discontinued study medication at 4 weeks because 
her lesions had spontaneously disappeared after the initial biopsy. One patient in the pla-
cebo group stopped at 14 weeks because of a lack of response. Two other patients, one in 
each group, needed a treatment-free period of more than 1 week for personal reasons. The 
median number of sachets of cream used was 32 (range, 27 to 33) in the placebo group 
and 30 (range, 6 to 32) in the imiquimod group. The frequency of imiquimod application 
was reduced to once a week in five patients because of severe local inflammation. Other 
side effects were itching or burning immediately after application of imiquimod or on the 
next day, flulike symptoms, headache, apathy, weariness, and muscular ache (Table 2). Skin 
reactions noted by the investigator included erythema, erosion, vesiculation, and edema. 
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Hematologic and serum biochemical test results remained within the normal range in 
both study groups.
Table 1. Baseline characteristics of the patients*
Characteristic Imiquimod (n=26) Placebo (n=26) P-value†
Age (yr)
 Median
 Range
39
22-56
44
31-71
0.08
Previous surgical treatment (no. of patients)
 Any treatment
  1 treatment
  2 or 3 treatments
  4 or 5 treatments
  >5 treatments
 No treatment
18
6
7
2
3
8
19
7
7
4
1
7
1.00
Symptoms (no. of patients)
 Any symptom
  Itchiness
  Pain
  Itchiness and pain
 No symptoms
22
2
3
17
4
19
8
1
10
7
0.50
Smoking status
 Smoking (no. of patients)
  1-9 cigarettes/day
  10-20 cigarettes/day
  >20 cigarettes/day
 No smoking (no. of patients)
23
3
12
8
3
23
5
7
11
3
1.00
Previous cervical neoplasia (no. of patients)
 Yes
 No
15
11
17
9
0.78
VIN grade (no. of patients)¶
 1
 2
 3
1
2
23
0
2
24
0.60
HPV DNA (no. of patients)
 Positive
 Negative
25
1
25
1
1.00
HPV type (no. of patients)
 16
 18
 33
20
0
5
21
1
3
0.47
Lesion size (cm2)∫
 Median
 Range
4.7
(0.0-20.8)
5.4
(0.7-45.0)
0.37
*VIN denotes vulvair intraepithelial neoplasia; HPV denotes human papillomavirus
†P values were calculated by Fisher’s exact test, except for age and lesion size, for which the Mann-Whitney 
U test was used, and VIN grade and HPV type, for which the Pearson chi-square test was used.
¶The grades were reviewed by two independent gynecologic pathologists.
∫VIN lesions spontaneously disappeared after the initial biopsy in one patient in the imiquimod group. No 
lesions could be measured at the time of initiation of treatment.
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Clinical outcome
Figure 1 summarizes the change in total lesion size after treatment with imiquimod or 
placebo at 20 weeks and at 12 months. At 20 weeks, lesion size was reduced by more 
than 25% in 21 of 26 patients treated with imiquimod (81%) and in no patients in the 
placebo group (P<0.001). The lesions had completely disappeared in nine imiquimod-
treated patients and were reduced by more than 75% in five (Table 3, and Fig. 1 of the 
Supplementary Appendix). There were no significant differences between the findings of 
the two investigators who evaluated the clinical response.
Histological, viral and immunological outcome
Pretreatment biopsies showed that 47 patients had grade 3 vulvar intraepithelial neopla-
sia, four had grade 2, and one had grade 1. Table 4 summarizes the histologic results after 
treatment. There was disagreement between the observers in the grading of 19 of 104 
biopsies (18%), mainly concerning grades 2 and 3 (13 of 19), and consensus was reached 
in all 19 cases. Histologic regression from grade 2 or 3 to a lower grade was seen in 18 
patients treated with imiquimod (69%) and in one patient treated with placebo (4%) 
Table 2. Side‑effects
Side effect Imiquimod (n=26) Placebo (n=26) P-value§
Reported by the patient¶
 Vulvar pain or pruritus 24 7 <0.001
 Headache 7 5 0.52
 Apathy 5 0 0.03
 Weariness 8 4 0.20
 Muscular ache 3 1 0.35
 Flulike symptoms 5 3 0.47
 Other side effects‡ 4 4 1.00
 No side effects 1 13 <0.001
Reported by the investigator
 Erythema mild/ moderate
    severe
14
6
2
0
<0.001
0.02
 Erosion  mild/ moderate
    severe
17
0
5
0
0.001
1.00
 Vesiculation 4 0 0.06
 Edema 11 0 <0.001
 Ulceration 0 0 1.00
§ P values were calculated by the Pearson chi-square test;
¶In the imiquimod group, one patient reported no side effects during treatment, nine patients reported 
one side effect, five patient s reported two side effects, eight patients reported three side effects, and 
three patients reported four side-effects. In the placebo group, 13 patients reported no side effects, seven 
patients reported one side effect, two patients reported two side effects, three patients reported three side 
effects, and one patient reported four side effects. The number of patients reporting no side effects differed 
significantly between the two groups (P<0.001).
‡The other side effects were loss of hair, excessive vulvar perspiration, loss of blood from treated skin, 
watery eyes, reactive lymph nodes.
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(P<0.001). Eight patients no longer had vulvar intraepithelial neoplasia; before treatment, 
six of these patients had grade 3 vulvar intraepithelial neoplasia, one had grade 2, and 
one had grade 1. One patient with grade 2 vulvar intraepithelial neoplasia at baseline had 
grade 3 after treatment with imiquimod.
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Figure 1. Effects of imiquimod and placebo on total lesion size at 20 weeks and at 12 months. Total lesion size as a 
percentage of baseline is shown at 20 weeks and at 12 months after the beginning of treatment with imiquimod 
(Panel A) or placebo (Panel B). The solid red line in Panel A represents the nine patients who had a complete 
response; one patient had no measurable disease but was treated anyway. Data were missing for five patients at 
12 months. See also Color Figures, page 148.
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At baseline, 25 patients in each group had lesions positive for HPV DNA (Table 1). At 20 
weeks, HPV was cleared in 17 lesions: 15 after treatment with imiquimod and 2 after treat-
ment with placebo (P<0.001) (Table 4). Fifteen lesions had HPV type 16, and two lesions 
(one treated with imiquimod and one treated with placebo) had HPV type 33. There 
was no significant association between HPV type and viral outcome. There was a strong 
association between viral clearance and histologic regression (P<0.001). Of 14 lesions that 
regressed to grade 1 vulvar intraepithelial neoplasia or to no neoplasia, 13 were cleared of 
HPV after treatment with imiquimod and the other lesion was HPV-negative at baseline.
Treatment with imiquimod increased the numbers of CD1a+ dendritic cells, CD8+ T 
cells, and CD94+ natural killer cells in the epidermis 4 weeks after the end of therapy. The 
increase was significant only for patients whose lesions regressed by more than 75%. In 
the dermis of imiquimod-treated patients whose lesions regressed by more than 75%, 
the numbers of CD207+ dendritic cells, CD208+ dendritic cells, and regulatory T cells were 
reduced; the reduction was significant for CD207+ dendritic cells and regulatory T cells 
(see the Supplementary Appendix for details).
Self-reported symptoms and quality of life
As compared with placebo, treatment with imiquimod reduced pruritus and pain at 20 
weeks (P=0.008 and P=0.004, respectively) and 12 months (P=0.04 and 0.02, respectively), 
Table 3. Clinical response at 20 weeks and at 12 months after the beginning of treatment*
Response 20 weeks† 12 months
Imiquimod (n=26) Placebo (n=26) Imiquimod (n=26) Placebo (n=26)
None 5 26‡ 5 21
Weak partial 7§ 0 6 2
Strong partial 5 0 4 0
Complete 9¶ 0 9 0
No data 0 0 2 3
*Clinical response was classified as no response (reduction in lesion size of 25% or less), weak partial 
response (26 to 75% reduction), strong partial response (76 to 99% reduction), or complete response (100% 
reduction).
†The difference between the treatment groups at 20 weeks was significant (P<0.001 by Pearson chi-square 
test for trend).
‡Progression to invasive disease occurred in two of these patients during the study. One of the patients 
underwent surgery before the end of the study, so the total lesion size was not measured at 12 months. A 
third patient did not have a response to the study medication and withdrew from the study at 20 weeks. A 
fourth patient, who had severe pain, withdrew from the study at 8 months to undergo surgery.
§Progression to invasive disease occurred in one of these patients during the study. She underwent surgery 
before the end of the study, so the total lesion size was not measured at 12 months. Another patient was 
lost to follow-up at 20 weeks because of unrelated medical problems.
¶In one patient, vulvar intraepithelial neoplasia lesions spontaneously disappeared after the initial biopsy. 
Another patient, with an original diagnosis of grade 2 vulvar intraepithelial neoplasia, received a diagnosis 
of grade 1 disease after independent review.
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according to analysis of covariance with adjustment for baseline scores. In a repeated-
measures analysis, no significant differences at baseline, at 20 weeks, or at 12 months were 
observed between the imiquimod group and the placebo group in self-reported health-
related quality of life, body image, or sexuality.
Follow-up
All but three patients were followed for 12 months (Table 3). One patient did not have a 
response to the study medication and withdrew at 20 weeks. Another patient was lost to 
follow-up at 20 weeks because of an unrelated medical problem. A third patient with grade 
3 vulvar intraepithelial neoplasia stopped treatment at 8 months when she underwent 
surgery (skinning vulvectomy) for severe pain. Complete follow-up information was avail-
able for 49 patients. All patients with a complete response after treatment with imiquimod 
at 20 weeks remained free of disease at 12 months. Two of 12 patients (17%) with a partial 
response after imiquimod treatment had enlargement of their lesions.
In one patient treated with imiquimod, newly developed vulvar intraepithelial neopla-
sia progressed to invasion at 7 months. A radical local excision confirmed the presence 
of invasion to a depth of less than 1 mm. Invasion also occurred in two other patients 
treated with placebo. Invasion to a depth of less than 1 mm developed at 12 months in 
one patient with preexisting vulvar intraepithelial neoplasia. A subsequent radical local 
excision showed no further invasion. In the other patient, progression of newly developed 
vulvar intraepithelial neoplasia was found at 20 weeks. A radical local excision confirmed 
the presence of invasion to a depth of less than 1 mm.
Table 4. Histologic and virologic results 20 weeks after beginning of treatment with imiquimod or placebo*
VIN grade†
Imiquimod (n=26) Placebo (n=26)
no. of patients no. HPV‑negative no. of patients no. HPV‑negative
No disease 8‡ 8 0 0
Grade 1 7 6§ 1 1
Grade 2 3 2 0 0
Grade 3 8¶ 0 24∫ 2§
Invasive disease (<1mm) 0 1 0
*HPV denotes human papillomavirus;
†The grades were reviewed by two independent gynecologic pathologists;
‡Two patients received a diagnosis of grade 2 vulvar intraepithelial neoplasia at baseline; the diagnosis was 
changed to grade 1 in one of these patients after revision;
§One patient was already HPV-negative at baseline;
¶One patient received a diagnosis of grade 2 vulvar intraepithelial neoplasia at baseline;
∫Two patients received a diagnosis of grade 2 vulvar intraepithelial neoplasia at baseline.
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Discussion
This trial demonstrates the effectiveness of imiquimod in the treatment of vulvar intra-
epithelial neoplasia during an observation period of one year. Complete response was 
achieved in nine (35%) and partial response in 12 (46%) of 26 patients treated with the 
cream. Regression from grade 2 or 3 vulvar intraepithelial neoplasia to a lower grade was 
seen in 18 of 26 lesions (69%), 15 of which tested negative for HPV DNA after treatment. 
None of the nine patients with a complete response showed any evidence of vulvar intra-
epithelial neoplasia at 12 months. Four of the nine patients who had a complete response 
had undergone surgery two or three times before receiving imiquimod. Three lesions (6%) 
progressed to invasion to a depth of less than 1 mm, two after treatment with placebo 
and one after treatment with imiquimod. These results are similar to those of other studies 
showing progression of vulvar intraepithelial neoplasia in 9% of untreated patients and 
3% of surgically treated patients.4,5 In our study, two of three patients with progression to 
invasive disease (one treated with imiquimod and two with placebo) had newly developed 
vulvar intraepithelial neoplasia.
The strength of our study lies in the randomized, placebo-controlled comparison. To 
avoid any bias caused by side effects of study medication, two independent observers 
using photographs obtained before and after treatment evaluated the reduction in lesion 
size. No significant differences between the results of the two observers were found. 
Histologic evidence of regression was evaluated independently by two pathologists, and 
consensus was reached when they disagreed as to whether lesions should be classified as 
grade 2 or grade 3. Difficulty in grading vulvar intraepithelial neoplasia25,26 led to a new 
classification in which grades 2 and 3 are combined as vulvar intraepithelial neoplasia 
(usual type or differentiated type).27 Grade 1 vulvar intraepithelial neoplasia as an entity 
was abandoned, since the minimal changes associated with this grade are usually a result 
of transient HPV infection. According to the new classification, all patients would have 
been classified as having vulvar intraepithelial neoplasia (usual type), and 15 patients 
(58%) instead of 8 (31%) would have shown complete histologic regression after treat-
ment with imiquimod.
It is not known why some patients had a response to imiquimod and others did not. 
Imiquimod binds to toll-like receptor 7, a cell-surface receptor on the immature plasmacy-
toid dendritic cell. Binding initiates an intracellular signaling cascade that results in innate 
and cell-mediated immune responses. Imiquimod promotes maturation of antigen-
presenting cells and secretion of proinflammatory cytokines and initiates a shift to type 
1 T-cell–mediated immunity.28 Imiquimod also has direct proapoptotic activity against 
tumor cells.29 We found that a preexisting type 1 T-cell response specific to HPV type 16 is 
associated with an improved outcome after imiquimod treatment.30 Perhaps induction of 
this specific T-cell response before imiquimod treatment would be useful.
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HPV infection suppresses chemokine expression, resulting in the inhibition of infiltra-
tion and activation of T cells and natural killer cells. Moreover, the number of Langerhans’ 
cells is significantly reduced at HPV-infected sites.31 The increase in the number of immune 
cells in the epidermis of patients with a clinical response of more than 75% after imiqui-
mod treatment may reflect reactivation of the resident epidermal cells. The decrease in 
the number of immune cells in the dermis of these patients may reflect a return to normal 
conditions after a successful immune response against HPV.
In conclusion, imiquimod 5% cream is a promising agent for the treatment of vulvar 
intraepithelial neoplasia. Regression of lesions is strongly associated with clearance of HPV. 
As a convenient, self-administered treatment, imiquimod is well tolerated, is less invasive 
than surgery, relieves itching and pain, and does not influence health-related quality of 
life, body image, or sexuality. Therefore, we consider imiquimod the first-choice treatment 
for vulvar intraepithelial neoplasia.
Supported by the Erasmus University Medical Center in Rotterdam and the Academic 
Medical Center in Amsterdam. 3M Pharmaceuticals provided the study medication and 
performed randomization.
No potential conflict of interest relevant to this article was reported.
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Appendix I
CONSORT Flow Diagram
Assessed for eligibility (n= 83)
Randomized (n=52)
Allocated to receive imiquimod (n=26)
Received imiquimod (n=26)
Lost to follow-up at t=20w (n=0)
Discontinued imiquimod after 4 w (n=1)
Allocated to receive placebo (n=26)
Received placebo (n=26)
Lost to follow-up at t=20w (n=0)
Discontinued placebo after 13 w (n=1)
Analyzed (n=26)
Lost to follow-up at t=12m (n=2)
Due to: withdrawal (unresponsiveness)
surgical intervention (severe symptoms)
Excluded (n=31)
Not meeting selection criteria (n=11)
Refused to participate (n=20)
Analyzed (n=26)
Lost to follow-up at t=12m (n=1)
Due to: non-related medical problems
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Appendix II
(Analysis of immunocompetent cells in epidermis and dermis of vulvar skin before 
and after treatment with imiquimod or placebo)
Materials and Methods
Immunohistochemical staining
Pre-staining, frozen tissue specimen were cut into serial 6 μm thick sections on a Micronic, 
Adamas cryostat, transferred to poly-L-lysine-coated microscope slides (Menzel-Glaser, 
Omnilabo, Breda, the Netherlands), dried and restored at -80°C. The following markers and 
their primary antibodies were selected for immunohistochemical staining: CD1a, classic 
marker for Langerhans cells (Okt-6 Orthoclone, Orthobiotech, Bridgewater, NJ, U.S.A.); 
CD207, marker for immature dendritic cells (DCs) expressing Langerin (DCGM4 Beckman 
Coulter, Mijdrecht, The Netherlands); CD208, DC-lamp marker for mature DCs (104.G4 
Beckman Coulter); CD94, marker for natural killer cells (NKs) (HP.3b1 Beckman Coulter); 
CD4 marker for T-helper cells (MT.310 Dako, Glostrup, Denmark); CD8, marker for cytotoxic 
T-cells (DK25 Dako); and CD25/HLA-DR, marker for regulatory T-cells (Treg cells) (AKT-1 
Dako/ 1E5 Sanquin). For plasmacytoid DCs (pDCs), characterized by the presence of CD123 
and absence of CD11c, antibodies for both markers were used (anti CD123 (9F5 Becton 
Dickinson) and anti CD11c (SHCL-3; Becton Dickinson)). Antibodies in staining procedures 
were applied in optimal concentrations varying from 0.1µg/ml to 1.0 µg/ml.
Single‑staining (CD4, CD8, CD1a, CD207, CD208 and CD94)
Sections were defrozen, fixed in acetone for 10 minutes, and rinsed with phosphate buffer 
saline (PBS, pH 7.8) for 5 minutes. The staining procedure was then continued in a half 
automatic stainer (Sequenza, Shandon Scientific, Zeist, the Netherlands), where the slides 
were incubated with 10% normal goat serum (NGS) (Sanquin, Amsterdam, The Nether-
lands) for 10 minutes, and subsequently for 60 minutes with mouse anti-human antibodies 
against CD4, CD8, CD1a, CD207, CD208, and CD94, respectively. All antibodies had been 
diluted in 1% block buffer (Blocking Reagent in PBS, Roche Diagnostics GmbH, Mannheim, 
Germany). During the whole staining process, incubation steps were always followed by 
rinsing with PBS for 5 minutes. After incubation with primary antibodies, sections were 
rinsed and incubated with biotinylated goat anti-mouse antibodies (BioGenex HK325-UM, 
Klinipath, Duiven, the Netherlands) and 10% normal human serum (NHS) (Sanquin) for 
30 minutes. This was followed by incubation with alkaline phosphatase conjugated 
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streptavidin (BioGenex HK321-UK, Klinipath, Duiven, The Netherlands) and 10% NHS for 
another 30 minutes. Slides were rinsed with both PBS and substrate TRIS buffer (TRIS 
HCl 0.1 mol/L, pH 8.5), and then incubated for 30 minutes with a new fuchsine substrate 
(Chroma, Kongen, Germany). Finally, the sections were washed again, counterstained with 
Gill’s haematoxilin (Merck, Amsterdam, The Netherlands) for 30 seconds, rinsed with tap 
water, dried, and embedded in VectaMount (Vector, Burlingame, CA). Control staining was 
performed according to the same procedure, using isotype controls.
Double‑staining CD25/HLA‑DR and CD123/CD11c
After fixation in acetone and washing with PBS, endogenous peroxidase was blocked with 
0.1% sodium azide and 0.03% hydrogen peroxide in PBS for 30 minutes. Sections were 
rinsed and incubated with 10% NGS and 10% normal rabbit serum (Sanquin), followed 
by incubation with mouse anti-human antibodies against CD25 for 60 minutes at room 
temperature. The sections were then rinsed, incubated with biotinylated goat anti-mouse 
antibodies and 10% NHS for 30 minutes, rinsed, incubated with alkaline phosphatase con-
jugated streptavidine and 10% NHS for 30 minutes, and rinsed again. Thereafter, the slides 
were incubated with 10% normal mouse serum (Sanquin) for 10 minutes, followed by FITC 
conjugated mouse anti-human antibodies against HLA-DR for 60 minutes. Rinsed again, 
incubation with HRP conjugated rabbit anti-FITC antibodies followed. After rinsing with 
PBS and substrate TRIS buffer, slides were incubated for 30 minutes in fast blue substrate 
(Sigma, St.Louis, Mo, U.S.A.). Finally, sections were rinsed and incubated with peroxidase 
nova red substrate (Vector, Burlingame, CA, U.S.A.) for 10 minutes, rinsed with PBS and 
embedded in VectaMount.
In a similar procedure as described above for double-staining CD25/HLA-DR, sections 
were incubated with 10% NGS. Primary antibodies were substituted with mouse anti-
human CD11c antibodies and with phycoerythrin-labeled mouse anti-human CD123 
antibodies. Secondary antibodies were biotinylated goat anti-mouse antibodies with 
alkaline phosphatase conjugated streptavidine for CD11c and rabbit anti-phycoerythrin 
(AbD Serotec, Duesseldorf, Germany) and alkaline phosphatase conjugated goat anti-
rabbit antibodies (Sigma) for CD123. Staining was performed with fast blue substrate for 
CD123 and with amino-ethylcarbazol substrate (Sigma) for CD11c.
Light microscopic evaluation
Light microscopic evaluation was performed in a blinded session. Stained cells were 
counted throughout the entire epidermal surface and 100 μm deep into the dermis of 
each biopsy specimen following at least 2 mm of basal membrane length (range 2-5 mm). 
After estimating the total area of both the epidermis and dermis by using the Leica Image 
Analysis System, the number of cells per square millimeter was calculated for each layer 
separately.
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Statistical analysis
Statistical analysis was performed with the SPSS 15.0 software for Windows.
Preliminary Kolmogorov-Smirnov tests showed a non-normal distribution for some 
cell types. Accordingly, differences in cell counts before and after treatment with study 
medication were evaluated with the non-parametric Wilcoxon test for paired samples. A 
two-tailed P-value of 0.05 was chosen to represent statistical significance.
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Supplementary figureSupplementary Figure 1.  
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FE
Supplementary figure 1. Clinical results before and after treatment with imiquimod.
Clinical pictures of three patients with HPV DNA‑positive VIN 3 showing the results after treatment with 
imiquimod. Picture A, C, E: before treatment; B, D, F: after treatment. All three patients showed complete 
regression of the shown lesion, histological regression to VIN 1 (patient 1 and 2) or no dysplasia (patient 3), and 
clearance of HPV. See also Color Figures, page 149.
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Abstract
Genital infection with human papillomavirus (HPV) is usually transient, as the immune 
system is capable of eliminating the virus. When immunity ‘fails’ and the infection per-
sists, vulvar intraepithelial neoplasia (VIN) may develop. In this study, we examined the 
distribution of inflammatory cells in 51 patients with HPV-associated usual type VIN and 
in 19 healthy controls. Frozen vulvar tissue samples were tested for the presence of HPV 
DNA, and immunohistochemical staining for the markers CD1a, CD207, CD208, CD123/
CD11c, CD94, CD4, CD8 and CD25/HLA-DR was performed. Cells were counted in both 
the epidermis and dermis over at least 2 mm of basal membrane length. In the epidermis 
of VIN patients, CD1a+ and CD207+ (Langerin) dendritic cells (DCs), and CD8+ T-cells were 
significantly lower than in controls, whereas the number of CD123+/CD11c- plasmacytoid 
(p)DCs was significantly increased. No significant changes were observed for CD208+ DCs, 
CD94+ natural killer (NK) cells, CD4+ T-cells and CD25+/HLA-DR+ T-regulatory (Treg) cells. 
In the dermis of VIN patients, elevated numbers of CD208+, CD123+/CD11c-, CD94+, CD4+, 
CD8+ and CD25+/HLA-DR+ cells were observed when compared to healthy controls. The 
numbers of CD1a+ and CD207+ DCs were not different between groups. In summary, 
hrHPV-related usual type VIN lesions are characterized by an immunosuppressive state 
in the epidermis, showing a reduction of immature myeloid (m)DCs and CD8+ T-cells. In 
the dermis, inflammatory activation is reflected by the influx of mature mDCs and pDCs, 
NK-cells and T-cells, suggesting that the cellular immune response on viral HPV infection 
occurs in the dermis of VIN patients.
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Introduction
Genital infection with human papillomavirus (HPV) is very common, especially among 
sexually active young adults. The lifetime risk of becoming infected with HPV is estimated 
at 80-85%.1 Most infections proceed asymptomatically, and cure spontaneously as the 
immune system is capable of eliminating the virus.2 Persistence of HPV infection, on the 
other hand, can result in neoplastic changes of the anogenital tract, presented in this study 
as vulvar intraepithelial neoplasia (VIN).
There is evidence that cell-mediated immune responses of the host are important deter-
minants in the course of infection, illustrated by an increased incidence of HPV-induced 
diseases in T-cell immuno-deficient individuals.3 The immune response to invading HPV 
is regulated by cells of both the innate and adaptive immune systems. During the innate 
immune response, viral antigens are recognized, bound and processed by antigen-
presenting cells (APCs) with dendritic cells (DCs) as important representatives. DCs can be 
divided into immature or mature myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). mDCs 
play a major role in the regulation of anti-bacterial and anti-fungal responses, whereas 
pDCs are receptive for viral interactions. pDCs produce in response large amounts of IFN-α 
that has direct anti-viral effects and stimulates cytotoxicity of macrophages and natural 
killer (NK) cells. Influenced by NK-cells, DCs maturate and transport “processed” antigens to 
secondary lymphoid organs, where naïve T-cells are primed to mature into CD4+ T-helper 
cells, CD8+ cytotoxic T-cells, or regulatory T-cells (Treg cells), all functional members of the 
adaptive immune response.4,5
Studies describing the distribution of immunocompetent cells in VIN lesions are 
scarce.6-11 Limitations of these studies include absence of or inappropriate control groups, 
an undefined HPV status of samples, or incompletely described qualitative or semi-
quantitative cell counting. Thus far, only a few cell markers have been analyzed. Detailed 
insight into the influence of VIN on the distribution of immunocompetent cells in vulvar 
skin might be helpful to explain clinical and immunological changes observed after treat-
ment of VIN with topical imiquimod.12
To examine the role of the innate and cellular local immune responses in patients with 
hrHPV-associated VIN, we investigated in this study the presence of selected DCs, NK-cells 
and T-cells by immunohistochemical staining in the vulvar skin of 51 patients with usual 
type VIN, and compared results with data obtained from 19 healthy controls. Our results 
suggest a disturbed distribution pattern of immunocompetent cells in VIN-affected skin.
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Materials and Methods
Study-population
Fifty-one immunocompetent women (median age, 43 yrs; range, 22-71 yrs) with clinically 
and histologically proven multifocal usual type VIN participated in this study. On the aver-
age, patients were diagnosed as having VIN 5.3 yrs before enrolment in our study (range 
1 month - 20 yrs). In all cases the histological diagnosis was confirmed at study entrance. 
Thirty-seven of these 51 patients had undergone previous treatment at least three months 
before enrolment (surgical excision, laser therapy, local chemotherapy), whereas 14 had 
not been treated before. Nineteen healthy women undergoing elective vulvar cosmetic 
surgery (reduction of labia minora) served as healthy controls (median age, 40 yrs; range, 
19-56 yrs). Histological examination of the removed vulvar tissue revealed no abnormali-
ties. The Medical Ethical Committees approved our study design and all women voluntarily 
gave written informed consent.
Clinical material
4 mm punch biopsies taken from patients with usual type VIN and from excised vulvar 
tissue in healthy controls were immediately frozen in liquid nitrogen and stored at -80°C 
until further analysis. Anatomically, biopsies were taken from the same tissue as used for 
histological diagnosis.
HPV‑DNA testing
Frozen tissue samples were analyzed for the presence of HPV DNA by using a standard 
GP5+/6+ PCR enzyme immunoassay followed by reverse line blot analysis, as described 
previously .13
Immunohistochemical staining
Frozen tissue specimens were cut into serial 6 μm thick sections on a Micronic, Adamas 
cryostat, transferred to poly-L-lysine-coated microscope slides (Menzel-Glaser, Omnilabo, 
Breda, the Netherlands), dried and restored at -80°C. The following markers and their pri-
mary antibodies were selected for immunohistochemical staining: CD1a, classic marker for 
immature mDCs, in the skin known as Langerhans cells (Okt-6 Orthoclone, Orthobiotech, 
Bridgewater, NJ, U.S.A.); CD207, marker for immature mDCs expressing Langerin (DCGM4 
Beckman Coulter, Mijdrecht, The Netherlands); CD208, DC-lamp, marker for mature mDCs 
(104.G4 Beckman Coulter); CD94, marker for NK-cells (HP.3b1 Beckman Coulter); CD4, 
marker for T-helper cells (MT.310 Dako, Glostrup, Denmark); CD8, marker for cytotoxic 
T-cells (DK25 Dako); CD25/HLA-DR, marker for Treg cells (AKT-1 Dako/ 1E5 Sanquin) and 
Foxp3, marker for Treg cells (PHC 101 Bioscience, Halle, Belgium). For pDCs, characterized 
by the presence of CD123 and absence of CD11c, antibodies for both markers were used 
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(anti CD123 (9F5 Becton Dickinson) and anti CD11c (SHCL-3; Becton Dickinson)). Anti-
bodies in staining procedures were applied in optimal concentrations varying from 0.1 
µg/ml to 1.0 µg/ml.
Single‑staining (CD1a, CD207, CD208, CD94, CD4, CD8 and Foxp3)
Sections were defrozen, fixed in acetone for 10 minutes, and rinsed with phosphate buffer 
saline (PBS, pH 7.8) for 5 minutes. The staining procedure was then continued in a half 
automatic stainer (Sequenza, Shandon Scientific, Zeist, the Netherlands), where the slides 
were incubated with 10% normal goat serum (NGS) (Sanquin, Amsterdam, The Nether-
lands) for 10 minutes, and subsequently for 60 minutes with mouse anti-human antibodies 
against CD1a, CD207, CD208, CD94, CD4, CD8, respectively, and rat anti-human antibody 
against Foxp3. All antibodies had been diluted in 1% block buffer (Blocking Reagent in 
PBS, Roche Diagnostics GmbH, Mannheim, Germany). During the whole staining process, 
incubation steps were always followed by rinsing with PBS for 5 minutes. All following 
incubations with antibodies were in the presence of 10% normal human serum (NHS) 
(Sanquin). After incubation with primary antibodies, sections were rinsed and, with the 
exception of Foxp3, incubated with biotinylated goat anti-mouse antibodies as second-
ary antibodies (BioGenex HK325-UM, Klinipath, Duiven, the Netherlands) for 30 minutes, 
followed by incubation with alkaline phosphatase conjugated streptavidin (BioGenex 
HK321-UK, Klinipath, Duiven, The Netherlands) for another 30 minutes. In case of Foxp3, 
the secondary antibody was alkaline phosphatase conjugated goat anti-rat antibody; this 
incubation was followed by incubation with rat APAAP (Alkaline phosphatase anti-alkaline 
phosphatase (Dako)). Slides were rinsed with both PBS and substrate TRIS buffer (TRIS 
HCl 0.1 mol/L, pH 8.5), and then incubated for 30 minutes with a new fuchsine substrate 
(Chroma, Kongen, Germany). Finally, the sections were washed again, counterstained with 
Gill’s haematoxilin (Merck, Amsterdam, The Netherlands) for 30 seconds, rinsed with tap 
water, dried, and embedded in VectaMount (Vector, Burlingame, CA). Control staining was 
performed according to the same procedure, using isotype controls.
Double‑staining CD25/HLA‑DR and CD123/CD11c
After fixation in acetone and washing with PBS, endogenous peroxidase was blocked with 
0.1% sodium azide and 0.03% hydrogen peroxide in PBS for 30 minutes. Sections were 
rinsed and incubated with 10% NGS and 10% normal rabbit serum (Sanquin), followed 
by incubation with mouse anti-human antibodies against CD25 for 60 minutes at room 
temperature. The sections were then rinsed, incubated with biotinylated goat anti-mouse 
antibodies and 10% NHS for 30 minutes, rinsed, incubated with alkaline phosphatase con-
jugated streptavidine and 10% NHS for 30 minutes, and rinsed again. Thereafter, the slides 
were incubated with 10% normal mouse serum (Sanquin) for 10 minutes, followed by FITC 
conjugated mouse anti-human antibodies against HLA-DR for 60 minutes. Rinsed again, 
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incubation with HRP conjugated rabbit anti-FITC antibodies followed. After rinsing with 
PBS and substrate TRIS buffer, slides were incubated for 30 minutes in fast blue substrate 
(Sigma, St.Louis, Mo, U.S.A.). Finally, sections were rinsed and incubated with peroxidase 
nova red substrate (Vector, Burlingame, CA, U.S.A.) for 10 minutes, rinsed with PBS and 
embedded in VectaMount.
In a similar procedure as described above for double-staining CD25/HLA-DR, sections 
were incubated with 10% NGS. Primary antibodies were substituted with mouse anti-
human CD11c antibodies and with phycoerythrin-labeled mouse anti-human CD123 
antibodies. Secondary antibodies were biotinylated goat anti-mouse antibodies with 
alkaline phosphatase conjugated streptavidine for CD11c and rabbit anti-phycoerythrin 
(AbD Serotec, Duesseldorf, Germany) and alkaline phosphatase conjugated goat anti-
rabbit antibodies (Sigma) for CD123. Staining was performed with fast blue substrate for 
CD123 and with amino-ethylcarbazol substrate (Sigma) for CD11c.
Light microscopic evaluation
Light microscopic evaluation was performed in a blinded session. Stained cells were 
counted throughout the entire epidermal thickness and 100 μm deep into the dermis of 
each biopsy specimen following at least 2 mm of basal membrane length (range 2-5 mm). 
After measuring the total area of both the epidermis and dermis by using the Leica Image 
Analysis System, the number of cells per square millimeter was calculated for each layer 
separately.
Statistical analysis
Statistical analysis was performed with the SPSS 15.0 software for Windows. Preliminary, 
Kolmogorov-Smirnov tests showed a non-normal distribution for some cell types. Accord-
ingly, the non-parametric Mann-Whitney test was used for evaluation of differences in cell 
counts between two independent groups (VIN patients versus healthy controls). The possible 
influence of different previous treatments on cell counts in VIN patients was investigated 
by means of the non-parametric Kruskal-Wallis test. Spearman’s correlations were used to 
investigate possible relations between cell counts and duration of the disease or age of the 
patients. A two-tailed P-value of 0.05 was chosen to represent statistical significance.
Results
Patients
Spearman’s correlations between cell counts for all investigated cell types and the duration 
of VIN or age of the patients at study entrance were not significant (data not shown). There 
was also no statistically significant difference in cell counts between previously untreated 
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patients (n=14), patients treated with surgical excision (n=18) or patients undergoing laser 
treatment (n=12). Groups for other treatment modalities (n=7) were too small for statisti-
cal evaluation.
HPV-DNA testing
Forty-nine of 51 patients tested positive for hrHPV DNA. HPV types detected were HPV-16 
(n=40), HPV-33 (n=8) and HVP-18 (n=1). All healthy controls were HPV DNA-negative.
Analysis of inflammatory cells in VIN lesions and normal vulvar skin (Table 1)
Dendritic cells
Immunohistochemical analysis of epidermis and dermis showed that the majority of 
immature mDCs were located in the epidermis. Staining for CD1a and CD207 identified 
immature DCs spread over the whole epidermis, including the basal layer. There were no 
DCs in the superficial layers of the epidermis. In the dermis, the majority of DCs were situ-
ated in focal infiltrates. Compared to healthy controls a significant decrease in CD1a+ and 
CD207+ cells in the epidermis of VIN patients was observed, but in the dermis numbers of 
these mDCs were not different for the two groups. Data are summarized in Figure 1a and b. 
Table 1. Immunocompetent cells in epidermis and dermis of VIN‑lesions compared with samples from healthy 
women
Epidermis Dermis
all patients
n=51
Controls
n=19
P-value all patients
n=51
Controls
n=19
P-value
median
(range)
median
(range)
median
(range)
median
(range)
CD1a+ 157
(23-478)
212
(104-311)
0.042 142
(17-498)
133
(51-277)
0.2
CD207+ 106
(2-407)
166
(14-319)
0.024 54
(0-278)
41
(0-103)
0.1
CD208+ 21
(2-148)
19
(1-43)
0.3 124
(3-539)
45
(15-172)
<0.001
CD123+/11c- 14
(0-78)
8¶
(0-35)
0.023 234
(56-1140)
160¶
(57-302)
0.004
CD94+ 22
(0-261)
28
(0-144)
0.3 52
(0-438)
30
(0-209)
0.048
CD4+ 279
(31-925)
269
(89-591)
0.6 1162
(237-2909)
748
(406-1060)
<0.001
CD8+ 83
(2-357)
130
(51-526)
0.011 354
(45-2430)
181
(76-491)
0.001
CD25/HLA-DR+ 0
(0-7)
0‡
(0-3)
0.5 53
(0-231)
26‡
(5-118)
0.007
¶ controls n=17; ‡ controls n=16; CD1a, classic marker for Langerhans cells; CD207, marker for immature 
dendritic cells (DCs) expressing Langerin; CD208, DC-Lamp, marker for mature DCs; CD123/CD11c, marker 
for plasmacytoid DCs; CD94, marker for natural killer cells; CD4, marker for T-helper cells; CD8, marker for 
cytotoxic T-cells; CD25/HLA-DR, marker for T-regulatory cells.
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Figure 1. CD1a+, CD207+, CD208+ and CD123+/CD11c‑ DCs in the epidermis and lamina propria of VIN lesions 
and normal vulvar skin. Median values are indicated by horizontal lines.
17 17
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The number of mature CD208+ cells in epidermis was low compared to the numbers of 
immature mDCs. In the epidermis there was no difference in numbers between healthy 
controls and VIN-affected skin, but at least twice as many cells were observed in the dermis 
of VIN patients when compared to controls (Figure 1c).
CD123+ pDCs were found evenly distributed through the whole thickness of both epi-
dermis and dermis. The numbers were significantly increased in VIN-affected skin when 
compared with controls (Figure 1d).
NK‑cells
CD94+ NK-cells were sporadically found in the epidermis, preferentially in the basal layer 
just above the basal membrane. In the dermis NK-cells were situated mainly in infiltrates. 
The number of CD94+ NK-cells was not different in the epidermis, but was more than 
doubled in the dermis of VIN-patients when compared with healthy women (Figure 2).
T‑cells
Predominantly, CD4+ T-cells were located in the dermis just beneath the basal membrane. 
In the epidermis numbers did not differ between VIN patients and healthy controls, but in 
VIN-affected dermis numbers were significantly increased when compared to healthy skin 
(Figure 3a). There were significantly less CD8+ cells in the epidermis and more CD8+ cells in 
the dermis of VIN-affected skin than in healthy controls (Figure 3b).
Treg cells were analyzed by a staining procedure targeting CD25 and HLA-DR expression. 
The number of dermal CD25+/HLA-DR+ cells was higher in VIN patients than in controls. 
In the epidermis no differences between patients and healthy controls were observed 
(Figure 3c). The results for CD25+/HLA-DR+ Treg cells were controlled in 20 biopsies by 
staining sequential sections with Treg cell markers Foxp3 and CD25/HLA-DR, respectively. 
Staining results with both markers were fully comparable (data not shown).
Cell distribution for different inflammatory cells is shown in Figure 4.
Figure 2. CD94+ NK‑cells in the epidermis and lamina propria of VIN lesions and normal vulvar skin. Median 
values are indicated by horizontal lines.
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Figure 3. CD4+ and CD8+ T‑cells, and CD25/HLA‑DR+ Treg‑cells in the epidermis and lamina propria of VIN lesions 
and normal vulvar skin. Median values are indicated by horizontal lines.
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Figure 4. 
 
 
 
 
Figure 4 (photographs A‑H, 10x). Representative photographs of positive (red stained) immunocompetent cells 
in VIN lesions and normal vulvar skin.
Compared to healthy controls VIN‑affected skin showed a strong decrease of mDCs stained with CD1a in the 
epidermis (photograph A and B). Twice as many CD208+ (mature) DCs were observed in the dermis of VIN 
compared to healthy controls (photograph C and D). NK cells stained with antibodies directed against CD94 are 
more numeric in the dermis of VIN‑affected skin than in normal skin (photograph E and F). Less CD8+ cells were 
observed in the epidermis, whereas significantly more CD8+ cells were seen in the dermis of VIN‑affected skin 
when compared to normal skin (photograph G and H). See also Color Figures, page 150.
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Discussion
To our knowledge this is the first study characterizing the distribution of a broad spectrum 
of immunocompetent cells in epidermis and dermis of vulvar skin from patients with 
hrHPV-associated usual type VIN and from HPV-negative healthy controls. There are only 
a few studies investigating immunocompetent cells in VIN-affected skin, mostly dealing 
with CD4+ and CD8+ T-cells and/or CD1a+ DCs.6,10,11 Study designs vary significantly, 
especially when it comes to the presence of hrHPV, but also in the choice of VIN-inflicted 
vulvar layers, in cell counting procedures and, most important, in the choice of control 
groups. In our study, vulvar material from healthy HPV-negative women was used, this 
in contrast to other studies where normal tissue was isolated from resection margins of 
vulvar specimens taken from patients undergoing surgery for carcinoma or for benign 
vulvar diseases.6,10,11
In the epidermis of hrHPV-positive usual type VIN significantly less CD1a+ and CD207+ 
DCs were observed than in epidermal vulvar tissue from control women. These results 
are supported by Singh et al who describe an inverse correlation between the numbers 
of intraepithelial CD1a+ DCs and the stage of VIN.9 The significant reduction of CD1a+ 
and CD207+ immature mDCs in epidermal hrHPV-positive VIN tissue could be the result 
of migration into the dermis under the influence of pro-inflammatory cytokines such as 
TNF-α and IL-1β.14 These cytokines are produced during antigen-induced DC activation 
and down-regulate the expression of the adhesion molecule E-cadherin on Langerhans 
cells.15,16 E-cadherin mediates contact between keratinocytes and Langerhans cells. 
Down-regulation of the adhesion molecule not only prevents stimulation of DCs by HPV-
infected keratinocytes17 but also facilitates migration of the DCs. A defect in re-population 
of epidermal DCs through suppression of migration of immature Langerhans precursor-
like cells by hrHPV-16 E6 and E7 proteins could also contribute to the observed decrease 
in mDCs.18
Interestingly, Mulvany and Allen observed increased numbers of CD1a+ cells compared 
to the surrounding normal epithelium in differentiated type VIN which is not related to 
HPV and behaves biologically different.19
The significant reduction of immature mDCs in the epidermis of our patients seems to 
be compensated by a significant increase in the number of pDCs, suggesting involvement 
of pDCs in the immune response. Our results are supported by a study of Lee et al, who 
report decreased mDCs and increased pDCs in peripheral blood of patients with cervical 
squamous intraepithelial lesions.20 The results are also in agreement with the suspected 
role of pDCs in viral infections. Lenz et al showed in an in vitro study that HPV-16 is bound 
by freshly isolated immature pDCs and CpG maturated pDCs, that internalization of the 
virus preferentially occurs in immature pDCs, and that it induces the production of IFN-α 
and IL-6, important factors for the production of antibodies.21 Bontkes et al showed that 
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pDCs are present in cervical cancer lesions and that HPV-16 virus-like particles are able to 
activate pDCs.22 In the dermal layer of VIN-afflicted skin no differences for cell numbers 
of immature mDCs were observed, but the more mature CD208+ (CD-Lamp) DCs were 
significantly increased. This seems to indicate that persistent HPV-infection may indeed 
lead to maturation and to accumulation of these antigen-presenting DCs, possibly caused 
by a disturbed migration out of the dermis.
The observed increase of NK-cells in the dermis of usual type VIN lesions is in accor-
dance with activation of the innate immune response and may contribute to initiation of 
the CD8+ T-cell response against viral infection, as suggested by Robbins et al.23
Dermal influx of CD4+ and CD8+ T-cells in VIN-affected skin has been described previ-
ously.10,11 The observed significant increase of dermal CD4+ T-helper cells, CD8+ CTLs and 
CD25/HLA-DR+ T-reg cells in our study indicates local activation of the adaptive immune 
system in HPV-related usual type VIN. This is in accordance with observations by van 
Poelgeest et al and Todd et al about systemic activation of cell-mediated immunity by 
hrHPV infection.24,25 Van Poelgeest detected HPV-16 specific CD4+ T-cell immunity in the 
circulation of patients with persistent HPV-16 induced VIN. Todd demonstrated CD8+ T-cell 
reactivity to one or more proteins of the HPV-16 oncopeptides E6 and E7 in the peripheral 
circulation of patients with high grade VIN.
It appears that Ag-presenting DCs are the key regulators of immune responses. DCs 
migrate from the epidermis into draining lymph nodes where they activate naïve T-cells 
and initiate cellular immunity. Different studies have demonstrated that this trafficking 
of DCs is controlled by soluble chemotactic factors known as chemokines.26-28 Recent 
evidence has shown that chemokines not only direct the trafficking of DCs but also can 
regulate their maturation status.29 Further studies of DC trafficking and the responsible 
chemokines in hrHPV-based vulvar lesions will be necessary to provide more insight into 
the immunological basis of hrHPV-related usual type VIN.
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Abstract
Purpose Topical application of the immune response modifier imiquimod is an alternative 
approach for the treatment of human papillomavirus (HPV)-positive vulvar intraepithelial 
neoplasia (VIN) and aims at the immunologic eradication of HPV-infected cells. We have 
charted HPV16-specific immunity in 29 patients with high grade VIN and examined its role 
in the clinical effect of imiquimod treatment.
Experimental design The magnitude and cytokine polarization of the HPV16 E2-, E6- and 
E7-specific CD4+ T-cell response was charted in 20 of 29 patients by proliferation and 
cytokine bead array. The relation between HPV16-specific type 1 T-cell immunity and 
imiquimod treatment was examined in a group of 17 of 29 patients.
Results HPV16-specific proliferative responses were found in 11 of the 20 patients. In 
eight of these patients, T-cell reactivity was associated with IFNγ production. Fifteen of the 
women treated with imiquimod were HPV16+, of whom eight displayed HPV16 E2- and 
E6-specific T-cell immunity before treatment. Imiquimod neither enhanced nor induced 
such immunity in any of the subjects. Objective clinical responses (complete remission or 
>75% regression) were observed in 11 of the 15 patients. Of these 11 responders, eight 
patients displayed HPV16-specific type 1 CD4+ T-cell immunity, whereas three lacked 
reactivity. Notably, the four patients without an objective clinical response also lacked 
HPV16-specific type 1 T-cell immunity.
Conclusions HPV16-specific IFNγ-associated CD4+ T-cell immunity, although not essential 
for imiquimod-induced regression of VIN lesions, may increase the likelihood of a strong 
clinical response (P=0.03).
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Introduction
Genital infections with high-risk human papillomaviruses (HPV) are very common.1-3 
Fortunately, the majority of infected subjects clear the infection.4,5 A persistent infection 
with a high-risk HPV, mostly HPV16, can lead to neoplasia of the anogenital tract, of which 
cervical intraepithelial neoplasia and cervical carcinoma are the most well-known.6,7 
HPV16 infection may also cause a chronic skin disorder of the vulva known as vulvar 
intraepithelial neoplasia (VIN).8-10 In contrast to cervical intraepithelial neoplasia, which in 
general is effectively treated by eradication of the area involved, VIN is a chronic disease 
with high relapse rates after standard treatments.11-13
Imiquimod therapy has been put forward as an alternative approach for the treatment of 
VIN. This immune response modifier acts through Toll-like receptor 7 of the innate immune 
system resulting in the secretion of a multitude of proinflammatory cytokines. There is 
recent evidence that imiquimod also possesses direct proapoptotic activity against tumor 
cells.14-16 Topical application preserves the anatomy and function of the vulva, whereas 
surgical excision or ablation of affected skin may be extensive and disfiguring and can 
carry considerable psychosexual morbidity. Clinical success rates differ and are estimated 
on 30% to 87%.17-21
The HPV16 early antigens E2, E6 and E7 are among the first of proteins that are expressed 
in HPV-infected epithelia. Our previous studies on HPV-specific T-cell immunity against 
these early antigens showed that type 1 (IFNγ) T-cell memory against the early antigens 
can be detected in the majority of healthy sexually active individuals but is weak or absent 
in patients with HPV16-induced cervical neoplasia.22-24 In combination with earlier reports 
that point at a role for CD4+ T-cells in the protection against progressive HPV infection 
(reviewed in ref. 25), our data argue that the CD4+ type 1 T-cell response against the early 
antigens of HPV16 plays an important role in the protection against progressive HPV16-
induced disease.
To examine the role of HPV16-specific CD4+ T-cell immunity in the success or failure of 
treatment with imiquimod, we have done a detailed analysis with respect to the magni-
tude and cytokine polarization of the HPV16-specific CD4+ T-cell response in patients with 
high grade VIN. Furthermore, HPV16-specific type 1 immunity was analyzed before, dur-
ing, and after topical treatment with imiquimod. Our data indicate that chronic exposure 
of the immune system to the HPV16 viral proteins results in the induction of type 1 T-cell 
immunity in about half of the patients. Importantly, the presence of these type 1 T-cell 
responses is likely to be associated with a more favorable clinical response to imiquimod 
treatment.
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Material and Methods
Patients
Twenty-nine women with high grade VIN (age range, 24-73 years; median age, 47 years) 
were recruited from the departments of gynecology of the Academic Medical Center and 
Leiden and Erasmus University Medical Center, The Netherlands. On the average, these 
patients had been diagnosed with VIN 3 5.4 years before enrollment in the study (range, 
6 months to 15 years). Eighteen women had undergone previous treatments for VIN 3 
(surgical excision, laser therapy, or imiquimod treatment (patients 20, 21, 24, 27)) before 
study entry.
Seventeen of these 29 subjects (age, 29-60 years; median, 43 years) were experimentally 
treated with a 5% imiquimod cream. The patients were asked to apply the cream to the 
affected areas on the vulva twice weekly overnight for a maximum period of 16 weeks. 
To analyze the effect of imiquimod treatment on the HPV16-specific immune response, 
we collected serial blood and serum samples before the start of imiquimod treatment 
(T=0), after 8 weeks of treatment (T=8), and at the end of treatment (T=16). Vulvar lesions 
were assessed by direct measurement and photographic records at entry and after 8 and 
16 weeks of treatment. Clinical responses were defined as a complete response; a partial 
response type 1, as defined by a reduction in lesion diameter from 76% to 99%; a partial 
response type 2, as defined by a reduction in lesion diameter from 26% to 75%; or no 
clinical response.
From 20 of 29 women peripheral blood mononuclear cells (PBMC) were isolated and 
directly used to analyze HPV16-specific proliferative T-cell reactivity. Of these 20 women, 
eight patients had also participated in the imiquimod study. In six cases blood was taken 
3 months (patient 1), 4 months (patient 10), 10 months (patient 5) to over 1 year (patients 
12, 13 and 15) after the end of the imiquimod study, in the other 2 cases (patients 2 and 4) 
blood was taken within 4 weeks after the start of treatment. Serum was collected to study 
the presence of virus-like particle L1 (VLP)-specific antibodies.
All subjects were typed for HPV by GP5+/6+ PCR followed by reverse line blot analysis 
as described previously.26 The study design was approved by the Medical Ethical Commit-
tees and all women gave written informed consent.
Antigens
A set of peptides spanning the whole HPV16 E2, E6, and E7 protein were used for the 
T-cell proliferation assays. The E2 peptides consisted of twenty-two 30-mer peptides with 
a 15-amino-acid overlap and the COOH-terminal peptide with a length of 35 amino acids. 
For the T-cell proliferation assays, the E2 peptides, 32-mer peptides of the E6 protein, and 
the 35-mer peptides of the E7 protein with an overlap of 14 amino acids were used in 
pools of two peptides per pool. For the IFNγ enzyme-linked immunospot (ELISPOT) assays, 
HPV16-specific T-cell immunity in high grade VIN patients 105
the peptides used spanned the HPV16 E2, E6, and E7 protein and consisted of the most 
immunogenic regions of the E2 30-mer peptides22 and 15 E6 and nine E7 overlapping 
22-mer peptides. The peptides were synthesized and dissolved as described previously.27 
The peptide pools are indicated by the first and last amino acid of the region in the protein 
covered by the two peptides (e.g., E21-45, residues 1-30 and 16-45). Memory response mix 
(MRM), consisting of a mixture of tetanus toxoid (0.75 Limus flocculentius/mL final concen-
tration; National Institute of Public Health and Environment, Bilthoven, The Netherlands), 
Mycobacterium tuberculosis sonicate (2.5μg/mL; generously donated by Dr. P. Klatser, 
Royal Tropical Institute, Amsterdam, The Netherlands), and Candida albicans (0.005%, HAL 
Allergenen Lab., Haarlem, The Netherlands), was used as a positive control.
Short-term T-cell proliferation assay
Freshly isolated PBMCs were incubated with 12 pools of HPV16 E2-derived 30-mer 
peptides, four pools of E6 32-mer peptides, and two pools of E7 35-mer peptides (each 
pool consisted of two overlapping peptides). PBMCs were seeded at a density of 1.5 x 
105 cells per well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in 125 µL of 
Iscove's medium (Bio Whittaker, Verviers, Belgium) supplemented with 10% autologous 
serum. HPV16 E2-, E6-, and E7-derived peptides were added at a concentration of 10 µg/
mL/peptide. Medium alone was taken along as a negative control, and MRM (dilution, 
1:50) served as a positive control. For each peptide pool, eight parallel microcultures were 
incubated. Fifty microliters of supernatant from the microcultures were taken at day 6 after 
incubation and stored at -20°C until cytokine analysis. Peptide-specific proliferation was 
measured at day 7 by [3H]-thymidine incorporation. Cultures were scored positive when 
the proliferation of ≥ 75% of the test wells exceeded the mean proliferation + 3x SD of the 
control wells containing medium only, and the stimulation index, defined as the mean of 
all test wells divided by the mean of the control wells, was ≥ 3.22
Analysis of cytokines associated with HPV16-specific proliferative responses
The detection of cytokines in the supernatants of the short-term proliferation assays was 
done using the cytometric bead array (Becton Dickinson, Erebodegem-Aalst, Belgium). 
This technique allows the simultaneous detection of six different Th1 and Th2 cytokines 
IFNγ, tumor necrosis factor α (TNFα), interleukin 2 (IL-2), IL-4, IL-5, and IL-10. The cytometric 
bead array was done according to the manufacturer's instructions. Cut-off values were 
based on the standard curves of the different cytokines (50 pg/mL for IFNγ and 10 pg/
mL for the remaining cytokines). Antigen-specific cytokine production was defined as 
a cytokine concentration above cut-off level and >2x the concentration of the medium 
control.23,28
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Analysis of HPV16-specific T-cell reactivity by IFNγ enzyme-linked immunospot
The number of IFNγ producing HPV-specific T-cells, present in the peripheral blood of the 17 
patients treated with imiquimod, was quantified using ELISPOT that was done as described 
previously.29,30 Briefly, PBMC were thawed, washed, and seeded at a density of 2 x 106 cells 
per well of a 24-well plate (Costar) in 1mL of Iscove’s modified Dulbecco’s medium (Bio 
Whittaker) enriched with 10% human AB serum, in the presence or absence of indicated 
HPV16 E2, E6, and E7 peptide pools. Peptides were used in pools of four to five peptides at 
a concentration of 5μg/mL/peptide. The peptides, as indicated by their first and last amino 
acid in the protein, were used in the following pools: E2‑I: 1-30, 16-45, 31-60, 46-75; E2‑II: 
61-90, 76-105, 91-120, 106-135; E2‑III: 121-150, 136-165, 151-180, 166-195; E2‑IV: 271-300, 
286-315, 301-330, 316-345, 331-365; E6‑I: 1-22, 11-32, 21-42, 31-52; E6‑II: 41-62, 51-72, 61-82, 
71-92; E6‑III: 81-102, 91-112, 101-122, 111-132; E6‑IV: 111-132, 121-142, 131-152, 137-158; 
E7‑I: 1-22, 11-32, 21-42, 31-52; E7‑II: 41-62, 51-72, 61-82, 71-92, 77-98. Following 4 days of 
incubation at 37ºC, PBMC were harvested, washed, and seeded in four replicate wells at a 
density of 105 cells per well in 100μL Iscove’s modified Dulbecco’s medium enriched with 
10% FCS in a Multiscreen 96-well plate (Millipore, Etten-Leur, The Netherlands) coated with 
an IFNγ-catching antibody (Mabtech AB, Nacha, Sweden). Further antibody incubations 
and development of the ELISPOT was done according to the manufacturer’s instructions 
(Mabtech). Spots were counted with a fully automated computer-assisted video-imaging 
analysis system (Bio Sys, Frankfurt, Germany). Specific spots were calculated by subtract-
ing the mean number of spots + 2x SD of the medium control from the mean number 
of spots in experimental wells provided that the mean number of spots of the medium 
control wells were either <10 or >10 with a SD <20% of the mean. Antigen-specific T-cell 
frequencies were considered to be increased when specific T-cell frequencies were ≥1 in 
10,000 and at least ≥2x background.30 The background number of spots was 2.6 ± 2.2 
(mean ± SD), with one exception (patient 23, 51 ± 10 spots).
HPV16 VLP ELISA
For the detection of HPV16-specific antibodies in serum we used an ELISA method previ-
ously described by Kirnbauer et al.31 Each serum sample was tested for reactivity against 
HPV16 VLPs (baculovirus-expressed capsids comprising the L1 protein) and against bovine 
papillomavirus capsids, the latter disrupted by treatment with 0.1 mol/L carbonate buffer 
to serve as a negative control. Both VLP and bovine papillomavirus were kindly provided 
by Prof. Dr. J. Dillner (LUNDS University, Sweden). The patients were tested for both HPV16-
specific IgG and IgA. A set of sera of healthy children (n=8; mean age, 7.3 years; range, 
4.3-14.1 years) was tested to determine background reactivity. For HPV16 L1-VLP IgG type 
responses a cut-off absorbance value of 0.230 was used (mean A=0.060; range, –0.056 to 
0.150; mean + 2x SD =0.230). For IgA type responses a cut-off of A=0.215 was used (mean 
A=0.189; range, 0.171 to 0.205).
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Statistical analysis
Statistical analysis of the HPV16-specific proliferative responses associated with cytokine 
production was done using Fisher’s exact test. Fisher’s Exact test (two tailed) was used 
to analyze HPV-specific immunity to clinical response upon treatment with imiquimod. 
Statistical analyzes were performed using Graphpad Instat Software (version 3.0).
Results
HPV16-specific cellular and humoral responses in patients with high grade VIN
VIN forms a unique aspect of HPV-induced disease because patients are frequently treated, 
but the infection often persists. HPV16 is found most often. To gain a more profound insight 
in the CD4+ T-cell response against HPV16 in VIN, we charted the magnitude, specificity, Figure 1 
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Figure 1a. HPV16‑specific proliferative T‑cell responses in VIN
Freshly isolated peripheral blood mononuclear cells from 20 patients with high‑grade HPV16‑associated VIN 
were tested in short‑term proliferation assays using a complete set of HPV16 E2‑, E6‑, and E7‑derived peptide 
pools. Responses were scored positive when the proliferation (cpm) of ≥6 of eight test wells exceeded the mean 
proliferation ± 3x SD of the control (medium only) wells, and the mean stimulation index of all test wells over 
control wells was ≥ 3. Memory response mix, consisting of a mixture of recall antigens, was used as a positive 
control. The stimulation indices of responses scored positive are indicated. Abbreviation: MRM, memory 
response mix.
Ch
ap
te
r 7
108
and functionality of HPV16 E2, E6, and E7-specific proliferative T-cell responses in a group 
of 20 women with HPV16-associated high grade VIN.
PBMC isolated from VIN patients were stimulated with peptides derived from HPV16 
proteins E2, E6, and E7 as well as with a mix of common recall antigens (MRM), in a short-
term proliferation assay. We have previously shown that this assay is geared towards the 
detection of CD4+ T-cell responses.23 HPV16-specific proliferative T-cell responses against 
E2 and/or E6 were detected in 10 of 20 patients (Figure 1A). E7-specific responses were 
detected in 5 of 20 subjects. Analysis of the supernatants of these T-cell cultures for the 
presence of type 1 and type 2 cytokines revealed the secretion of the Th1 cytokine IFNγ in 
8 of 20 patients. In some of the patients, the production of TNFα, IL-5 and IL-10 was occa-
sionally detected (Figure 1B). Although the overall frequency of proliferative responses is 
similar when compared with that previously found for cervical cancer patients, the number 
of patients with IFNγ-associated HPV-specific T-cell responses in these VIN patients was 
higher (8 of 20 versus 4 of 17, respectively23).
Figure 1b. Supernatants of the positive proliferative responses indicated in Table 1 were analyzed for the presence 
of IFNγ, tumor necrosis factor‑α, IL‑2, IL‑4, IL‑5, and IL‑10 by cytometric bead array. The indicated layout is used for 
the six measured cytokines. Antigen‑specific cytokine production (). Cutoff values were based on the standard 
curves of the different cytokines (50 pg/mL for IFN and 10 pg/mL for the remaining cytokines). Antigen‑specific 
cytokine production was defined as a cytokine concentration above cutoff level and >2x the concentration of 
the medium control.
B
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In addition to T-cell immunity, the humoral response to HPV16 was measured in 28 VIN 
patients by ELISA using HPV16 L1-VLP as antigen. Overall, HPV16 L1-VLP IgG and IgA anti-
bodies were detected in 25 of 28 (89%) and 13 of 28 (46%) subjects, respectively (Table 1). 
Based on the absorbance values, the HPV16 L1-VLP-specific IgG response exceeded that 
of IgA (Table 1). In general, HPV16-specific IgA responses were detected when patients 
displayed relatively high levels of HPV16-specific IgG. If IgG absorbance values were ≥0.5, 
11 of 19 (58%) of the samples contained HPV16 L1-specific IgA, whereas at IgG levels <0.5 
only two of nine samples were IgA seropositive.
In conclusion, HPV16 L1-specific humoral immunity was detected in the great major-
ity of patients, whereas HPV16 E2-, E6-, and/or E7-specific IFNγ-associated type 1 T-cell 
reactivity was detected in about half of the patients tested.
HPV16-specific immunity is associated with a more favorable clinical response on 
immunomodulatory treatment with imiquimod
Our analysis of HPV16-specific proliferation indicates that a high number of the prolif-
erative T-cell responses is associated with IFNγ production. To examine the role of these 
HPV16-specific type 1 T-cell responses in the success or failure of treatment with the 
immunomodulator imiquimod, we studied this immune response in a group of patients 
with high grade HPV16-positive VIN. PBMC were isolated before (T=0), during (T=8), and 
after (T=16) treatment and stored in liquid nitrogen. HPV-specific T-cell reactivity against 
HPV16 peptides E2, E6, and E7 was analyzed by IFNγ ELISPOT. This is a sensitive method 
for the analysis of antigen-specific type 1 T-cell reactivity on frozen material.32,33 Three of 
these patients had been treated with imiquimod in the year before inclusion in our study 
(Table 2; patients 21, 24, and 27). Of these 17 patients, 15 were HPV16-positive. Preexisting 
IFNγ-associated T-cell responses (T=0) were detected in 8 of 15 patients by IFNγ ELISPOT. 
In 5 of 15 patients, HPV16-specific T-cell reactivity against E2 was detected, whereas 4 of 
15 patients displayed a response against E6 (Table 2). None of these patients showed pre-
existing T-cell responses against HPV16 E7. In two cases the T=0 sample was not available 
and the reaction in PBMC from T=8 are shown (Table 2; patients 1 and 22).
Despite that for some patients one of the two follow-up samples was not available 
(patients 5, 13, 27, and 28), it was clear that we could not detect a direct influence of 
Table 1. Distribution of absolute absorbance values among IgG‑ and IgA‑seropositive samples
Immunoglobulin type
(npositive/28)
∆A415 nm
Mean (SD) Median (range)
IgG seropositive (n=25) 1.10 (0.61) 1.22 (0-1.93)
IgA seropositive (n=13) 0.34 (0.26) 0.31 (0-0.88)
HPV16 L1 IgG and IgA antibodies detected in the sera of 28 VIN 3 patients. Serum antibody responses were 
measured by VLP-ELISA. Depicted are the absolute absorbance values at 415 nm. The absorbance values 
were calculated by subtraction of the background response value and the mean absorbance value of the 
young children’s sera.
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imiquimod on the numbers of HPV-specific T-cells. In none of the patients was a clear-cut 
increase of HPV16-specific T-cells detected upon imiquimod treatment (Figure 2A-B). In 
some cases, patients had already been treated with a course of imiquimod before this 
study, but even this repeated treatment did not result in an increase of HPV 16 specific 
T-cells (Table 3; patients 21 and 24). In addition, the HPV16 VLP-specific IgG and IgA 
response did not overly change when patients were treated with imiquimod (Figure 3).
Table 2. HPV16‑specific T‑cell responses in patients treated with imiquimod
Patient* HPV 
type
clinical 
response†
VLP‡ T E2-peptides E6-peptides E7-
peptides
MRM
1§-
75
61-
135
121-
195
271-
365
1-
52
41-
92
81-
132
111-
158
1-
52
41-
98
1 16 no ++ 8 - - - - - - - - - - 179
2 16 PR1 + 0 52 54 15 31 - - 3 - 9 - 295
4 16 CR ++ 0 - - - - - 1 - - - - 124
5 16 CR ++ 0 - 32 9 3 - - - - - - 32
10 16 PR1 - 0 - 4 - - - - 84 - 5 - 54
12 16 PR1 ++ 0 15 - - - - - - - - - 32
13 16 CR ++ 0 -** - - - - - 104 - - - 105
15 16 PR1 + 0 - - - - - - - - - - 179
21 neg PR1 ++ 0 - - - - - - - - - - 364
22 16 PR2 ++ 8 8 - - 4 - - - - - - 25
23 16 PR1 ++ 0 - 1 59 5 - 74 - - 21§§ 11 52
24 16 no ++ 0 - - - - - - - - - - 172
25 neg CR + 0 - - - 4 - - - - - - 444
26 16 CR ++ 0 - - - - - - - - - - 21
27 16 no ++ 0 - 4 - - - - - - - - 70
28 16 CR ++ 0 6 - 45 18 - 7 3 2 3 - 20
29 16 CR - 0 - 2 7 - - 40 - - - 2 157
Abbreviations: CR, complete response; PR, partial response; MRM, memory response mix.
* PBMC from 17 VIN3 patients were tested for type 1 T-cell reactivity against HPV16 peptides. PBMC were 
stimulated with different pools of HPV16 E2, E6, and E7 peptides and tested for antigen-specific IFNγ 
production by ELISPOT.
† Clinical responses were defined as no clinical response; a partial response type1, as defined by a reduction 
in lesion diameter from 76-99%; a partial response type2 (PR2), as defined by a reduction in lesion diameter 
from 26-75%; and a complete response (CR).
‡ Sera of the patients were tested for the presence of HPV16 L1-VLP specific IgG antibodies. Indicated is the 
presence (+) or absence (-) of antibodies.
§ The first and last amino acid in the indicated protein of the peptide pool used are indicated.
** Per patient, T-cell responses on T=0 are shown. In case of a missing T=0 sample, data from T=8 are shown. 
Specific responses were calculated by subtracting the mean number of spots ± 2 x SD of the medium 
control from the mean number of spots of experimental wells. The number of specific spots per 100,000 
PBMCs are given. Responses were considered positive if peptide pool specific T-cell frequencies were ≥ 10 
in 100,000 PBMCs. These values are indicated in bold. Values below this threshold are shown in italics. (-), no 
specific response to E6 or L1. MRM was used as a positive control.
§§ Responses considered negative because values did not exceed ≥ 2 times the medium control.
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Thirteen of the 17 women treated (76%) displayed an overt clinical response upon 
treatment with imiquimod as indicated by 76% to 100% reduction in the size of their lesion 
(complete response or partial response 1; Table 2; Figure 2C-D). Three patients showed 
no reduction in size of the affected area of vulvar disease and one woman showed only 
minimal improvement upon treatment.
Importantly, when the group of HPV16+ patients (n=15) was divided in patients either 
with or without an HPV-specific Th1 immune response, all eight patients with an HPV-
specific immune response displayed a complete or near complete clinical response (com-
plete response or partial response 1) upon imiquimod treatment (Table 2). In contrast, 
patients without an HPV-specific immune response were less likely to show such a clinical 
improvement (P=0.03, two-sided Fisher’s exact test).
Figure 2. 
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Figure 2. A and B, HPV16‑specific IFNγ‑producing T‑cell responses in two representative patients with high grade 
VIN (patient 2, left and patient 10, right). T‑cell responses are shown at week 0 (before imiquimod treatment), 
week 8 (during imiquimod treatment), and at week 16 (after imiquimod treatment). Local application of 5% 
imiquimod containing cream does not result in enhanced systemic HPV16‑specific T‑cell responses. Note that 
the magnitude of the T‑cell responses varies slightly over the different time points. The mean number of spots 
and SE induced by the medium control or the peptides present in the E2, E6, and E7 pools per 100,000 PBMCs 
are depicted. As positive control, the memory recall mix (MRM) was used. C and D, patients with preexisting 
HPV16‑specific T‑helper type 1 responses show objective clinical responses after imiquimod treatment. A typical 
example is shown. C, biopsy‑proven VIN 3 lesion of patient 5 before imiquimod treatment. D, the same vulvar 
area of patient 5 after 16 weeks of treatment. See also Color Figures, page 151.
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Taken together, chronic viral antigen exposure can induce type 1 CD4+ T-cell immu-
nity against the HPV16 early antigens E2, E6, or E7 in patients with VIN 3. The presence 
of these HPV16-specific Th1-cells as detected by IFNγ ELISPOT, although not essential for 
imiquimod-induced regression of VIN lesions, does increase the likelihood of a strong 
clinical response. The presence of L1-specific humoral reactivity was not correlated with 
imiquimod-induced regressions.
Discussion
We have analyzed the HPV16 E2-, E6-, and E7-specific CD4+ T-cell responses in a group of 
29 patients with high grade VIN, 17 of whom were treated with the immunomodulator imi-
quimod. HPV16-specific type1 (IFNγ) CD4+ T-cell proliferative immunity is present in about 
half of patients with VIN 3 (8 of 20). Virus-specific CD4+ Th1-type T-cells have emerged 
as an essential component in the immune response to chronic viral infection, fulfilling 
a multifactorial role, including the activation of antigen-presenting cell maturation for 
efficient CD8+ priming, the release of cytokines important in CD8+ T-cell proliferation and 
differentiation, and in the recruitment of other effector cells such as eosinophils and mac-
rophages. Indeed, a substantial number of patients with VIN 3 were reported to display 
high frequencies of HPV16-specific CD8+ T-cells.34-36 In contrast, only in a few occasions 
HPV16-specific CD8+ T-cell reactivity was detected in patients with cervical intraepithelial 
neoplasia 3 and cervical carcinoma.37-40 However, these latter types of patients display an 
impaired HPV16-specific CD4+ T-cell response.23
Figure 3. 
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Figure 3. IgG and IgA reactivity to HPV16 VLPs over time in 17 VIN 3 patients treated with imiquimod. At least 
two serum specimens were tested in every patient. Serologic responses are shown at week 0 (before imiquimod 
treatment), week 8 (during imiquimod treatment), and at week 16 (after imiquimod treatment). The absorbance 
(OD) values are depicted as median ± SD of positive responses. The absorbance values were calculated by 
subtraction of the background response value and the mean absorbance value of the young children’s sera.
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Topical application of imiquimod neither enhanced the preexistent HPV16-specific 
CD4+ T-cell responses nor resulted in the induction of such responses in any of the other 
subjects. Todd et al made a similar observation with respect to HPV16-specific CD8+ 
T-cells.36 Notably, we found that a preexisting HPV-specific type 1 T-cell response was asso-
ciated with a more favorable clinical outcome upon topical imiquimod treatment of VIN 3. 
This indicates that a combination therapy, in which the HPV16-specific T-cell response is 
induced or boosted by vaccination and the affected skin is treated with imiquimod, may 
increase the number of patients that benefit from treatment.
Compared with normal vulvar skin, a number of VIN lesions display increased infiltra-
tion of CD4+ and CD8+ T-cells.41-43 The clinical consequences of the infiltration of immune 
cells in these VIN lesions are poorly understood, but the immunological make-up of 
the vulvar microenvironment may determine the clinical outcome.43 The local cytokine 
microenvironment in high grade cervical neoplasia is associated with a decreased 
expression of the pro-inflammatory Th1 cytokines, TNFα and IFNγ.44-46 It is conceivable 
that similar to cervical intraepithelial neoplasia, the vulvar microenvironment also lacks 
pro-inflammatory cytokines. Imiquimod is known to directly stimulate Langerhans cells 
and macrophages,17,47 of which the latter are increased in VIN lesions.42 Furthermore, it 
stimulates natural killer cells and T-helper type 1 cells via indirect mechanisms.17,47 Upon 
stimulation, the antigen-presenting cells release pro-inflammatory cytokines, predomi-
nantly IFNα, TNFα, and IL-12.14,15,17,47 This may restore an inducive environment in which 
the innate effector cells, macrophages and natural killer cells, as well as activated HPV16-
specific T-cells may act in concert to form an effective immune response. The requirement 
for these additional signals to activate T-cells is sustained by recent observations in animal 
models. In the HPV16 E7-transgenic skin transplantation model, Matsumoto et al showed 
that despite the presence of large numbers of E7-specific memory T-cells E7+ skin trans-
plants were not rejected, except when these E7-specific memory T-cells were activated 
through vaccination.48 This suggested that the presence of the HPV16 E7 antigen itself is 
not sufficient to evoke a strong skin-destroying immune response but that additional acti-
vating signals were required. Similarly, Van Mierlo et al showed that adenovirus-specific 
CD8+ T-cells developed in the draining lymph nodes of mice bearing adenovirus-positive 
tumors, indicating that tumor-antigen was detected by T-cells of the immune system.49 
The tumor was rejected only when strong pro-inflammatory signals were provided. 
Likewise, HPV16-induced VIN 3 lesions may fail to endow the immune system with strong 
inflammatory signals and exogenously provided signals will be required to provide a state 
of inflammation. These signals can be delivered by imiquimod, electro coagulation,50 or 
by vaccines.32-34
Currently, it is not clear whether immune activation causes the HPV16-specific IFNγ-
producing CD4+ T-cells to migrate into the HPV-infected tissue or whether these T-cells 
should simply provide help to activate effector cells in the draining lymph nodes. Therefore, 
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we are currently examining both local and systemic immune response in patients with 
high grade VIN.
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Vulvar intraepithelial neoplasia (VIN) is a difficult disease to treat. Symptoms can be 
long-lasting and severe and progression to invasive vulvar carcinoma is seen, although 
the available literature suggests that the progression rate without treatment is low (9%).1 
To date, treatment is aimed at the surgical removal of all visible lesions.2 Unfortunately, 
surgery does not prevent progression to invasive disease and recurrences of VIN are com-
mon, the latter presumably because persistent infection with HPV, the viral cause of usual 
type VIN, is not affected by surgical treatment. In contrast to what was previously thought, 
VIN associated with lichen sclerosus is also of the usual type and related to HPV in 31%.3
From our systematic review it appeared that no difference in progression is seen after 
different surgical procedures. Iversen et al showed that free surgical margins will not 
prevent progression.4 Whether free surgical margins diminish the change to progres-
sion in comparison to involved margins could not be established in our review. Another 
observation was that untreated patients are more likely to progress to invasive vulvar 
carcinoma than patients treated for VIN (9% vs 3.3%, respectively). According to Jones et 
al, this figure is higher. In a large study of 405 women with VIN, 10 (18.5%) of 63 untreated 
patients (i.e. biopsy alone or grossly incomplete excision) progressed to invasion in 13 
months to 7.3 years (mean 3.9 years).5 Importantly, invasion may occur many years after 
VIN 3 is diagnosed. In our review, the mean time to progression was 4.6 years (range 4 
months to 18 years), indicating the importance of a long and careful follow-up. Another 
problem highlighted in our review was the high recurrence rate after surgical treatment. 
Recurrences were seen as often after local excision as after (partial) vulvectomy (22% 
vs 18%, respectively), showing a lower percentage after free surgical margins than after 
involved surgical margins (p<0.001). In 2005, Hillemans et al also reported high recurrence 
rates for different treatment modalities (>40%), showing a significantly increased risk with 
VIN grade (P=0.02), multifocality (P=0.01), multicentricity (P=0.05) and presence of hr HPV 
infection (P=0.001).6
VIN is being diagnosed with increasing frequency in relatively young women.4 This rise 
in incidence could be the result of a higher awareness and knowledge of VIN, but is more 
likely due to the overall increase in sexually transmitted diseases, and especially the rise 
in HPV infections. For this reason and the above mentioned limitations of surgery, a new 
treatment strategy for VIN by means of imiquimod, a local immune response modifier 
with antiviral and antitumour activity, was examined and described in this thesis. After 
the first positive results from our pilot study in which 13 of 15 patients with VIN showed 
a partial or complete response,7 a placebo-controlled, double-blind, randomized clini-
cal trial (RCT) was designed to investigate the effectiveness of imiquimod in VIN (n=52) 
during an observational period of 12 months.8 Twenty-one (81%) of 26 patients treated 
with imiquimod showed reduction in lesion size, whereas none of the placebo subjects 
experienced a response of more than 25% (p<0.001). Complete response was achieved 
in 9 (35%) and partial response in 12 (46%) patients treated with the cream. Compared to 
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placebo, imiquimod was significantly associated with histological regression, viral clear-
ance and relief of itchiness and pain. All complete responders (n=9) remained free from 
disease after 12 months of follow-up. About the same time, Mathiesen et al published 
similarly positive results for the only other RCT so far evaluating the use of imiquimod in 
VIN.9 In his study thirty-one patients, most of them presenting with unifocal VIN (n=22), 
were treated with imiquimod or placebo in a 2:1 ratio using an escalating dose regimen 
during 16 weeks. Seventeen (81%) of 21 patients treated with imiquimod showed a 
complete response (defined by complete disappearance of dysplastic changes), whereas 
a partial response was seen in two patients (defined by reduction from VIN 3 to maximally 
VIN 1 in biopsies taken two months after last treatment). Long term follow-up was not 
mentioned. As in our study, local side effects were a common feature, but tolerable after 
dose-reduction. The use of immunotherapy is also encouraged by Le et al who investigated 
the clinical response in 39 VIN-patients treated with imiquimod with a median follow-up 
of 16 months.10 An overall response rate of 77% was shown. Recurrence data within this 
group were compared with data from a historical cohort of surgically treated VIN patients, 
showing recurrence after treatment with imiquimod in 20.5% compared to 53.5% in surgi-
cally treated patients (P=0.013). Neither Mathiesen nor Le et al found progression of VIN 
or cancer during follow-up. In our RCT, three (6%) of 49 patients progressed to invasion 
(<1mm); two of them after placebo, one after imiquimod. These results are not different 
from the progression rate in VIN after surgical treatment.
So far, 17 studies published from 2000 to 2007 reported on the effectiveness and safety 
of imiquimod cream in the treatment of VIN. Summarized recently in a review article 
by Iavazzo et al, data from these 17 studies show complete regression in 26 to 100% of 
patients, and partial regression in 0 to 60%.11 Recurrence was observed in 0-37%. A lack 
of response to imiquimod treatment did not seem to be associated with a higher risk of 
lesion progression.
It is not yet clear why some patients showed a better response to imiquimod than 
others. Since involvement of HPV in the aetiology of VIN suggests an immunological 
defect in the diseased, we investigated the influence of imiquimod on the presence of 
immunocompetent cells in the epidermis and dermis of VIN-affected skin. Treatment with 
Values as median (range), logarithmic scale
1: controls (n=19)
2: imiquimod group before medication (all 
patients, n=25)
3: imiquimod group after medication
4: imiquimod group before medication (patients 
with clinical response > 75%, n=13)
5: imiquimod group after medication
6: imiquimid group before medication (patients 
with clinical response < 75%, n=12)
7: imiquimod group after medication
8: placebo group before medication (n=26)
9: placebo group after medication
* p<0.05
Legends for Figure 1 and 2
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imiquimod resulted in a significant increase of immature CD1a+ myeloid dendritic cells 
(mDCs), CD8+ T-cells and CD94+ natural killer (NK) cells in the epidermis of VIN-patients 
with a clinical response of more than 75%.5 In the dermis of these patients, immature 
CD207+ and mature CD208+ mDCs, and T-regulatory (Treg) cells decreased after treatment 
with imiquimod.8 Combination of these results with data obtained from healthy vulvar 
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Figure 1. Results of immunohistochemical staining for 
CD1a+ DCs, CD8+ T‑cells, and CD94+ NK‑cells in the 
epidermis of healthy normal skin (controls), and in 
VIN‑affected skin before and after treatment with imi‑
quimod or placebo. See also Color Figures, page 152.
Figure 2. Results of immunohistochemical staining 
for CD123+/11c‑ and CD208+ DCs, and CD25/HLA‑
DR+ Treg‑cells in the dermis of healthy normal skin 
(controls), and in VIN‑affected skin before and after 
treatment with imiquimod or placebo.
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skin gave us more insight into the immunological effect of imiquimod in VIN-lesions. Com-
pared to normal vulvar skin, we found VIN to be characterized by an immunosuppressive 
state in the epidermis, showing a reduction of immature myeloid DCs and CD8+ T-cells.12 
In the dermis, inflammatory activation is reflected by the influx of mature myeloid and 
plasmacytoid DCs, NK-cells and T-cells. It seems that for certain cell types the disturbed 
pattern in VIN-affected skin is normalized by treatment with imiquimod as presented in 
Figures 1 and 2. This repair towards normal cell levels is only observed in patients with 
a clinical response of more than 75%, suggesting that the immunological make-up in 
VIN-affected skin is directive for the clinical outcome. In addition, we found that chronic 
exposure of the immune system to the HPV16 viral proteins resulted in the induction of 
systemic type 1 T-cell immunity in half of patients, which is likely to be associated with a 
more favorable clinical response to imiquimod treatment.13
Similar to our data, Santegoets et al reported increased levels of mature CD208+ DCs 
in the dermis when HPV-related VIN tissue was compared to HPV-negative control vulvar 
tissue from the same patient, suggesting that DCs, after recognition of viral antigens, are 
stimulated to move into the dermis and to access secondary lymphoid organs.14 Accord-
ing to Santegoets et al, however, this migration process seems to be disturbed because 
of a lack of accurate chemokine signalling. Most DCs will therefore stay in the dermis, not 
able to present the viral antigen to naïve T-cells in the lymph node. This may be one of 
the reasons for an inaccurate initiation of the adaptive immune response. During cervi-
cal carcinogenesis, Caberg et al observed a virus-induced altered expression of immune 
mediators necessary for Langerhans cell chemoattraction, suggesting a similar inability of 
the local immune system to mount a protective cell-mediated immune response against 
HPV-infected keratinocytes.15 Further studies are needed to fully understand the role of 
the immune system in HPV-infected disease.
Recommendations and future prospects
Although VIN is a premalignant disease, it already displays several hallmarks of cancer as 
shown by our research group.16 For this reason, we recommend that VIN should be treated 
pro-actively. In our opinion, imiquimod deserves a prominent role in this treatment. Show-
ing a clinical response similar to or even better than after surgical treatment, in a way that 
is less invasive, well tolerated, and does not influence health-related quality of life, body 
image or sexuality, we would like to propose imiquimod first choice treatment in VIN. To 
achieve an even better clinical response rate to imiquimod treatment, it is hypothesized 
that boosting different aspects of cellular immune responses, for example by means of 
vaccination, will further enhance cellular immunity, and stimulate disease clearance in 
patients with VIN. Study protocols combining imiquimod with vaccination against HPV 
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are currently under development. In addition, therapeutic HPV-vaccine studies - that until 
now have not shown high efficacy in clinical trials17,18 - are also ongoing.
In the meantime, it is planned for prophylactic HPV vaccination to be implemented in 
the general population, hopefully resulting in reduced rates of HPV-related vulvar (pre-) 
malignancies. Recently, Joura et al showed evidence that prophylactic administration of 
a quadrivalent HPV6/11/16/18 L1 virus-like-particle (VLP) vaccine, developed to prevent 
cervical cancer, also prevents HPV-related vulval and vaginal pre-cancers in 16 to 26-year-
old women.19 Yet, even if prophylactic vaccination effectively prevents HPV-infection in 
the majority of the human population, it is not to be expected that such a vaccine will 
abandon HPV-related disease within the next few decades. The fact that prophylactic HPV 
vaccination is targeted against a limited number of HPV types might contribute to ongoing 
disease. Until then, effective treatment is needed and imiquimod should be considered 
first-choice treatment for patients with usual type VIN.
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Summary
Vulvar intraepithelial neoplasia (VIN) is a rare condition from which an invasive carcinoma 
can develop. Most women suffer from severe and long-lasting symptoms, such as pruritus 
and vulvar pain. The incidence of VIN has increased over time, and nowadays patients are 
being affected at a younger age. As there is hardly any data on the follow-up of untreated 
patients, it is difficult to predict the outcome of disease for the individual patient. Studies 
with untreated patients who hardly ever progress to an invasive vulvar carcinoma have 
been published, whereas others have seen progression in nearly all untreated patients. 
Currently, standard therapy for high grade VIN comprises surgical removal of all visible 
lesions to relieve symptoms and to prevent the development of invasive disease. However, 
there are limitations to surgery. Despite extensive treatment, surgical margins are often 
positive. Recurrences are common, presumably because persistent infection with human 
papillomavirus (HPV), the viral cause of usual type VIN, is not affected by surgical treat-
ment. Progression is seen as often after vulvectomy as after local excision. Moreover, one 
should realize that surgery can mutilate the vulva, thereby causing psychosexual distress.
The aim of this thesis was to investigate a new treatment strategy for VIN by means of 
an immunotherapy; a treatment that is effective by focusing on the viral cause of disease, 
without being mutilative to the patient. In the different chapters, attention is paid to clini-
cal, histological, viral and immunological aspects of (this immunotherapy in) VIN.
A general introduction on VIN is presented in Chapter 1.
In Chapter 2 we tried to establish the true natural history of VIN 3 from litera tu re data. In 
a systematic review, data of 3322 women with VIN 3 (97 studies) were analyzed to assess 
both the risk of progression of VIN in untreated patients and the effect of surgical treatment 
in relation to recurrences and progression of VIN. From this data, there is no indication that 
recurrences of VIN depend on the type of surgery used, except for cryosurgery, which has 
a high failure rate (56%). Recurren ces were seen as often after laserevaporization (23%) as 
after local excision (22%) or vulvectomy (19%). Recurrences were significantly lower, but 
not absent, after free surgical margins than after involved surgical margins (P<0.001). It 
could not be established whether free surgical margins diminish the change to progres-
sion. Untreated patients were more likely to progress to invasive vulvar carcinoma than 
patients treated for VIN (9% versus 3.3%). Spontaneous regression was seen in 41 (1.2%) 
of the 3322 pa tients; in 17 (41%) of them regression was related to preg nancy. From this 
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data, there is not enough evidence to support the removal of all involved vulvar skin. It is 
evident that only a prospective registration using a standardized pathology examination 
will provide information about the real natural history of VIN.
Chapter 3 describes the histology and HPV status in patients with a history of lichen 
sclerosus (LS) and VIN. It is commonly assumed that differentiated type VIN is related to 
LS, although evidence for this is limited to a small number of studies describing epithelial 
alterations adjacent to vulvar squamous cell carcinoma (SCC). In this study, we revised 
original biopsy and surgical specimens from patients with a history of both LS and VIN 
without coexistent SCC. In all 27 patients that met our inclusion criteria, LS was found to be 
related to undifferentiated VIN. HPV DNA was demonstrated in 31% of the lesions, and was 
strongly related to high grade VIN. During follow-up, three patients progressed to (early) 
invasive carcinoma. In two of these patients, differentiated VIN was observed overlying 
early invasive SCC.
In Chapters 4 and 5 we investigated the effectiveness of imiquimod, a topical immune-
response modifier with antiviral and antitumor activity, as a new treatment for patients 
with VIN. Imiquimod has been shown to be safe and effective in the treatment of genital 
warts. A pilot study, presented in Chapter 4, showed promising results, and was followed 
by a placebo-controlled, double-blind, randomized clinical trial (RCT). Chapter 5 describes 
this RCT, in which 52 patients with usual type VIN were randomly assigned to receive either 
imiquimod or placebo twice a week for a period of 16 weeks. The follow-up period was 
12 months. The primary outcome was a reduction of more than 25% in lesion size at 20 
weeks. Secondary outcomes were histologic regression, clearance of HPV from the lesion, 
changes in immune cells in the epidermis and dermis of the vulva, relief of symptoms, 
improvement of quality of life, and durability of response. Lesion size was reduced by more 
than 25% at 20 weeks in 21 of the 26 patients (81%) treated with imiquimod and in none of 
those treated with placebo (P<0.001). Histologic regression was significantly greater in the 
imiquimod group than in the placebo group (P<0.001), and was strongly related to clear-
ance of the underlying causative HPV infection, as was clinical regression. The number of 
immune epidermal cells increased significantly and the number of immune dermal cells 
decreased significantly with imiquimod as compared with placebo. Imiquimod significantly 
reduced pruritis and pain at 20 weeks and at 12 months. The lesion progressed to invasion 
(<1 mm) in three of 49 patients (6%) followed for 12 months (two in the placebo group and 
one in the imiquimod group). All nine patients (35%) showing a complete response at 20 
weeks, remained free from disease at 12 months. Following the results of our studies, we 
concluded that imiquimod is effective in the treatment of VIN.
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Genital infection with HPV is usually transient. However, when immunity ‘fails’ and 
the infection persists, VIN or other HPV-related diseases may develop. In Chapter 6 we 
examined the epidermal and dermal distribution of different immunocompetent cells 
(dendritic cells, natural killer cells, T-cells) in patients with usual type VIN and compared 
this with data from healthy controls. Our results demonstrated that high-risk HPV-related 
usual type VIN lesions are characterized by an immunosuppressive state in the epidermis, 
showing a reduction of immature myeloid dendritic cells and CD8+ T-cells. In the dermis, 
inflammatory activation is reflected by the influx of mature myeloid and plasmacytoid 
dendritic cells, natural killer cells and T-cells, suggesting that a cellular immune response 
on viral HPV infection occurs in the dermis of VIN patients.
Chapter 7 describes the impact of type 1 T-cell immunity on the clinical outcome of treat-
ment with imiquimod in patients with usual type VIN. A detailed analysis with respect to 
the magnitude and cytokine polarization of the HPV16 E2-, E6- and E7-specific CD4+ T-cell 
response was done by proliferation and cytokine bead array in patients with usual type 
VIN. Furthermore, HPV16-specific type 1 T-cell immunity was analyzed in patients before, 
during and after topical treatment with imiquimod. HPV16-specific proliferative responses 
were found in half of the patients, mainly associated with IFNγ-production. Although 
imiquimod did not enhance or induce T-cell immunity in any of the subjects, the presence 
of these type 1 T-cell responses is likely to be associated with a more favorable clinical 
response to imiquimod treatment (P=0.03).
Chapter 8 provides a general discussion based on the main findings.
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Samenvatting
Vulvaire intraepitheliale neoplasie (VIN) is een zeldzame aandoening waaruit een invasief 
carcinoom kan ontstaan. Het merendeel van de vrouwen ondervindt ernstige en lang-
durige klachten in de vorm van jeuk en pijn. De incidentie van VIN is de afgelopen jaren 
toegenomen, en de diagnose wordt op steeds jongere leeftijd gesteld. Er is weinig bekend 
over het natuurlijk beloop van onbehandelde VIN. Het is daarom moeilijk een uitspraak te 
doen over de uitkomst van ziekte voor de individuele patiënt. Er zijn studies over patiënten 
beschreven met onbehandelde VIN die vrijwel nooit ontaardt in maligniteit, terwijl andere 
studies berichten over progressie in vrijwel alle onbehandelde patiënten. De huidige 
behandeling van VIN bestaat uit het chirurgisch verwijderen van alle zichtbare laesies, om 
klachten te verminderen en de kans op maligne ontaarding te voorkomen. Helaas heeft 
deze chirurgische benadering nadelige aspecten. Ondanks uitgebreide behandeling zijn 
chirurgische snijvlakken vaak positief. Daarnaast is de recidiefkans hoog, waarschijnlijk 
omdat de chirurgische ingreep weinig tot geen invloed heeft op de onderliggende 
causale infectie met humaan papillomavirus (HPV). Progressie na behandeling komt even 
vaak voor na vulvectomie als na lokale excisie. Het is van belang zich te realiseren dat 
chirurgische interventie een mutilerend effect kan hebben, hetgeen gepaard kan gaan 
met seksueel dysfunctioneren en psychosomatische stress.
Het doel van dit proefschrift was het onderzoeken van een nieuwe effectievere behan-
deling voor usual type VIN in de vorm van een immunotherapie. Hierbij ligt de nadruk 
niet langer op het verwijderen van de afwijking, maar op het uitschakelen van de oorzaak, 
namelijk infectie met HPV. In de verschillende hoofdstukken is aandacht besteed aan 
klinische, histologische, virale en immunologische aspecten van (deze immunotherapie 
bij) VIN.
Hoofdstuk 1 geeft een algemene introductie over VIN .
In Hoofdstuk 2 is de beschikbare literatuur bestudeerd om het natuurlijke beloop van 
VIN te achterhalen. In een systematisch review zijn data van 3322 vrouwen met VIN 3 (97 
studies) geanalyseerd, waarbij is gekeken naar de kans op progressie bij onbehandelde 
VIN en naar het effect van chirurgische behandeling bij VIN in relatie tot recidiefkans en 
progressie. Uit deze data blijkt dat de kans op een recidief niet afhangt van het type chirur-
gie dat is gebruikt, behalve bij cryochirurgie, waarbij sprake is van een hoge recidiefkans 
(56%). Recidieven komen even vaak voor na laserevaporisatie (23%) als na lokale excisie 
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(22%) of vulvectomie (19%). De kans op een recidief is lager, maar niet helemaal afwezig, 
wanneer de chirurgische snijvlakken vrij zijn (P<0.001). Of vrije snijvlakken de kans op 
progressie ook verlagen, was in deze studie niet aantoonbaar. Wel is duidelijk dat de kans 
op maligne ontaarding groter is bij onbehandelde VIN dan bij behandelde VIN (9% versus 
3.3%). Spontane regressie werd gezien bij 41 (1.2%) van de 3322 patiënten; bij 17 (41%) van 
hen was regressie gerelateerd aan zwangerschap. Concluderend kunnen we zeggen dat 
er onvoldoende aanwijzingen zijn om het radicaal verwijderen van alle zichtbare laesies 
te ondersteunen. Alleen een prospectieve registratie waarbij gebruik wordt gemaakt van 
gestandaardiseerd pathologisch onderzoek zal duidelijkheid geven over het natuurlijke 
beloop van VIN.
Hoofdstuk 3 beschrijft de histologie en HPV status van patiënten met een voorgeschiede-
nis van lichen sclerosus (LS) en VIN. Algemeen wordt aangenomen dat gedifferentieerde 
VIN gerelateerd is aan LS, ook al is het bewijs hiervan beperkt tot een klein aantal studies die 
de epitheliale veranderingen naast een plaveiselcel carcinoom van de vulva beschrijven. 
In deze studie werd histologisch materiaal gereviseerd van patiënten met een voorge-
schiedenis van zowel LS als VIN zonder carcinoom. Bij alle 27 vrouwen die aan onze inclusie 
criteria voldeden, kwam LS voor in combinatie met ongedifferentieerde VIN. HPV DNA kon 
worden aangetoond in 31% van de laesies, waarbij duidelijk een relatie werd gezien met 
hooggradige VIN. Tijdens follow-up ontwikkelden drie patiënten een invasief carcinoom. 
Bij twee van hen werd naast het carcinoom gedifferentieerde VIN aangetroffen.
In Hoofdstukken 4 en 5 is de effectiviteit van imiquimod, een lokale immuun modulator 
met antivirale en antitumor activiteit, als behandeling bij patiënten met VIN bestudeerd. 
Imiquimod is veilig en effectief gebleken in de behandeling van condylomata acuminata. 
Na veelbelovende resultaten uit een pilot studie, beschreven in Hoofdstuk 4, werd 
een placebogecontroleerde, dubbelblinde, gerandomiseerde klinische studie opgezet. 
Hoofdstuk 5 beschrijft deze studie, waarin 52 vrouwen met usual type VIN zijn gerando-
miseerd voor een behandeling met imiquimod of placebo twee keer per week gedurende 
16 weken. De totale follow-up periode was 12 maanden. Primaire uitkomstmaat was een 
reductie in laesiegrootte van >25% bij 20 weken. Secondaire uitkomstmaten waren histo-
logische regressie, klaring van HPV in de laesie, veranderingen van immuuncompetente 
cellen in de epidermis en dermis van de vulva, vermindering van klachten, verbetering 
van kwaliteit van leven, en duurzaamheid van de klinische respons. Een reductie in lae-
siegrootte van >25% bij 20 weken werd gezien bij 21 (81%) van de 26 met imiquimod 
behandelde vrouwen, maar bij geen van de met placebo behandelde vrouwen (P<0.001). 
Histologische regressie trad significant vaker op in de imiquimod groep dan in de pla-
cebo groep (P<0.001), en was net als klinische respons sterk gecorreleerd met klaring 
van HPV. Het aantal immuuncompetente cellen in de epidermis nam significant toe na 
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behandeling met imiquimod, terwijl het aantal immuuncompetente cellen in de dermis 
significant daalde. In vergelijking met placebo waren klachten van jeuk en pijn significant 
verminderd na behandeling met imiquimod. Na 12 maanden follow-up waren alle negen 
patiënten met een complete respons bij 20 weken nog steeds vrij van ziekte. Progressie 
van de laesie naar invasie (<1mm) werd gezien bij drie van de 49 patiënten (6%) waarvan 
follow-up bekend was; twee daarvan zaten in de placebogroep, één in de imiquimod 
groep. Uit deze studieresultaten kunnen we concluderen dat imiquimod effectief is in de 
behandeling van VIN.
Genitale infectie met HPV is meestal van voorbijgaande aard. Echter, wanneer het 
immuunsysteem ‘faalt’ en er sprake is van een persisterende infectie, kan VIN of een 
andere HPV-gerelateerde afwijking ontstaan. In Hoofdstuk 6 hebben we de epidermale 
en dermale verdeling van immuuncompetente cellen (dendritische cellen, natural killer 
cellen en T-cellen) in patiënten met usual type VIN onderzocht en vergeleken met data 
van gezonde controles. Onze resultaten lieten zien dat hoog-risico HPV-gerelateerde 
usual type VIN gekenmerkt wordt door een immuunsuppressieve status in de epidermis, 
hetgeen wordt geïllustreerd door een afname in het aantal myeloide dendritische cellen 
en het aantal CD8+ T-cellen. In de dermis wordt VIN juist gekenmerkt door een influx van 
mature myeloide en plasmacytoide dendritische cellen, natural killer cellen en T-cellen. Dit 
wijst erop dat een cellulaire immuunrespons bij een virale infectie met HPV plaats vindt in 
de dermis van patiënten met VIN.
Hoofdstuk 7 beschrijft de impact van type 1 T-cel immuniteit op de klinische respons op 
behandeling met imiquimod bij patiënten met usual type VIN. Een uitgebreide analyse 
van de HPV16 E2-, E6- en E7 specifieke CD4+ T-cel respons werd verricht middels een pro-
liferatie assay met cytokine-profiel bij patiënten met VIN. Verder is gekeken naar HPV16-
specifieke type 1 T-cel immuniteit voor, tijdens en na lokale behandeling met imiquimod. 
Bij de helft van de patiënten met VIN werd een HPV16-specifieke proliferatieve respons 
gezien, voornamelijk gepaard gaand met de productie van IFN-γ. Alhoewel behandeling 
met imiquimod geen invloed heeft op de omvang van de T-cel respons, lijkt aanwezigheid 
van deze type 1 T-cel respons te resulteren in een beter klinisch resultaat na behandeling 
met imiquimod (P=0.03).
Hoofdstuk 8 geeft een algemene beschouwing gebaseerd op de resultaten van de 
beschreven studies.
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Dankwoord
Het begon allemaal in Mozambique.
Februari, 2000. Ik had m’n coschappen net afgerond, en ging voor een paar maanden het 
avontuur tegemoet in Mozambique. Eerst een maand reizen, en daarna drie maanden als 
vrijwilliger aan de slag in een klein hospitaaltje in Namapa. Een dorpje zonder stromend 
water en zonder elektriciteit. Bericht dat het land geteisterd werd door overstromingen 
kwam bij pas bij ons aan, toen het thuisfront al drie dagen in rep en roer was. Dus wat 
schetste mijn verbazing toen er ineens een fax binnenkwam uit Nederland:
“…. Laat even weten of je geïnteresseerd bent in een baan als arts-onderzoeker. Er komt 
een onderzoeksplek vrij bij de gynaecologie en het is in eerste instantie voor een jaar….” 
Afzender: Aagje Bais
U begrijpt, het is niet bij dat ene jaar gebleven.
Professor Helmerhorst, deze fax kwam natuurlijk eigenlijk van u. Ik heb even over het 
antwoord na moeten denken, maar eenmaal uit de Afrikaanse droom ontwaakt ben ik vol 
enthousiast het onderzoek ingestapt. Na de eerste kleine tegenvallers (het project waar 
ik instapte lag na 3 maanden volledig op z’n gat), hebben we de VIN-studie opgezet en 
zie wat er van is geworden. Zelfs het tweede proefschrift is bijna in aantocht! U heeft me 
geleerd altijd net dat beetje verder te kijken. En, als ik vond dat het daarna nog steeds 
beter en mooier kon, liet u me inzien dat het ook weleens goed was zoals het was. Bedankt 
voor alle vrijheid, en voor het vertrouwen dat er een einde aan zou komen, en dat er een 
goed einde aan zou komen!
Marc van Beurden, beste Marc, je bent een co-promotor uit duizenden. Eigenlijk was jij de 
motor achter de VIN-studie. Ik vind het bewonderenswaardig hoe jij in de beginperiode 
van mijn onderzoek de energie en de tijd kon vinden om mij op pad te helpen. Ik kon je 
altijd bellen, en als ik je weer eens op de valreep een nieuwe versie van het een of ander 
had toegestuurd met het verzoek dat svp zo snel mogelijk gecorrigeerd terug te sturen, 
kreeg je dat ook bijna altijd voor elkaar. Zelfs als je ergens op een vakantie adresje was… 
bedankt!
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Ilse Beckmann, lieve Ilse, je meisjes zijn eindelijk klaar! Zonder jou hadden we het nooit 
gered, maar nu kun je de boel met een gerust hart achterlaten. Dank voor al je hulp, en 
voor je luisterend oor. Ik ben heel blij dat je op de valreep nog mijn co-promotor bent 
geworden!
Professor (Matthé) Burger, bedankt voor de productieve maandagochtendbesprekingen. 
Ze hebben ervoor gezorgd dat we de problemen die konden optreden altijd net een 
stapje voor waren.
Professor ten Kate, bedankt voor uw beoordeling van het manuscript en voor uw bereid-
heid deel te nemen in de kleine commissie. Ik zal onze revisiesessies ’s ochtends vroeg om 
zeven uur niet snel vergeten.
Professor (Curt) Burger en Professor Lambrecht, hartelijk dank voor de beoordeling van 
mijn manuscript.
Professor Jones, dear Ron, thank you for making the long journey to Holland to participate 
in my thesis defence.
Patricia Ewing, Rene Eijkemans, Alex Kleinjan, Claudia Heijmans-Antonissen, Chris Meijer, 
Marjolein Kagie, Mariëtte van Poelgeest, Sjoerd van der Burg, Ton de Craen, Neil Aaronson 
en Freek Zijlstra: bedankt voor de fijne samenwerking. Zonder jullie was dit proefschrift 
niet geworden wat het nu is. Een speciaal bedankje gaat naar jou, Claudia, wat een mon-
nikenwerk heb je verricht met de celtellingen…!
Lieve Anne en Aagje, dat jullie mijn paranimfen zouden worden, stond van het begin af 
aan als een paal boven water. Jullie kennen me allebei als geen ander, en bovendien heb 
ik bij jullie de kunst van het verdedigen af mogen kijken. Ik ben er hartstikke trots op dat 
jullie straks naast me staan!
P.S. Neemt een van jullie Tipp-Ex mee, want er is bijna geen plaats meer op de muur van 
het zweetkamertje…
Lindy, het is geweldig als je onderzoek wordt voortgezet door anderen die er met net 
zo’n enthousiasme tegenaan gaan! Veel succes met de afronding, en geniet straks van je 
werk in de kliniek! En aan alle andere onderzoekers bij de gyn: het einde komt een keer in 
zicht!
Vera, Roy, Martine, Ed, Femke, Hans, Anne en Guy: al meer dan 15 jaar vriendschap! Ik ben 
hartstikke blij met jullie, en trots op wat we allemaal hebben bereikt! Dat er nog maar heel 
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veel etentjes, ski-vakanties, weekendjes Frankrijk en middagen gewoon-omdat-we-zin-
hebben-om-te-kletsen mogen volgen.
Jaarclub Blixem, vanaf morgen ga ik de schade inhalen. Waar moet ik beginnen met 
kraambezoek?
M’n tennismaatjes Ellard, Nienka, Ad, Kaj en Carola, bij jullie kon ik letterlijk alles van me 
afslaan! De (champagne-)ontbijtjes houden we erin. Volgend jaar kampioen??
Lieve (broer) Marc, het is geweldig om jou als papa te zien! Doet je beseffen dat er veel 
belangrijkere dingen op de wereld zijn! Ik ben heel blij met jou, en Mandy en Robin.
Lieve papa en mama, zonder jullie onvoorwaardelijke steun was dit nooit gelukt. Bedankt 
voor al het vertrouwen dat jullie in me hebben. Dit boekje is voor jullie!
Lieve Mark, I can’t believe that you’re still there! Moving over from Brighton, living here 
with me in a time that I was in a constant hurry and did not have time for anything, but 
work. You helped me through the final bit, and made your sandwiches famous!
Morgen 1000 leuke dingen doen in Nederland???
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Figure 1. 
 
 
 
 
 
 
Figure 1. Patient 1: (A) vulvar biopsy with both condylomatous dysplasia and classic lichen sclerosus (LS; H&E, 
x20); (B) in more detail, verricuform dysplastic changes that tested positive for human papillomavirus (HPV)‑
59 DNA, showing mild‑to‑moderate disturbance of the epithelial architecture with acanthosis and koilocytosis, 
conform vulvar intraepithelial neoplasia (VIN) 2 (H&E, x100); (C) classic LS in more detail, showing oedema and 
hyalinisation of the dermis, vacuolisation of the dermal‑epidermal junction, and hyperkeratosis, with normal 
architecture of the squamous epithelium (H&E, x100). Patient 2: (D) local excision of the vulva in a patient 
with a diagnosis of VIN 3, showing undifferentiated HPV16‑positive VIN in the background of LS (H&E, x80); 
(E) a higher magnification of (D), showing the transition of normal to dysplastic epithelium (H&E, x200); (F) 
histological findings of LS in the same tissue with hyperkeratosis, thinning of the epidermis, and oedema with 
homogenisation of the dermal stroma (H&E, x125). Patient 3: (G) coexistence of LS and undifferentiated VIN 2 in 
the vulva (H&E, x200); (H) a higher magnification of (G), illustrating dysplastic changes that tested negative for 
HPV DNA (H&E, x400).
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Figure 2. 
 
 
Figure 2. Patient 4: (A) lichen sclerosus (LS) showing a broad band of hyalinisation underlying an atrophic 
epidermis with loss of rete ridges (H&E, x50); (B) undifferentiated human papillomavirus (HPV) 16‑positive vulvar 
intraepithelial neoplasia (VIN) 3 biopsied at the same time in the same patient, but in a different lesion (H&E, 
x100). Patient 5: (C) LS with normal epidermal maturation (H&E, x100); (D) undifferentiated HPV‑negative VIN 
3 in the same patient, which was diagnosed 6 years after the diagnosis of LS (H&E, x64). Patient 6: (E) classic 
LS showing extensive dermal hyalinisation with vacuolisation of the dermal‑epidermal junction (H&E, x64); (F) 
undifferentiated HPV‑negative VIN 1, with focal VIN 2 diagnosed 2 years after the diagnosis of LS (H&E, x160).
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Figure 3. 
 
Figure 3. Patient 7: (A) lichen sclerosus (LS; H&E, x50); (B) undifferentiated vulvar intraepithelial neoplasia (VIN) 3 
not related to human papillomavirus (HPV), which was diagnosed 9 years after the diagnosis of LS (H&E, x60); (C) 
one year later, this patient developed a lesion suspicious for squamous cell carcinoma, which was surrounded by 
HPV‑negative differentiated VIN (H&E, x50). Little or no atypia is shown above the (para‑) basal layer; (D) pearl‑
like changes can be distinguished (H&E, x250).
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Figure 1. Effects of imiquimod and placebo on total lesion size at 20 weeks and at 12 months. Total lesion size as a 
percentage of baseline is shown at 20 weeks and at 12 months after the beginning of treatment with imiquimod 
(Panel A) or placebo (Panel B). The solid red line in Panel A represents the nine patients who had a complete 
response; one patient had no measurable disease but was treated anyway. Data were missing for five patients 
at 12 months.
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A         B 
 
    
C         D 
 
     
 
 
 
Patient 1
Patient 2
Patient 3
FE
Supplementary figure 1. Clinical results before and after treatment with imiquimod.
Clinical pictures of three patients with HPV DNA‑positive VIN 3 showing the results after treatment with 
imiquimod. Picture A, C, E: before treatment; B, D, F: after treatment. All three patients showed complete 
regression of the shown lesion, histological regression to VIN 1 (patient 1 and 2) or no dysplasia (patient 3), and 
clearance of HPV.
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Figure 4 (photographs A‑H, 10x). Representative photographs of positive (red stained) immunocompetent cells 
in VIN lesions and normal vulvar skin.
Compared to healthy controls VIN‑affected skin showed a strong decrease of mDCs stained with CD1a in the 
epidermis (photograph A and B). Twice as many CD208+ (mature) DCs were observed in the dermis of VIN 
compared to healthy controls (photograph C and D). NK cells stained with antibodies directed against CD94 are 
more numeric in the dermis of VIN‑affected skin than in normal skin (photograph E and F). Less CD8+ cells were 
observed in the epidermis, whereas significantly more CD8+ cells were seen in the dermis of VIN‑affected skin 
when compared to normal skin (photograph G and H).
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Figure 2. A and B, HPV16‑specific IFNγ‑producing T‑cell responses in two representative patients with high grade 
VIN (patient 2, left and patient 10, right). T‑cell responses are shown at week 0 (before imiquimod treatment), 
week 8 (during imiquimod treatment), and at week 16 (after imiquimod treatment). Local application of 5% 
imiquimod containing cream does not result in enhanced systemic HPV16‑specific T‑cell responses. Note that 
the magnitude of the T‑cell responses varies slightly over the different time points. The mean number of spots 
and SE induced by the medium control or the peptides present in the E2, E6, and E7 pools per 100,000 PBMCs 
are depicted. As positive control, the memory recall mix (MRM) was used. C and D, patients with preexisting 
HPV16‑specific T‑helper type 1 responses show objective clinical responses after imiquimod treatment. A typical 
example is shown. C, biopsy‑proven VIN 3 lesion of patient 5 before imiquimod treatment. D, the same vulvar 
area of patient 5 after 16 weeks of treatment.
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Figure 1. Results of immunohistochemical staining 
for CD1a+ DCs, CD8+ T‑cells, and CD94+ NK‑cells in 
the epidermis of healthy normal skin (controls), and 
in VIN‑affected skin before and after treatment with 
imiquimod or placebo.
Figure 2. Results of immunohistochemical staining 
for CD123+/11c‑ and CD208+ DCs, and CD25/HLA‑
DR+ Treg‑cells in the dermis of healthy normal skin 
(controls), and in VIN‑affected skin before and after 
treatment with imiquimod or placebo.
Values as median (range), logarithmic scale
1: controls (n=19)
2: imiquimod group before medication (all 
patients, n=25)
3: imiquimod group after medication
4: imiquimod group before medication (patients 
with clinical response > 75%, n=13)
5: imiquimod group after medication
6: imiquimid group before medication (patients 
with clinical response < 75%, n=12)
7: imiquimod group after medication
8: placebo group before medication (n=26)
9: placebo group after medication
* p<0.05
